var title_f38_16_39168="Verbal children UTI";
var content_f38_16_39168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for verbal children older than 24 months with urinary or abdominal symptoms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 564px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     UTI: urinary tract infection; LR: likelihood ratio.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaikh N, Morone NE, Lopez L, et al. Does this child have a urinary tract infection? JAMA 2008; 298:2895. Copyright &copy; 2008 American Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39168=[""].join("\n");
var outline_f38_16_39168=null;
var title_f38_16_39169="Pharyngocele AP Ba swallow";
var content_f38_16_39169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70946%7EGAST%2F51936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70946%7EGAST%2F51936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pharyngocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior-posterior view of the hypopharynx during a barium swallow shows two lateral pharyngoceles (P) which have developed immediately above the esophageal inlet (E).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pharyngocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of the pharynx during a barium swallow shows two small anterior pharyngoceles (arrow) which have developed from the hypopharynx (HP).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39169=[""].join("\n");
var outline_f38_16_39169=null;
var title_f38_16_39170="Fallopian tube CA ultrasound";
var content_f38_16_39170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fallopian tube carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 252px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD8AT4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Ym/1rfWo6muf9c3TNQ0lsKOwUUUUxhRRRQAUtJS0AFGaKSgBa7/wl44h8P8AhKTTIbZZbmW582RrmztrmNV45TzVbDcdMYrz+p3tZ0tluHhdYGO1XIwCcZ49aUknoxNXPX734m6Bpvg/V9C8NwatdpqhZpW1FEhWFj18tYn4HtnA9K8gtEWSZUeaOBT1eTdtH12gn9KgooUUtCrks8axzMiSxyqDgSIGCsPUZAP6VFRRTELSVJDFJPKkUMbySOcKiAkk+gAp1zbzWszQ3UMkMy/eSRSrD6g0AQ0tJRQAvaipoLO5uIZ5oLeaWK3UNM6IWWME4BYjoM8c1BQAtJRRQAUtTWlnc3hlFpbzTmKNppPKQtsRfvMcdFHc9BS3dnc2UiJeW81u7osirKhQsrDIYZ7EdDQBBSVPe2dzYXUlrfW81tcxnDxTIUdeM8g8ioKAFB5zgH2NKAdpOR6dalls7mG1guZbeaO2uCwhlZCEk2nDbT0OCRnHTNQUALRU17Z3NhdSWt9bzW1zGcPFMhR14zyDyKgoAWikooAd1wMgD1xSsdxZjjJPQDFMooAKWkooAKKKKACiiigAooooAKKKKACinxxs5woHpknA/M8Vv6V4be9BUyjzsZVQQEbjp5hOM+wB+tAHO1LCoLZcOYx94oOQKu3NrPpl81vMjrKBtdMEAg8cc5NOSKGPZmRlil/iGC3pgrk4oGWdHmtrS786NNgyNks67tvrxjH4/T3rpviK0M/h/TLi0uluonkIMigD5scjA6fSsUWzaRavdeSig8IzkFj+Xb6ZqDV4zPp1sUkdpXfdsYqo5zyB/wDXpITZztFaMGi388mxLfB7b3VQfoSQD+FacPgnX5rX7RHZxFM42m6hD/8AfBfdj3xTA5uitq98MavYgm7tBEg6u0qbB/wLOP1qnbaXd3M/kxoglIBVZJUTeD027iN2fbNAHofwG1Wx03UfEcT6na6NrV7pclvpWpXT+XHbzEjP7z/lmSuRv7c8889PoaW0t1qi+LfEPhfxJ4piis0tLjVdQE9qtt5rmZPOYhXkAKnkkgN8uTkDw26tprW4eC5jaKVDhkYYIp00EcdvFIl3BK7/AHokD7o/rlQPyJoA+gvDP/CsrfUHSO28P3Nhd+K57MPqMuHh04wKQ65cFU35Cuw/Wk8O6V4Q8TXfh+a20vw8LxtF1Zruzhl2xRvC7C3eUFyVJUBtzEEjnOK+dqtWGoXmnSySafd3FrJJG0LtBIULIwwykg8gjgjoaAPfNQvPCFjo/iW1S70W3u7rQLGPUYtKnQwS3IugZBBzh2EeCdmRkfWpfGdt4HNxpCeGbPwg8Q1SH7PPLqMKI9oUIdLhd28DgEvIAwPTOQK+dKKAPSPjPbeFrW+0tfAb6fLoJikKSxy77ppPMbd56n5lA4CZABXBGcmvS72z+GAi8L/bn0CzsvttvHc2trJHcyOnlnc5njfzAhfG7zVBx0xivmyloA+iIbvwxpkV+zXXhqz1+58Kaxb3y6TcJ9kd2wLZEIYqZGXd8qnJ4yM1VaPwhJNqklhL4audZj0HTPsC6pdq1r5hAF1ks23zVGMKTkc4HavAKKAPctd8SaRD+1gmure6fc6QNTgY3fmCSAKY0UvuU4+U5Oc4BXnpVttJ8La7eaqdQvfB9nqUHii3uZmW+RYZtOMfzLE24h8kgsAeG3Zx0rwOtIaFqR0htU+zFbEHHmM6rn6KTkj3AoA+kmn8Ey2OmWN5c+FJvC9hqGvC5ikvI2uIbZ5iYPsyBtxLbVKlQcgDnB55Uaf4JHwbnWa48OXGqnR0uoJopYYbpLveN0JTcZWYAnJOFb+EY6eJDS7olMLHhxlW85Np/HOKaum3b3SW0cJlnc7VjiIck/hmgXMj1P4hXmiaz+0y1zPeWF34fuNXsxPcCdWt3h/dCQlwdu3G7JzxzXaWdz8Ory+0y2udL8HW9vc3WrWNxKku0xW8SM1tICZMKzsABIeT0UivDLnwfr1tMkM+nskr4wpkTPP48VoS/DbxXDAs02lCJGGR5lzCpx64L5oGenW+m+Bz8InS6ufDVxqbaTHcxTJNFBcx3XmDdCV3GUsATkngj7q4rb1e0+HI1fw7JDB4W+z/AGlxJpi3kHEYgbDm6WQqy79uFm2sxxnAznw6HwH4kmjDxacHjOcOLiIr+e7FEngPxHEpaSwRVHUm6h/+KoA1vjTDokHjCNfDl1ptxam0jaT7BCkaRyHdlG8tmjZgMZZDt6DqCa4GurtPh94lu0ZrewiZV6n7ZAP5vTpvh34nhXdJpyAdeLqE8evD0AclRXVTfD/xNFafaf7M8yPbuxDcRSvj/cVi36Vy7KysVYEMDgg8EGgBtFFFABRRSgZ6UAJS11UPgm9OiyahcXFvAwTfHbnc0kgx/sggfia6P4daHp+p6JLexRBNRs33NJku3HIIB+UfkaBXOG0PQrzWJ/Lg2RJjJlmJVB+QJP4A1of8I1JHEJEP2jY+JFCkAfyP45Fdzrdk2lXEOsWQlupJf9eC2ZMdz7fhUWoeHb2Wym1HQpVmtgpZ1dQSTnpgdzSuM5bxJGlnBADbffX5XA2iP24H8/Sr2gPd6VpSX7xxSLuOzKFm9sfwkemMGr+hamurQMrgwXcYMYLMcHkZ69+2KTVS17pM9hbhhOuQwQDBHqRQncNtGc5eX1rrWpy3t8BvfgRoCGPpxnA79/y4q1Dc2TQi0kX7OFOQkwwH4z16en5ise4s5bWBUdWZ1OS8S7kA44PvTtUlt47yCS1l85SB5kZO5R9D/k0cumgb6G3bQQXFrMI7yK2lAz5RiLrnHGSOnTr+hqOytfKs5Eu540vGIVVkwFccHquSe3BFVry/06yEI0S4nbzf9cJV27T7AcY7djxWde3MTyAxXRZlGFaOLDHnoTx+lJRsCRtTSXtt5Ul1dt58WAkCMQp7hgd39AKdZ69qNpqS3217pFU5ilbMYOT94be307da56GR2lCeZLE5APlpuYyH1IzSMhLlgVVhxsLEfn+tDQNM7XS/E6X0lxcapDEkmf3aiPfEg/2cEkH/AHcfWo11SDUS9pYCG3hkOWuZSfMzz/GTn8Dkf04meGQYJdSVJyFyCB9TzSR3TRSpLiOVx3Zf5jjJ/wAaaTIs73O7urSz1G0WyuxEIITldQgZmYnnh/4SP91RmuN1nQrrTR5u1prMnCXKowRvzHBrqdHmstUiS4vrto7mA5YzSkbV7BMYH4HNbW9bRZdQ06XVZAxwVhEeH+sWMMP196ZZ5LRXomraVp0qrcatZLYNOA3m2ZCBScfejJ2g+wIrnbrw2AhlsdRtZocFlEpMLkdsBgMn6UAc9SVozaLqMMCyy2kqxscKcZLc44HU1Wayulm8lracTddhjO78qAK9LV630jUbiZYobK4Z2O0AoRz9TwKnXQrzdPHIYIp4hnyZJQGf/dH8X4UN2AyamtLae8uEt7SGSadzhI41LMx9gK6bS/DUE0G66lnWYthY2Ty0b2LHkH8K6rT/AAtLJq9slnZxafNF0Cr5xmHuSSOcdeOtJuwHL2/h5dKj+0ai0Et0gDi1WRw8Z9HXZyfYMK210fWtdtTfTGSK3OQouCgLcfwBl4Hv7fl6pB4U0WeC4uPENvHp9/FwscsoHmD1BHI6A8msLW7/AE+zv7YiWI28YwA5WVW+p7UCtc5Gw8OjUbBo5LOQmDrJFtbb/vE4P681p6foH2CWG4lhV4IjlJfLKbzjpuBO7t97NLrXiywd2khkUMThY4/lz0HBUVXh8axyQq4zawpn5dx3SfUd6YJJHSXOpO8jOMrcEgRBdpYdenAUDHfrW5plxawxR20/nJfS/M8zqFToOucgn6AVx9p4ygREkltorq5fmJnHEXBzjGD271LqXjbT9bubYSq32pBtYSr830UH/wCvSA6e6muLK2up76OO7dVxD9lBVwP91Xwf0rlEuLyW1+0RytmR8tFK2GU5J+bHv25+ppdT1O1eWO3uH8pFyUSOQbgfcg8DkVj6lrRlBCy/Z1QfKsJGXHbJ796TKN23vp7a63pdSK5X/cX8D7fX8KdpuqvazTJPchpWOCFGVH+8eprzrTPELrfSy3EW4ZIWJRnBB7/yHNTwatLIHaR5F3HBeQliOeFXvjpTQdDtNX1p4kCOJRGpBO04J91wc/pXKa3dQ6x892sLjAAbCiQ+mXI3fQHjiq8VzmxzsIWU8o+STnuB/wDrFZ+rTSRKIEdwjDJYoAPxOABQu4ipcaLFPKU0uV96na0VyQpz7Pwp/Sse8tZ7OdobmNo5F7H+Y9R710MuoRoqzWy7JE4eTb07dcc1Rup0mkM292hPAwuBkZxwfb+dGvUSOgl8DR2Wn3El1ei5vo87YLf5UOP9tuTx22iptJtE1Xw8yWcGGQlZreNQOQOpz8xPv+ldP4rlkGrwtaZaWRMkEYVge+SPf0NcrYSSaPqb3sMAmmDbZYGII688f5/pRcL3Ou+GWnWuvaXPp1+ySXNqp2b+o9g3T2waowhtJ8Q3WmwQlY5uC8Z69uR3xUU+q6fBMdX0u4NtdvxLGJNpB9MnoMA9MU54ruPyNSlfdFeso81uRkkZxkc+2KLj8zf1fQmttKS9E/7tPnMQ4PXPGRmqFvqs6Fp7KXfBMm18nGB/tda6Xx1q0Vv4asINUtkh+UBbkjPmegxjj8cfUVzuoaDqMNlZXNqUgjlAKuzHy5F9jk/5NTJ9hO/QwVa2tZzEWSeN33b1yApPoeo5x/Krs8aQlp4LsRFRuwvAAHHc88/54rS13T4xp0cNvbEy5HnRrhOfZun8v5VheIry0uNLt9NvbFIZAu2B5SEAPTO4Hnr0/Wq8wOc1S+BkaWKVJC4+cZG1xyOeRnv+Vc0imSRxuSLAJ+b27VsX1rDpMkKzKzyAkMzLuVvw6fqabbWgEjTtbExyklCjqMD2B4pc1hqSK2kxQ3V/HHcT/ZLTgyM7DHHsev0q3cNbTSylD5cURKwyiMeW5684HGanlgaOaI2cErbfvpKowB6+jd+M/wBah+RNQ85IozbjDOJPkVM9tg/DoDQpXQNopDfAAbuFisvIkZMEfRunX61a1HT5bCGKZjbXBcAgxtvC9+nGT+daFhYy32pmK3lhhtQQ/wC8YHA9h1I46VZ1yygG82kDeQnLXMfQn028kUW6kWe6OajnCBnCj7SePNdydgPoO1VmVnzJKzOn97v17dqvXEENwjyWTSSqrfPvXnJz0wBTUtII4POu2YIclEVs+4/A89Kab6FFe1K3M8cdxJgEhQT0HPtW7p2p33h67UqrTWbADY7na47YYEgf54rBYAyh/KVV6EEj+XWpSiMAsAkdzzgoACB6YJJ/Ck32HsdzNrFtePHDd2UVvA43K10TIIj7OMHNalrJp1yh0+4urWVBwsd5J5pYED7jA7h06+35+Wy3Uo2QtlUjOCjjI+pBpRNGJI2jjYhSNxB246cqccH65ovoJPuesW+jwW11+9a1zGmIo1lAdMjrknPXtWdY6XqFzq891abGnTCq6zyO6jP1IHTtxzXNz6lpcGnfZ7BLxJpFO6SUxkhs/wATBfmHX0/Ws+y17UrIutsUhmPDvCdjH64OP0oVnqFkes2FhZ21wYdfuhO903zrcXPzJ34To361mt/whNr4jeAq0m5QI2dVMYPb5F6HOOTXE2vie5bS3hWOwiQccoTLJ7bsn+QHSsbWdQOpOhbERzygdnJPqeME0MNNj1mLxfommXEloy3V1CG+UwsoiHTAPPP0xXPax8Qbw3iw6CVitgMEeTux/UfUV53aGMFvPuWRAPl2DcSfpkY6n061ErZGFJJ55ZtoI9D/APrp6iubV9ql5eXcs91KrSE/eJYNnPbBz7c+1Zd3Lclw0wY7uzr1/wAnNQQpKZm8hSzqCSAucevFPNzcGLymmc4ONrHp9Cen/wCqjUd9SZ2VYCEDLJ1Kjlfw/wDr1Ukdiy5GGXjpg1YtZoUikjnjV2JypbOFOPY81HKjBw0kgDk5JJyfXtzTvYehtz3kNxaC4kEeY8LsPDE8ZG3v279KWGdpraB7h2aPOEDpvYHOOMdsdKz5oUlija3hllx8rOW4+vt+NS39vBB5QhOGxlysgfaDg+p7n2pPyYPsTyXcUs63ELOjpxnb1B6DHOe/Jokvomut8okR2U7jIevHtyOnWslWkDySRq+VOQ46L+f1p0iyM3nXjlGPKll5f6cYP44pIlJ3uWftIWQzQPtyeowXHH5etWo2ht447iWeIluRGMsq8eg4zzWasTou4QurNyMrnIPQgYpshJDRmI4yDuK/MPxxnFFyrK2prT380jI12rSL1UIcMB6AY7YPbp3ps0zauRhljij42E5bPrVM25jt0lZiy4wgPQ+hGM4PX8qah+QeXGGLY3Hd83X2/lz+NNMQ90M0zIhViowM/MDjGPp1Hb1qKCKS5jJXc204wMKPz6f59qjCSwN8pAkJ7Ehh+Hp/hTZJpVXaWAOeflwT79OlN+QHsvxAtvNOkX9tGVnRQ20BQy9u/WsiO1ury/W9AQDZhomB+btnOMCuo+H7R+IPC9lGkSu8Z8sqWwQR+uPx71evdFhsZ3iZwl3g7ApxuP1pWKTOeHh2O4uEvYoCjBsyoIt2fqeOK1I9PEAS3kG20lIwW6KfQcdfb+laeh65LoN2d4eVWQ7lAB/HpzVe+tbWffOjSRQzNnbIxIU57HkiiyEQ+MZfK0+Gyvm89YxlI5AEJXHGOatTaoLnwrbxs+7TIgA0chDtGO+Ce30xU0sv2K3ij1CFSB9x0G/f6DHXofWuX1cyebcJZWoHmqcpkN164U8H6ZpgxYdb0uKN20yWGdVUhlJB4x0z/TP865Eout+MgsTxqjA/u9wAQjg5wMDP406LwjqJ0z7TbSSFYW3PDcEgnHoAc46/56WIrPS9Rih1B4J4WUkFlQMgYevvn9aSv1EjL1OxuV1e5sri0nuLZPubVDEZ6Yc9uc1PF4TuraO3u02z25OTLDljH6Bmxx6dhxXb6ZZaXLbStdyXUFzsO0lgxlHbnt2OKqaRp8kMFzdaRFJdWu4b8naOuTkf4VLj2A5SWO7e4fCJIYyfmJDLwfTBJPqO9UL2NrsG51dWhEZIVFhETAe6gZI6c11+t2LWb22oRSy2tyzAbQAYT7HjPrWh9vhsNStmvLBLa+nQAl4w0bjHUA8A8mq0S1FbU4qxtHvLFEsrBruwyd05jGyM/Ujg81px2U8GntBaXCXNzkeXAFVVQe4ZcHHsRXSQ6TLDPdnRmlSOUFpI51HU/wBxcY6fSpFt7e30Nhqtu/29/ljkUZMY7ZOOlA02cta2a3SXL3kkAMPLSLFvRev/AHz0/D8KwBEbm3niisy5c4jumw/mY44c8D6ZFdnHoMFjpkrTSxSGXl5oYfNcjsCQQf8A9f52LK008aOLSwSdrkgFR5aqpwehLf1/maVh3PMRZeXCxa5tiU+8jnDg/hyfzxTLPTZrq3lufNgCoMiMksWP0AOPx/8Ar12f2DWUuXN7BbTbwSJvLDGMez8AVlw2EVpBNCGDtNnc4bf5g9MjgdT+tNJCsjlAmJc/u1YZypIYH6DGKPNZZJAgdHHZBt+ucc//AKq27XT2e4kgiiVI8/MxiDleeME/0OaifTLWz1EJeSb7ZuEc5VT9e9CQWRlJJA5Tcrqw5IU53H8v8ajuF/eYwQx55zkD3rXu7W3+1+VbBZrdnG64SMrtHoAeDgeg5q5dabb2tzEbIuyNyHbHt1GDzQu6FZIxo44mhCuhKLjdIvzBT6HgEf8A66hNsdz+UizRqM7wSM1c1Wwa0lDy4TzPnVmPLeuNvv64qR9OmKCSaYbATgOwQ49R14z/ADFNoLMyEiYkFkbae+KsmVCSZFjLKMJyNoH0A5/GtSO3aQZeCK2dcFLiU7VP58E8UsOl3GoTxm/kaFOpnb5lbPIA7D8KVxmfJbSwGJbjdHu+YKxwPy61VuFwpJRQSeCp479B1rsorKK6i+xJdMzdFdl/kB14FUdLskj1uOxZt8+4BRsOTnsQOn1/wo2EtDn4bVxF5jRuRnldmOPYkH/OKnjtGkgDW0UZ28Eu21sn64Bx7V3HjDSpNOtXBt0sUAy626c5926+naqdjo/l+H4Y7nyBHcMRHcRsNxz22nqevPFTrfQfmjm7qxigghFzfqZegAyygenYgfpUbWctncpLermN1yrIyyZ7++PxFXtV0M2kypEYyqZy8g+Zu/3ee1SWzMsTCGAJKozum2gD3GOvf/Oap6g79yhcPBPG8yHbKmCBIxdjz+A/IYpba0uLtw0rmPcOJHBwR1wCAf6VWlnkiXzN8DSMTnaASv8AnrVu2s77ULc3FpM0zIMSLknYPc+lFtB3kMNtHbyfvMzKpzjv+XP6mq9y8MuAi4XrtYhcenoB+tdBa6PJcWwWJ7p751y+xSAo9OO3vms+905rO3CPKBk/OFTHfjd+OaTbQbmW7sI9sMrIG+8oJA9OmMfrSTEsv7j5UA5CucA985pt6kYclPlI/hHT65qFAdmCuAx+8fT+tNak26jiDLIGmZUU5AYLgN+QpiSNG5JALdDuUH+dOikIQoiBmYjBxk/gKbcJskwG3Z5yev481VmtRrQ9p+HkL+HNOvLPVN1tfLIWgYnKt/wEdav+P5jqMdjdXzvY6khwk8RbD+x7fmKzb67uZrBZWtPNgjAaNiBgD+efxqzLqi+I/C6Wlk267jOQEwy5B7lgQfypMZs+E7v+0C9hqBhSdlyjAfJKCOnsf89axH1O8tNeuNLns9lnnlO/HdWz/OuPHiMwXyJIrWl/bMY2XkK3YYx0rVvfEcc8Uct+qrMSM7gOfq3Tn6du2KSQrWLeo6tcwSTQrMzxhT5RP3lPue/5Vb+FyQa/qclxeXDLewk4Vm8tW+nf3/ya4mTWI7zVNizPEzHACgFHzjj19e4r0zS4dL0+MJc2csU04HzRE4Pvnd8v45pgdTplpHqmuXGnz4R8bUYJ5bMeuMk/Nx3rzy/t5fCniybRtW03/QbmUiCUv8gBB5I7nqev+Nd9ataacba0tIi5PzCcKZSn1PXHOTgjrUOr6UNWY3N8wvJ4DlJoOSg9SuB+uaBmNZW+n6TrcjXqJeWZQbgpB8s+o7//AFqv2D6HcWd7A4ezD5Fvd24bHtvWuc8XQDQp7Ka3YXFrK+H4EbR++D1x+FaqSRyEW1hqNsDJwFdvLUk9sevPc0hGEBrljdHT4LjT7y1frckc498nrz6H/Fmo2cuqXUFmt0iwq+PKkfd8w744wPet3xLpSaVp8ZsLaN5gQ06zNt2n+8iD734MOtc073Qk3Pp4uomjJWeGIgj2IJJUf57VPMloGmx1GpWbWF9ax3sZh+XgSlnRv91weD1qLxUIPEGmx2ekyf2ZMh2s4JZ3HTGDg49wa5DTNUmuEa2i36gQ5Y25beF55Ibkqfauy1K8v7u0sokAb7NgkSxt8vH95WBP4iqTurj2OZtLC/8ADBaWdbkB+PNupAyv9MDOat6XNLbebO0XmwSHL2yrg556E4Y9+nrUSao+r3txb3l5Fe2yHDmcpsjx2wg5+7nkelXEl3ae15Y+TeLF8iTYYxxe3tj3/Si+ovQu6LqOnXEcsV5YyeYPuIbkAAejZOf0qhf6XZPdb7e+WyMgwbaFFWM+x+UFj/hUeo2mmXWh/b9PvLYagW3SGLAjYjtkDbnHv+RrLj1TUJCl1ZvPJBB/rA7KcnHIDNz+R70k76DZY8Q+Hp7i0hezt2jhQjMqkkenBXG0/WqOtaVbWtmgW1N25XLwtIXkGe4//VRp+sX893NeXL3EdhL8hWPOenodoP45q7aXramGsorm9uIAeIZ4YY0HtnGMfjTBeZlQ+HdPEFvKJbiOdiCBFISFPcMCM/5H4ytp2nNMFuruY9AyRx7CSOPTJrantdXF5DaLBClygARYx/rF7AkNjH6VHDpuqX+vJEyWGnz243GIjaCfUkZzQ0D7HJarpws7hIrZJPKlxsW5jzn0Ix0/Om3miWelqPtU1q084wImH3ffOcfliuxvtFkuNQkvJb22W9A2+akDEZHGByT09D61gSWdjI7Lcz3PmbhvPkrhueevI6DsaWtybNbEi6Ii6HIt1ZPOyfccuCyDjpuOPwq5q4X/AIRaG3bUbuSdVAjtEKqFHTkgY/DNJFJFpUJazt2KSjaAqNID6cEkr9QO9PkSWC4Wyu/sdvHc4aS4t3Ej/iOmfrzRey1GZ9jbxnSlNzctb36n5dw2qnpgnAOOuRmpfD11Y29w1tLCdRvZGx9sY+cYR/urz15zVy70i589LSG6W4sojuEEsS5fnrwAcfn/AFrY0iyRruSYQQSzQLtEe8RBB2HB5/E9alVEwTuznbyFotdd7eaW6WbCu0kRZI+vRT931702OwlsvMW0LXDFsmSVtzKP93/6wrQuIpNUu50t79bS6gI8y2R+Nue5x+HH/wCraF7bizXTLNo45T8s20nLH65LsePWqQGDr8FnCluNMlvY72T74RNwkz2wSSoJ9q5zVrKeyR2ubeKC3OSUnOZNxz279c9K6+2hX7cmnWK+bcqMiHYd3HfAzj6kUrwMs0xuophNBkhXXCDgds5P6dar0BHnELNN5iXCQwb12qyLtDf7xwSMirmiXMejR3f2mCQluE2SBFP/AAI84rQvAlrbS3qmKOVmKpuh2Fvdd3X9az71UuoFuZLmWUPw3mMDg9M9doOMjikncJF7QtWlSymZJfLMvDK2EAz33ZGfwH51gz3F1DJISFxIxfLuCDnHcHntXR2VjpVuFaKVftpPyxS/MzfT071jo0sk832y5WK3z8yRgbT6hn6E+3JP8peuoWZksVeMmVXeUjKkA9e2PUY5qIwiZhsm8wHJwFO78q2Y4TdOxsCBCgOSpwo79DnuByD2qFBADNEHInYH+HIbHpzgfj/OhXJT7op3NqFiBbCS9NpHGMdQRx+tUZCVkcZLvn5mJ6n/APXmtC7RxbxtMfmDYBOSQPTJ4PPoKqyBIAo+Q5HXaD/X+eD7VV+hpypo77TNavItR/su0ZPJl+/H5WQwPfsT+Oakm0O6tNQZ7NjGVyVZCAp5PG0gDn6Vi2891fIbi1t3W+gG4KQQ3vjua9G8LyjWLAXl/JJFcIMMJRtkc89s0egjh7HS2vNQuPOaIy854XcT0+v5e31qrf2QkRozIDJGclWYnPOMj/69dFJpsE2vS3pufs8sP+rKnHbu36de/tSeKrRYfI1R7ZmC8sVGd69Oo+tJakWb3OVbTLq3e0ubZZJok/1ixEll9eM/pmvSE1nMMIhZnZky6KMHOO64/X3HWqvhDUtHF3NLYuZEuI9pgkyCpHpzjv8AWuo0KTRxplzbajbCOZWLRMo59fm/PqKoouWLJb2lprOnyr9qgOWFu2cHOMSDHH4VL4v1GHxLAuvG1mtNQtMEzWqnY2O5UDB/4EPy61j6dKmm6ybu1inFsFAkUtvhb1yp59O9ddb64niHw7qEOlw2aQhWSW3Rhnp2AOD+P/16hxuP1OA/tu41jUYLizjjluSpRlhnBBA9Vzx9BTLiPSzJtuUmW5DZaBT8iN7A4yfwrntM06Lw5pl1Ilt96QD7TK4R07YDDt7Zqzd6LdXkEdxEJII3wftLEE/nyDVJBsbzX9lqkiw6ldW/yDbCGTzOfQjoD75qvqemS6bpV1d+HYJo7vGXQb3EijsuGJ6evoKz7bTNTto1+xPZXCr99j/rT71qQtrmm6dHeRQKsTNhwYyGAOB+XWhRQk7mToM66/pouHWN9UibAZc+fHjttz079a1W1BNS860+0MNUjXD7JNshGP4lxz16+9PltlOqxTaXoaX010n7y6hYKYvc4xn/AD7VO2mLZzyW8f2O4uOD5rIUkXPY5xn60ajOE8Q6db29sH05zYXe8kgR/K3szDJ9Ov8Aia3PCz6re2CWWkaVYXd4/F1OCY2IB7DIBOB6U3WNH+yztcXqTTRk7lS2OcdewGR1P51d07WwkcdtqdtLAE4t3hi2HB9WJGPwpW1FqUptAl0e2uII45gjEu0saeY0b+hHIHX8DVOwaTzHNpKYdyncGYHzOeoB6fgDWne69PLex2s800umMRvjAEy9eCXwQv1PSrmqnTrW/tZI/D73FvtDKkcnnMvuGz+nFOw3qYkk9o2jSwXV1eSk8CzmiVo1I/3cYGfXHWsO0l1O3t4zJfqkecxQQDJRcZ+Xdx6DBBrqtT0rSNYga9t9TtLCOMHzLeZdjgDoCD1x7ZFY134Xk1SwSLRL6HUWDbgVY71+hB2/p609QBbq0vkkFxNctdRcliwjIPY/IFB/KiCaTEjJcXAjRfmmUFgeehyePxNW79LzSLC2fV7WIRwBQxcCIt14ORyat6La3kJTU9O0nyLSc5Dzrk5P90AkGlqBk2etWsGmSyT6fMqA4aR9yE89SRnI9uKdqGnrcQ2OrrcGCxcqUh8tNpIPGQSCe/H5VDqCNq2rzw+IppLa1UfulUlkY9fur0PXrSPdvJcQPc3VncJAxEXm/fRcHGFPTt1pNdRHTF5pR9u0JporiJceWv8Aqzj2xgD86z9UN9NLbTXVuou2fCjaqofqR1+hx0qO2v7S0E9zLqEkqnI5BjKZ6AMpA/Oumjntl8PwSfYb+4uZpNyXATeFB/2uR+WKbQytP4Ya8ljivTJFLjdGIO/HZgcelTeRFHbrYPcpbvEMMDKhkI47FTz781u6n4tn02yt7HT7uaFpFxJM1mZT9Bubg89RWFb289nFcLPMDC53cW5aRmPUnjjOc8UJJaImy2LEFvMjgiFZYxztcEyN/wACIwPwFYF3p9vHqJPk39lezEBI1HljH1xzXQadrNpYNDZX07XN7cH9yquCI2zx+75P61fe4kGoS6d4ga3vJtu6KYKUAHZT3B6dDTuMwLS0k0W3muLOa+OoN1aGMEnPY/Lj8cZ/rWv7zULi3SGATruP7xlQnGTyTj6VoPe6p4fjuI5J41S5JWG1EZZm+gGSfx/XNWNM+03WmzNJPGlwg+eKX7w/D+H8aAOd1Pw/DPEokktvIUAh5Ygjbvop/n/Ws+XTL3QNKnu57eJFk4jlBDZU+gHIH0FWPF0X2HT7WW4vN1yxCxWysHlc+x64og0S+hK3Xi25ja6kXdbW104ZkH+7z+lTZXIkubRnP2WnLLafareQXE8/LxFC6gdjt9eO9Utk91K1lPcSSnaSLeKPBUD1z068V1ItLO0Ess8i27gncQxG7uOMY7fyqrpqBblrtoy0WCYoImZyzY6n0HJoV2UlZWMO1lOg6POISWM77SxXAXp369MdMHn2qBIIYbQRInmibkbjgFvw6/jnpW3Lv169kXWojbqnEUS8uPrj/GmS7dOinZ4A9y64SWT5do9x3oWg2jn73T5rEBIpVeUruLLgKo64DDp9BWMilVKySxLg9T8wz9RWveSvqC/6O0j7F6opVDn1z7VjxRt5rDMe4Dk7Qw/I/wA6Lg7o9T0a0sm0R7q3uoVu0fJbO1lwfun1H4106Q2+p6fBLbSiCc/fMJB8wY759aoxaI9zFMiKggyHHlpjB9+annjltEhhNssTD7sgYD2x14oukNuxtQeHf7Q0ieORY5oU+VsLk/y+v/1qni08z+D5bRDFfabH1hkJJj9uM4+hq3oeq6loOJp4/NLp80bDG4cdT17f/qpl7euqS3dnYyxwT58y2ij35/EAn9aYjzrStN0h7mS0gf7FeRsWEbsFJAP8Iz0/Ct7w5qH27UbjSb+1IEOfLuIyFcc5yD3Hsayk0201nUpvLmWKZOTG8u4g/UAlfoSK0fDOjv4cvnulWdf+emctu49OhHHbmjYHJJnUyXtukSwzRxyRxtt84RkH/gWOKwPESW1jaS30donkgHfJAdrEY5+7jP0Nbek3c91rLypZyPag5kFtiPjg/MGBBPPSo/HEFrqWk3Eenw3CEj5cn7OWz2DAFfzHei4zzHS2stXv3kvWmngkyRBMoWI+hyOc47mr+mRTQzXGlwXbRWMmSLVJvOi79Cfu1RCahZadJaXdp+4OQCGDMuP9tcZ7dhTtL0dkks2gntYY1fJAA8wnHA3Yz/PpRohaHW6KPILR/ZVjij4eOUncR2Ksee/61W124dtLukCXk0DZKws/bI/L8av61Bc28KvbJF8yAFZXL7vowAP/AI6etZ0Z1GS3aSJBp5PG/b5m7n+Hp+oFTzoLmx4BGnweGI3nvHFwh3C1uMq8OO4yf69qivdUk1jULqeDSX1OK3Qqb15PmRvTb6fTPesg2UDRMlxBMJGJLBl3LIfcHGP1rqFjsotDg26SZLyE7vs9rInOT1KkjH507sLvqcfp08qXwurMW15dKx3CKcSFAD3XOP610GsfbrlHungjvYzjzYbWEZi9c5G316Go9GFlqWp3bX0MdnIoxFGE8sEc8NIuR2712Gn2iN4YmghgWaMg5nSNLhYzz0b19O1GyuM85sDY6MY5ofLt7SUYKb8CUHtjvnNM1HWoLG92QWebeQggBhuT6DjHT0zT5dG1K0tbqHTYEv7OPczvPDtkz1O0nC4HpgfWse11ozaYzXdobtCdn2YxDIOcfeGB69zVCv5mlbkXV0sVtFY6rO+N6RozzovrtwAeg4zXQPo6WF7BJpG9LdRmZvJ8lkbuHRT0+uf8OSWO4mZIbbyo7sruWS13K8HPccZPPatPwd4v1nQZ77SrkTX1tIdsl0vLj3YEFhjp/nNLW4zoF0nT9fkuVubmxULzv/1qyNxwc/d/LisS40ecQPaLIbGIfID9pDxkdMKrYA/CsvQoLCfxDcJaXUmoCds7E3v5LdjuxkD6n8K2/EelBIgdQvLKfUI/mto4FGM44BJ/xoAq3PhXURPaJ5FtpUIb5rhnLSTL6qGGPy960dT8MeEI5me7DTgJzLcSHdnoPuj17Gug0ORb7QoJNfkVr9P9VFc25VQM8HeCQf8Avqq+paNBdyw3JnaCSMnaluytG3pkDDfhz0oAxvD9vY6XOLa4s0uraU5hF+5dIz1yF/z2re17xDe6nC2lpf2LWsWN8NpEYUVfxx2qbUbGXTbN7nUbiCO0kT99Ku0zqMdBkAqefWuTi0ewmKzWnm/Y87oZZ5MySkj7xJyfwzRuB1smt2V5oUelWFgd0Y4upSmdwzyh7c1y2nTP9rddcj1S6uVOLdLWXavcfO3T06+lDS6vZ6kkt+tpsj4gKv5foB8pc7jwOorbvdG8SJdpqF9AVWUZje3THH0QkLx7flQBm6rooneK8ju7aK+XkSROHMfPTOMZ+lV/Jmv9St4/ELy2trCQXuBueWX6KBkk+9dJDaX+vT2pk0tLKCHma9lBhX3LEkEn6VnaxBMurxm2uBc2SEA3QBCKfVSx5/A9aBXsWPGdjd+HbGDWNN0/7JYSYWOe/lEbyA99uM+/UGoZozatZ3k7WxkcCVY0cop6dc9fzrd1m50TULSKzhe6vpEAD3N2TKEb/ZTkAfU1zSGK4c2cjxXjF8ZkT5gOMEgHA/KhuwytLqN34h1GW4XR7azWHgTNH5jcdwBwPzFYviCezadDdoWvuF3TNl8dOBn27Zrptau7DR9J8oSxpGi/O4kG1On3UAJ/TivJtDvUtdblvYoXkt5nObi4w2RnnaCMZ6en9KBX7nWTvNLa/YLXTSWfkXMygKPwPJq34aFtbPPFqFybi4jU/ubNfLjHuW9vQdav6DYjxDNNcut0phB8tZUKls98nI7dOK4jxAl5p2qXAkWzkExyGQF3bk8ZHT8Bj+dGhL1VzRvdZlSeWZEjW1DkHBL847sMjHToe9YPiO7sNQEDNLuJOWlGGI/2cY4+tR2+omMtZyWks8jDIWD5in1JBJ+n51Sa6dskpBGkZyYyMlfc8Zz+XbmlzJahFu12akaTy2scVlbGG3yEG5Sdx44x0PqOapa7bW9s8ZvUczHI8uLkADvjj6davpdf6CZpLhvLB4YMCqn26r+G78qxbW2W4d5bsPGjfdlc7Q/pjB549z0qir2PpDwQksOhpKVM9oww0Minzozjrjqf8+tZ1rp17q2tXFgL62htX+aFXQgr9eRXZWniLTfstnf+HUEzuQLy0XloT3z3x9K2fGHgzTtWFn4m0Qi3lQDzfKXaffdjH60rDOBsvAtzeNIRqFzJdW5w0WRhxjrjr2/UVY8GR3PhnVruykmGoWs3+tt5SMp9FPPp1reeK5aeK6gvlMqfMJ0JBznOCP8AGuZ8T6tLeaustzCDMAAt7CQpJ9AOpPHNFluI5H4m+HrFvE0Or6LcNbTs372JgGDccgKRgcf56U68umnlt7e/WGCx27QLaQxMGx1yCP51j+JZ11O6dL2433VudwG4JJj1xxmsa21gTahH5F5mGH5WWZDuOO2Mf0pjPRLqzj06yWO3uJ5I5F/dXDFiY/qfX35pbbU7q204WhjW5nxuEpBaQ9+Pzqvo5m1O3aM2xgiHBmtG3L/wJOo+op08MOmwt/Z7uXX+LqhP9P8A69IDA1WS5uoHeeBbK6YEIw5Un0ZSMNT9NvNRgtI7e4FtFKWGckxo2emMnjP0FdBZ6nbz2cltqtrIbx+Y5oCJfL+qmictJb/ZdVghuIU5imA3ZPuuMr1pisYdzol4/iC3bU4lEOBtVXdAM9852t+Rzmr19czeDZZWmuU1mznIKQxqxaI+23GPyrsUtbeLw9EmrWIiM5xBfWc5bA7bgax30vULp47e2k+02seN9wMRyH0wAOef5dqTSYzPlvn1bT1lu40S0YAie3uF85M9iDyfyqtNG8dubmZJ7awQYS4ZS5J75U/0qjrV1babqH2M3duLo4CwXKhGOTx8w61Pb67fW7LF5kdtEvBBn8xST7HkUlGwrCWk8ZUyb5Z1cE4jIiJH0I9PpXTeGdYt1Js72IW8S/cukYKQeOGOTk/WuLe6a11V7yaGG4aY7fMBZeD2A6fp2qi+nx6jqkiLqNxZvIM+aZAFGc8ZXindAdXrF5rr3N5C13ayaYcqs6Ph888cYBHtmuf8IQTeHdRlurKWxtmzgwzDMcnX7w7fgRUWlWniDQZrixuY76AHIimj+eKUf3iOf5d66TQdCGiwS39skOtajcHMySOybPqD8v8AKmM5X4g3V7I8Nzf6TY3UZbcBYs6AehyDv9/TgVLFc6d9kt5GUxSgArCV+Ven3sE/+PYNdt/YOlardpqN9PLpl7AfktI7cvhsdQwOKi1q9itrlI7uSAFvuMiKXcDj5vX8amwXOcuNMXzE1PSBDZg8Ty7QX6dEEf3PxPapZVsbWOVrIESykea8gjmkf35BZa0BpdneQ3Elld2FlOmWMVyhDueeQV4H8qseC9cXS5JbfUbXTo2JJFxOFcDHIIPXH4UeojOkuPMt7exsmW0uwOZpFd3I7/K3A/z9KLqw0pLhBaXNxJOxAmlUM25s9CpUYH0/+vXUa/4rvdTsrtLa70m7twuwmCMqSO3LDpXG+DJzp1swv9PkmmdjtSG5VNvPsBVDOp12w8vT7Sz1GNLmdwDDDBsD9Op7fme9Zet6PcaTbW91K0cLgDFnDtaQD/aK5A/OtB9LWa8W4F62lAjnzIjE0hx2cjP5U6fR4YAwkumg3ZbzfJaV5Pcb/b09aAKVpqkcsTQFHhbGTIWEpb8TkipdK1S6tUuvJ8q4hcYLTopwe3OMflXNa3qEutw/YNL05raOJ8TXF+ghMoyMhVHJ4/zmtbQbH7Po01lZNd6ekgJe0ihMkbHuWLc0rCOh8OyyXlubG71NrpdxK2MSiNB9WbH5VX8SSy/2xareWrXZiwscAYCONfcBtpx6kVzEGtQtcy6deaYJIrQZElujRqeMcgYbt61uQWh1LTjKLq1srYtwqSkMfYq2SfxpjNEX0lrM8UT2NpZuMvNDGWRfYgdT+NYfiWGy1KJZ7bUHv7lTmKSRxBHzxxGnJH1Oas3Md1/Zf2b7ZBZWfRmjlCiT65/zzUej6F9hjWbSrO1mueSjqm4gHqQegPP50gMu9ks9L0Ca41qGaVmXAfG2MHPULndnn/PWucsb6KPSWuoGt7iaU7obKMHkemeMY/Gul8TStd2B0+SNYbwEBpz++Y/jziuV1+wnuJLK10yW4nuguH8lcsAO59PrxSaRLb6G74BafVJby6u3lggXJe3O0KCO2R8xrO17VZbtbu1sNMaKcKVS4QhsDsAT8wznv71eskTRIPLgkl89l/eICHkAx354/CmxT2kOZI/NmlYZIlY4HPPGPloSvuNN9UcEv9o2SeQ8nlhwGkjVd0rDBzyTnHXkGtDS/DUerW0rW0TTuDu3lTx65/irsoNMhvQDIq73bOEGWI/Cs3xZqL+H3jtdPVW3fK0MZ+f1yQDk9OvvTHY4tYLeLUUsECygE71U5bPcEjjHXjmn63dTTy+Q8TmCI4WFR8q9ecEYz9PU1bt7VkuxdRnbcypyYiCIxjPJ4xxxz61keJbOdZxLMGYN1LNzn6elS5q9gSPbNPt7x/GMUthYQxSzH5iD5bt9T3+mK9s8N+Jm0bUFsdYkeFXGDkYAJ7lc89uRXI6fZixgay1C3BMfzRvy4J9RzgH6Cuvt9f0vVNFWw11fNZV2xzSZ3/mMfoTVgZnxQ8LlbA32lwR+af3q3MGIw464Izj864m01KDxHpAEWnPbalEpUiUj7/TIbgHp2Jq3pl3rugXN/pb3k15o8uTDFdSCRQPQN19Ov51zX/CVPo+obDbu8UbbjHsDKRnoGGcH60mB5lqlnqv9oXcOuSJaXsZ/cF0Kq6/75+Udu5+lZEVpeLcOdQt0nXOS4OTEc8fN0x0719CeMb2w8VafaarptsI4OBumjy8Z/wBknBx9K8q8S6Lc2d8t3YRSXtixxOUcFgfQjBJ59DUba3G2N+H921hc3Oy4ndSu0qsm2Rseh6Hn1rqw1j9pF7aX7yTKSGaePaYz6bRwfyFee6zoFzc3qy2EVskLEMZZVYOvPTpkj6g/Wuntm1DT9Ot0+yqs2QEnjk3/AOBHfjNOLuhGr4maKSS11G6VJCrDFxp7YkT3ZAelXbG8udTu444tStLsuPkecle33TjnOfrWt4bv2t4Fa+s5raeQfNI9uXjm9wMEj6gGup03wxpF4sps7pBdEbyIxt2nr0PH6VYWOOhiudFaaDxGuoKS3+jiM+dH2/h6/mK6q812W50W2FtYC8ljwrvEFRgPUqSCOMdK5q/iu7m4k06SSG/mh+ZZVfa0Q7Zi6n0zisXwr4xuYPEL2esR+fcWpwHmtzAknYgfNk9e5FAFzxnZDToV1S5ih1GwwTLbFfNb8WPzKf8AGvO3is5LVtU0KzmsNPck+XMDJjP9zjA/z617b4iuNA1uGSPVNIubISHHlXCOFOR1jkXp371yA8NHwtLnw/ey31rK26SznkVlx6BwSG/HHepauJozE8K+KtS0q01GK5to9LwMyQD067wee/8AnFR65p1rp1nClzbhZyR5csEJMcpxnO5Sdv0revY7iwcajpNjcQWbc3MBumWJuM8R52H+eKuJqOna1pLCCGKGKUYDxEKIyM/xGTP4E9qOVAUfDb3uLddVu7kRnPkIkiO+7thWJIHGeSKt+K4dav7hI9bt3bT0w0I2CFsg8fdGD09afoGjTxRNbWut2XnsMB3VlB79icfWrMkWtRobKZUu7qPG2ZLlQmfYZyfzpOyElpsQW8ctvbC4itJrWYLgSu3EmBgAgZ45xmpdT1Uajof2fUtJi02cjbHcxAOh98svX6UyX7XcMLaUP9ujwzokheLb33IcDpn1PI9qsWf243YVTZXaKCfIQFAv1Yk+/GRVK3QFJ32MMaFqNtoYW11KzdtvzlWQswP16Gub0LRrOJ5WM9wjlsyz3vAQ9yuTz/Ku6vZbCCaa5kt92qqu0rdbHRPoFJIH4+tZeieG7LV/Pvb67FzfxNuSGOFjt9ANzZGPUEf4BRX/ALLsftkF5p90t20YCmeacc4PAEY61fnt7WXUBdNo+n3twPuT+a2Iz6gKMg45xVrT4tVv/Nju4ZoLWP5RtmEch7dHxn8zWj4Z1nU9Fs763021sovMBDSXMeHI9dwwD0Hc0LUDPbT/ABJdwpdXEhNshygdw5A56BuQKx9avPsWqW8t9rExnyBHBMpC59iDWwhullMJ1eJUmcs7NI3yZOeOvtxiufmGk3PikJb6hFfXsQ4cRByhB7Rhie/XApiNXVtL02a6h1rxBqkllKoAjQr87j1XGcin6vqF8lvbS2Op3M8GQBDKRGSOOvBI/HH1qNjHHqQ/taaa8PVkjEauAO2eg/X86kVrWXWTc6VEum6fF/rDcS+Z52Dydx4P0DD1pMZNZLLrup+c+n299HbJvMJYRoh65JPU8d6q3epXL/aHvbA2VjF8rPIg8sf7rL941PqmsaIrbNMtmdpvvvgqh69Bn1z/AHhVPUr2C40X7PHdy28S8JG06yEt24O7j24obA5W4gebWUnk1Ef2ey/u1kIZm/3RySOO+K6/wrcX+rWl1punNOsMa7nZYRGzj/aJO0Csyx8QW+kQG11CPT7xnAP7pxHt57jv0x3ptvFeXl04tLmGKGQEpZ20gOfdyOgx6/4Uk7ivc5XxZ4wvbkt4ZR47Fg4HnRSqwceh2DqfQ4/lWho+t3ug6RFplppUtsuAJJSjK8vHUkjv7VlMZj4sNmjWMKJ88n2OMzEY4w+FOD+PWuviv7S8vY0nvryW7jwI1lyWX8M8VYK5kfZbKESsumvBPIN8jhsB/X5j8x/Squj6dHd3ou5Egks7ckjBKrkcdup/z2rX8Tedezm3sneWMjExwiK3/A2OCMZ+7mse88Oxiwhhhubi7ePDskGVjiA/2jwTj2xSGV9c8S6zLq32HSbeOAEEGd4MhBj+Ak88e2adMmkXRMc13LCyjM80mftEp5yE44qbRHtb2786zimuXgBU71LqCcdDnbn6H+lb0+nadJaArNHFcMfmUrwBx2P+FTuJSdjmtY1u3vfD8Wh+GbGfS13AHEIaWYYOSSCcdPUGq3inQnGlabBHZM08a/PLNkOf+AjPHuMdPeuz0/w+Rbvc2EOAo/1s6gLwOxfnHGOK4vUL6MXTW2oXy3t4uWYRxuQo7ZJI5+nFPcdz6JhvEeOe3hCxMpJiWdsn6e446VxN7dXd/cy2c8EdpODkrL/qGH94c8HPvThrIt5PLvVlcKckdMe4PSugmS1tba31G3Q6ishGItn7wDvnPB/CmAzSbCUWCw3Niuox9EaOZsj25II/A11mkeA/CetQtaSwyRXRGWinUiWJvVSSQR+dYFvqX2PxBaW1tby2nnsCS/yqh91P5da7rxtpWpadHHq9i6XbxY3LtCv9Vb0+tLYDjfBFtd+B/FOpaH4jvIVsLjK2VyYT5MoP8MnAAOOODir5+H0EWpyy215ZW0cuXa2QZgY56qM8ZqprsF14vtbN9UgcyRYdJU6q3oSM10Vl4et5Xhi1eWMQquPOiOdx9G96YHITeAbjWnmtEsFRofuXkLDa3tgnn9Kt3/hzRYLODRPEenSRX3PkXNo3lkkY+bb930rvYb7UtMtpINAhh1CxgyA0r7Nn49SOvasOa4m8XFbe6S2F/HzGvmFAw/2WHU/jQByFvdX2ixvod/PFcRKS0MpjDTqvYMvfA747U77VY2dhO39oxsdp5U+Uw/4CQQO1dXp7eGba8+zapbXNh4ktuVVmImmX1jb+NeD0q9rcelapbPd21npurTIn7y1ukEE546DOPm+vegDyjw5FpviFZbyyvpIry3Y72u4Bh8ZB+YbT685/Opda0LU7kQ3psIpogfnubSUOn/fXB/z1rRbSNMv5ZbjRba50+Qg77G8ODn2IPSp/DWhPdWd8LDVLjRboceRMu+3lH8vb1oA47VJoCDbWWoJEx/1sFwd6ZHbr/LFXdJl8Pxaa9rqdi2oT9m09juX14HJH51n2Fvax6lcWGt2F9aTbzid1CLOSe2Oo69RWb4smaLUrS0s4J0lGPLntJSCP94cigC+0u64ie0uUj02M48hgxlGOuTnI/EGnq+jy6gktjcXEM5GWhYo6OOeucH8sVakMslgssWqyrf7cSQy2/lSSfRwMGsZAkFi6zwWZgdiWiuLfLluDnOOT79vxoA0V823vXTw6r2Kn5Z0ndkhx34bcPzqlr+qzKn2TSVe7nIO57aKNFQ/9dFyB+K1qaNDd6g0NtbrezqoyqvcoMD0Abt7Vh6hrV74d8YxWsunHR7Rz96O38ozn03KNrfpQD1N7R7O/fRRc3M1jdY4ZZZSsw/4GCAfyHpVy60yeLSFeLzRGvJEKLtHrljyRmsfxfq+o2dudStlktoFXdid1fPH93Gc1k6Dr1xrlkbu3F1CBn5hKDAxHqvUetAGpqM9rqNjDa6af7LuGwJbu3bzS/qDuJHbtWz4X8QTWtz/Y+nO1xKi/NggTOce67RXCQ6/q0t/NdWclqLi1kMJbynkTPrgdB9cjrXc+HdZ+2wFr/R0j1dh8spgMQfj+Fl7cUAS+Iv7M1K8JbRL/APtJVxuFwxPr1UbcdaytYuruPT47Bk8i2b5TDLFlQP8AeUjp64qpqguJr94PEF5LEUJeEwwZVfbeOSP96s/UPFWsSBbXTI7W8sIiA0sEYJ49VxyePWgRbNlo2jLax6XDHHeSYLPbnzM8++WP4kVvXNpZJpD3N55tzfKuV8zZbovplRknnHbPNcre3OoeLtPa2shawPbn5gxSORCPYZxSWGnz2Zae9H2m4jXC/bgXiA9j90fWgZb8D6xplz9pvNcLXVsNwEVpb+UMj+85JZvyArFvbhbzxE9zFcW9lorDK2xTIPORzjdnFbGhaxpyTsyWEl/qJJIeDmJPx6EfSl1LXxdXxQWVnOnSZeCyk9sjp3qdRGfcXGozeVbyXN1BZStgLLEcyr/s85HfuOtaLSxh1t7fTy0EaBXW4Ybs/QBj+ZqUvJrt1DCuorBbQDi1QGVxx+Y/CrNvObDUJS0sIjHBW2gA3D/bYnNMZz8th9uSaLbBarn7yRhRj/e4/Gn6dc6Tp9nLYrLukcEO8THcRjn5gMD8a3I9EvvEaTv4es5pL4ZMbS/JGOoyByWqbTNEvLG+h0W6ih1TxHJ8xtA3kxRfVQck80CPMryxW2s5Ws9Z1N7QNvaFwU2+o80jOOOnHQ1puwvtNh1TT7a3R4Fx5ychfXdISefoa9S8U+A5tK097zxbZ211AcEpE4KQnrwuee3rXm9rYvczLFpXljQG+YPODIYz7fw+nBpvUZL4Jl1S9eaee1W4tkBxLMxYOfYnn9K1xq9tNa3UOuB1zlYbGD5Ay+pIwayTMl1dtZaJqdzFb2/EswwB/uqOorTa70+1u4jb6Wt3cdHmdPNYn1Y44/8Ar0lcRS0PULayFxCkAJlJCRxjbtB67s9frUmoz/Z540iVJHJ52DKr9eOT+NS6ov8Ap6X08pEmRsV3Cxr9EHf8awNVuJRqcEskrTydVhRhGrDtleSR+P8A9YBaHT3cd8yKbi6H2coSEBIG3HoMD/PeuZTVJELyW4txGWIVnwgI/I1Z8R648cMCXbRYYcJEDsXjvz/Wq7G0v4kENtI8nVnAH5c/X9KYHoelmw1jTTctG11ZzjAkQ4kgJ9eO3r7UzwvBcaXc3VrNexajbqS8LMAXUdcUnheXSLyFrIMLBXyYjICF+g5J9O1UHsp57qe1gd5ru1bcrhijEZ67gdxHtikO51+laleeJvNitVimktzt8skCQ4PYZ9hXpcWpXNz4Ne0jDQSxJ5chxllHptIPGOK8h0SOWLVrXV4IFh1OE4kIOzevAwST7V6D4l1lEsX1jQJBNKV23OnTna7+6Etj16k9aYEejap/Z95bRTXEUMEuEW5hYtCT6MDnaa7LVWvAXs5LWNi3MM0Y2H8DjH5461w/glorqxvJtQtpktrgZ2Oqt5R54wjYH1H6V0fhW9v1klgspJtS0uIYaCdg0qL22s2GP0OaATua9nBdtCszzeTfQriRFUEyDsGFY1pqVxc+IGisYLCGZWJSGaFkyR3z0z9Kx7qNbvWprrTrq6ManDo5JMZGcr/z0X8DW9pcFpqNiwvkmdY+Qq3AZx/tAtgn8KAL3xJ0F/EPhdYDZltQV1aOWCQh7Zu7q2Mn6Y5rL1LQtSHhWKO81RtYnt0DPJNbhJ1GO2zB49xXVaZf2z27RW15czFB/wAvClnH1Aw3515/rE9vqWsm8m1SS/tYHKtavCB5B9VbCHHHv9aAINZ8EvqHhqC7gnn1JUHmFGIimUZ5weOmCOT+dT2AtdW8MxxeHYZ49QtxtlSRTk47MB16dRWqdL8PoBcWmtXli82fljnZkJ/2o3zj8MVR8KalpCeIL3TdVFr9tB3QXkNy5Mi+ykAofoT9aAOL17W4NRMnhvxXZpYyum2N7v8AdgHsUYkZ/XtWDF4GntQll51w2xspqFzCQkg7BWxz+X416V4p2a3HJa3hS5igbdA1wQJlx9YsEfXn3rK0XR9f1S2eGzbTVEYyI3YrnHomW/MYpAji/EvhTUZHhhsLOLU5iOMXBVz9FwQc+gPeksPBuri2a3utGmknPSK4kdHwfQHj/wDVXrFjY3Wq2ZtYvKs7y1OWaeJ0Vj/ssDxgircWoeKzaeTFp1nqCIdhkdzgHpkNksfXOPxpi3PG9Z02+0SO3sJ4DCJcKkEkmyX/AIDnH6HtW5pfhWHUbcSahNb4jAwomYzI3qd3f8a7XxDBrUtpENT00xoDu+2SXRmSPn0BDAfWsYtPprSQy3Ju7aVf3nlYXAP90svH4ZoAqHwvpyTbr67mvQowiuuWP1XoR9MVJZalpXhXw/rF39nt3EFu0i25bylcgcBkI5JO3jNIsmiWunvFaarHtzkQyrskDf7yrzzjuBXMa7p9te6bcWmqLPFb3GBut7hegORncfUDrnpQNHmnwY1SKDxxBaahKEtdSPkyO8nlgOeVJbtk/L/wKvpnUbnwmtodOfSmvrhk+Vs+chPbMoP0r5/8JeB/Dtz4u1S01XUrm0srRYZYLgsrD5hk7iuOc4xj8a9U8Q6rpuh2qjTNWv8AUMAAxabY72bJxlkwF/E5ouNiaZ8P0VpLm+1y3E8ufL023kbyowemFyeffj8K4b4iWGq+DRH9n0Z44rhtgmubrhugGFADfme1dbf+IZp7KEWloXhPWRYIoZFPuV+6c9sj9KsaDo2reJ7RjPCsVtDwb69xIVA9i288d/f8aRJ5z4e8I382sO8d3PFdAb22x/uyO2eCMDtyOldlcaBd6raCKW4haZflG0uTn2iXj8ga7ixnbwZarDpYm1gSAtNcJIsEMeP7zO5YfgGrO0DxXc+Jtfe08NaTbrOmfNvoJmKJ6je2C34CmM4e98OjTxFba61yrNgCR4CrduiAA/p2q9F4cjtLASael1FY4yZWhCs2OeT1P09q9Si1uXSbqXTtRsJbu/UbtybOe+S7k59awtM1C91fWZhNqC28ByFhZ1CR/wDbQg4PTgZ+lAHnM+l6hrji10yCVWkXAigh+zPKO/7zP9e1dhp3gZ/D/h3bepbWILF5YQd7MT2aU9fwzXYwaxZWT3FvYTNdOy4kuoi0rLjH8TYHT+6MVk6R4R0zxBc/bbXVru1MbbnkiZUZv0Pp1J/CgDn7VdQfVIhoiGzbG1Rbvh39gByB7k1s33he80fS7zW9dvLKwljG9ZROVcnr87kE547H1o8UXkMEv9m+CYLjU9ciAdtQnuyYkwOAzg5z7KK563TW9Ult5tZa2uNWQhVjAkk3ey+g46kj3oAsapfy654Wgn1e8uLsIw8uCJAiuvqS/LflzWH461mHVvCkVjpklvpMWzDpFtWSQDtgZwfpWn4ngup/EFtp+r2kFxNgMLC2n2ovf94F4/Oqmq+B0a5+0XMdnZmTjyEDInT1YDP4ZoA8h0+b7Lp76bp+my2rN8gucgSH/a3k8VrQ6lHoOl22j/2nKGm+Z5oowWJyD80hHvXY2mm6Boc7WVy76jfSHMdrACgHu2QB374q9f8AhkRMHht7RLhwCquvmYGPYjH60Cuef6zZ+ZZifTbl2uY13Kbj94JMD1GAPwrntPnvLi1e6uLOIXycKYxkAD69/wA/x6V2bWt6l3OkttJcTR8Nn7i8eg6/jisiXRJ7+8Mk0syxrglFYkL9EHAIHc0DObj829vVvLi3e5lQ4TC7UVuPStSUDRzv1eVrR5iSsMW1iOnJ3DHr/nNdYYpZLiO38NW7DYv72ebDSds9No6fWtGy8Hf8JLKxtIG1KeFcSTSD5R2wGI9u39KTt1AyvFtpos0sl34S1E2LXPzS2l1+8izjptPKn3BH0rW8CXizQix1VWW9iGYbqE7l+mOvb0rzWPWo4buJNRtGe2m4SUIf3Y6ZP6c13HhnUrS0zE7tFxvivFy34c/MKF5ge1+ANT0qa3e012GIz5x50igA8+w47flVL4nWK6cLNtPmgm06UhWUSFZF+kg4x9TXEReMJRIql7b7WCFBPyiT8Of1qK/1SC+LNJHPb5+/GXKKT6g9D3pgdPo2oxaNdRwQyOgIziQ7v1P+NaF7qZlvYbzS5wkoPJB2Sfg3IP0NcJe2utW+n/btNt5p7ZRlpVYOQPTZVvwPd22u2072hZrpDtkiLFCT67SB/hxQB63J4svdNaD+07MXcMi43qoWVfqBwR1+7WbYayyaxldRnZHOVWSLeqj0bCg1wdz4ti0i5Sw855UB+ezmOSnuFPT14xVu+15dQsd0TQ3Fgww4DFZIj7EdaAPZ5JrLXLJra5Szun2/PbPghvpkZH9KzNNm00xtbWMJjkX5PIucyFD2AbdwPxrzSLULeysUCTm8gzkSYIaP2PNdzZ+HxqujwXCXKxzFd6SiMNH24ODntQBy/jPw6Vu41mttVtg7g/u5ke3Y98Z+Ydu4qvrfgOe506K+0jWXjeIfPazuVLewYf8A161/E1xrFlatZ6vbTXm0Zikjy0b8dm5wfrXDaV41e9uPsd3FcLeq2EgkBVtvtjG6lZbgdrBoOkap4deLzZLK+CfPBdkNvOOzDDYPs1c34H03Up7S7sYluZCkhDQSnzcDOQUlYZH616L4S0/QNRjDzSQzX3Roi5VlPXocH8qn8a6TcWtg1x4c1ibSb+MZRBGJ45P9ko3TPHIIpitrc5KVdVulSxv5723gX/lusIZk68M68kfWsyO9ufD95MkVyYAvCT2Kysknp5in5f0NSG08VazapcX2paf9sA2utvOwHTncCOD7dKXw/wCHbjTnk+2PHcQvkGRpgoQnuNv9aBl618WTatYva6pBdXNwc7ZoIVYAf7Srj6dKt+Hbm5u7j+yr63haxLYR7ObkfVW6H19K53VND1Wx1BJrOODUrVuTJZMplj92AILf/WrH1yW088G21QxatGMlVb7O7exyDQB3XjazvNDt1axia5tUG7z5P9dH/ujac1wU/irWZZAb6zuLeI9JG+R3+oZh69h/9bqfAWqadebZNfn1WzvIhhZZpXMbHjnd0P403xo1lrGprFLaT6lZr8yTrHlNw5+8DlaTv0A8tkkjvPG2rXcKRzSG1gfE6sVDdDkDHb6812mm6sDYeXb/AGLT5HXLiKYqufUKc/rWXoV1JY/FW4CQ2rGTSVCCWA3ChRJjOOTkdOtauq6jFfai9pe2+mAKOZo0+z7R7qQDRbqFi5NFcS6E8b6xFfXCnK+Sitg+69Tj6j8Kv6XpesS6dE95NYbIlDLIyKuOvb5m/WuYuobexMZ03UJ9TTOSMMY19QcDOPxres7K31hF+yvYDaMPHFIyFD6sCcmmI63R/sHiDTG07X7TzYM7PMIWCI8/w4Ct+Io1jwTBZWZg8L6JM1yoASaXU5Qie/zOSa5a8l1jQykej28+rRPgPFb3A4/4D3796oa/4nutPhR9Rs7nRVbC5WVo2OR6jNJtIbdh+uaBqOmrbN42ntkt3faPsIa4mk9irdfrirU9rafZ5BojaktkoBaLyUR2+o+UjPt6iq2hPLqMomgnuNPmK5juGdpWdcdmJyKfZ2WrR3spW8uVYn5miYMT6k4GcUwINQ1rUl0hbfSlt4g/34Y40MpXuWkYfL+BrG062TY8Hhxrm8JObtBdu8anuGklyOx+7xXa2fhqxvPOe61F7+6P3oJFZx07hfy570eGfCaate3VpcWtpp8UOfKFs4OfqB0+hoA1tG1Gx0zQ0s7Ga2s9SlXEkpfz5OR1Ut8vr149q5PTmhtNakh0s3ep6nPnz7uY7mHc4LEIMeiiuiudGi8Myltal0yTTyTsjJ8ueU/4ewo1STSrrT/N09YrDYMo1smW46gkd6AOb8R6fLoks165lO7mWczLH5Y9iTx+ArCXUoP7PYabciaGTO66vFZm6c4Y9f1rp7G3n1BDHFpM8qqcrNeH7x9fb8awpvD18daP2u3ncnhZ3TMUYPoq9TyaLAYi/a7ttul2qGOPPmXMwAXj+6BXXeFFW0sriQqLy/YEHeTtbjsoG4n6V0Vz4RCWEENxqMsVmVz5ZUqZT22xj5j+NZ0N7/wjCSxaPp0Ntu+V7q+bDEeiofwoFoWrMG5t40uLS5nJYGSC2jVFH1GST3611Gv2dpZeHZbhorfRLBFyzNGrTyHHCjPAJ9Oa5i38WvDFHslNvk9SqxqTjPH6VDrUUWs2keqa+kc1tAd0LTvwzf7KnjPTnFAzU8KeHtGi0s6jdSG3S5z5cTMu9vckZ5+lW49T8HeFlKanqMc08pz5WN20eoH4DmuI1ZR5S395dzQW207IIxucjHcnoPyrE8L+H9V8X3N5cQ2P2awQ4jlmOS5z/wDXoA8o0me0uYz9lAE6/wCuiUsRjr34HB9auJrUJk+wwDakhwwIOVP4dv8AP1x/KubbZLcxvDKuMSZ+b0HGen5/Wq41FkuGmmsWnj4bzbc4bA7gE8/1pCOyjuGtLaSO5hMqx/MsjgFRnr0qxYeI5A6Qxv8AarPOJIF2ybcZyQOtUoL+PUNOE+m3Qu9q7XVlMc0XttI5HPbP6VS0Ga70/VhNIIrq1kOWjlHI5Pfp+HbnrxRcLnov9nXVtZG/8I6pLHaSf66MOWCH0KH5l/WtDTzYXljEuuhPtaZaLUYMpIfrg4NcrdX9tCyXls0luAcEqSu0fVeo+vaqkWtuhnlsJY5Vkz5m35lY+/v9aYzqNXudLmv4pbi9kOoQfKZ1TLBfUnGPU4Oajv2u21C0l0jUtMuImwWWSPynfpxkcH06CuN06883zfLWGN26xTgwg98qTwexwPStKzvJLNfKvbSzltZOnnId/r8r5PegVzt7W5v/AO2vIg+z6PKAP30uWiY/QdB9c9a7b+3dY8MWsU2oWltPat1nsJAkbDH3v7ufpXlum6lIZ4rC3jlYDHlMkhJX6YYHH510mr3klxHFZGUwXIX94hXy1kHvg4/GgZ3vhfxFp2qTvE5Z4Jjkwy/N9dpB6fhXJ/FDRLTT7+3vtJlW4hyFkhXbOyf7o+8PzxUtikixRpcQfZyo+WWH5ZV9+PvD8KyNbvL3Sb5DqlzE9lNwl5bFmcE/31Uk/jx/SgDotOtYtUtYJb1r2GJQAJ2iDFencdOtP1qPUfCSG4stWnubCf8A2N2Pfk/1rLsm1e8R7ZrzzrAjIkt8MSPRlYqR09TUccrSubK2RpZYjk29xA8Tcd9x/wDr0AZ13rWox3ELfbJtkjfNPbopIHcEN1r0KKC3ubCE6dex6lfuBhWHlgntuxwPy/8Ar4ulaTPp+7W9N0m1gdeJwX3gj+LcOwx/kVv2OqWdyIrvTdNtUuD8reRKrRMeOw4/rQBxHjbS9Q0i5gvYbi40y8b/AJdIpFZJvofr9Kz9PuLzUsjVp4UbB3PJDEJoz7kcN+vWvQvGmqPa2IuWtLdZM8CcN5JPvtz+dc4L9rzybqSCwcLjdFGquo+hOD/KgDDj8T3ulbLG0n0zV23DCtCpYD0ILBP5VujU45tkus6MNLdgMtAzJG31IJGPz/GpbmyhvrkXVvoumLZDHmtEEjbGO4LEe9Uks5/Ed2ItHsbi4tIm2slwNsSfQ4K9vWgDlfENrf6T42ttZt9S0ptLliERWKVftGwnOAVAJGecE0vi2C/WaK/06OC5RsFWvEbfg/3Tn613H/CESaJZz3l1cpp0Crl2EKuijPorcflTvBPh0axex36SWt7aRnKTM/mK/wDwHgigDjLbWfEV5GnmXEFpbx8mJUTc/fsB/MVoXWp6X4glghv7DTgYiMYPlSMee5Lc/j/jXoOv+Hbq3ujcWHhy0uyRgC1uFh/NWAB/76FeX6xpsun6/EdShl0G4uP9XakJIsv/AANCwz7E0Adb4i1LTdIsUXRobjTLiQAeZJMoVx+Dc157q1q+pXdrcaxdNAqtzK+Qh/Uj8zXVz+GLySUT6rHBCCoaOUmMN/48WI6DtXZ+DNPjvI2jvpdPmK/KjNtmlz6LuyuPwoA4LVL7Q5UitYdXvpmVRl40Vk9/u5xWjb+L7LTbCGx/tCWztRyzfYgGl556fMa6vXdC8NWsoh1GS2BY8Je6j5X5Iuf0C1JceIPD3h3T/Is30uFyAse2IDPpgHBb65NAFvwxq82oRFPDtqBZt80k92hixx/d5/WsF9YsNE1ubTdKtI7ZpOZWt1yshz2YHrk+naq2n209xdyX+qiWO1kOYyzhCRjoFOAPqB+NRa1pumRW7XNndpBfO3EVtL500v8AsnNABa2Oi2evvfRNfapfkZma5Xzkh9l3/KvSrmpa7Y6rbGLT4fKKt80dsgkkc/QZx+Vcdpia9NqQg8QW0lnbEZFvEMkjn77ZODj2/wAK6SyjsRq4iivf7Ntd2WNvBJI7D/eI4z9D+WKAOqsdTtIdFSK8SW0ijGWkuI2dx9FxxVbQNRt9cv8A/iRowhQ/vb2+ZWk+kcXX8eBWF4iSw8+CPSrS4mGMNdXVztx9F7/hjrWpp+iPZ23mXD3LCT7sWWhQ+hb+JvyoAv63qLaVffZtIaOG7m5e/wBQm8xgO+1Cf8B7V5T4inSbxILndHqFxGf3l5MWITudv8PTJ4Fek30E1navLZ28dxJnojYCDHIyxHH0rJurS30+ySe9llSQjiNR8p6fxE5P5CgDAiit9Y2NZJcyMuPMu7teFPoq5/rVq70SadUmunN79n/1SoMKCPocd/esi41Yx3TtLeTQqDhQ+Nq9emDk8D1rRttZuBApWS4ntxg+fP8AImP9kcn8BSTT2Ar6PpDX+sQtrUEvlg/6mP5Ilx/e9sV69Z3llbwJDDb/AGmOMbQ0KkRL7L2NcbpukreWp1rWrxYdOX/VQHjzR9OPb1qrq/jyGaFLe3eeCKIgJFbJwBjrnHP/ANemB8tvrFzNF5EsxvYU+VGb5tpHqDz/AD/xzLfUYYGlimk8l1O4rvJjbHoOn4Ukuox31yJIEFndIRm3YYL/AEP58cUfarZ7sQ3YltZQOBIqjdn17EfX6UbAblhqsLt9otJFNumFzsC5x+A789K6DSNTgkuWGqF5UcZSWMHcntx+PU9q8/gknTU3ihjj89+EZlKo2e2Dxn3GOa6WNb+TSZLW6tfNjJI80NtkHupGSR3/ACpX6Bc2rC7kkvrqGBFEKE7ZFflxnuvIH4n8K2NFt0Mkt1YxwibkSBQA3445rh/Dj3WlXJls7jBQkESruLA9ifWuqh/tBG+1QGLyXbLBBggehHXrTAkaOG1mkmAeYMTmKVSoB9iDk/iagh1ESRlIlZYZCFL4+6D7D6+hrSupIp7Ym3iNzOo2tFu2np/dPBrO0bxFHGpt30pxK5Ie3lQAgZx19PcelK4tFoad/a3Gl2cFxazJcK4BHk4Kg8YBCjjH0rp9O8XOumpFrLuZB0jkizGw9FkX5gfqPSue+VIUazkjCH70QBJQ+5PHWqV9fSxfuprW2nifkOCylfUjrzTGdvY6ppct4Iba7vbJZONglJQHnn51JJ7VsWyaTZzgara+fISPLvFXLKPw4/SvNrCKXTp7e9tbu1v4ncFYbxGaSI+xHNeuaX49tmtFs7jSlluH+Vop0GG/3W7fjQBzl/8AZ11+OS9v54bIgeW4Gxvr8o/rV7U9AuniWS0muNQQ8x3CYV4/TkYz+Jqnr19ZyWVzFYWN1KJM77C8O8D/AHWqn4Ovbq3sP9FElkkRybTzG3KPb1H1yKAuWtIfUYzcHUpLxnhHE0qmIge5GVb9K1NJEk9o93BdThBndNCRLHnphuOPyrK1l5daZZdM1a8UIf3kE0W12GOcEAZrU0e3trO0eTTp4LSUriRJTlW4/iUUAQXuvJFfJZavDNdW7cHyXbb+IBA/lW/b2MNvsvfD4nvbfblrX5lx/wACAGO3euLdNRkv2kv4ovJUkh0hbYwz1U/41pRTI8ELaJdS6dLkj7TK7PGT9AcUAbUF3NeX+dKgtXumyHtr+58sp7Kwyx//AFVa0bRdUs9beefR7yC1f732SZznPbKMD+ZqbQtNl1W42eJxd3ybcLdQONv1AUZH4HvWrfXdj4aRLK01fU7hHG0Wcr/Pg/3WZeB9TQBF4i8I6xq8irBcTyaeeTb38nmg/wDAWbj8cmsKDwXoMWovFJe2VlfWxB8toPLUH3Odprd+yaXFGBZeK9S0ubIZlvZTIvuAGwPyNXCNRnl8hLnSrzRCv7yUQxxknHPykkH60AR3em+IWigFn4qtYLRcbRCq4Yem4dvfHaqOrLdWVobhJmur5RhWiUX7E/7jfMOgqeztvCfh2UtFaT2yyEkzQTO6rz3UcAc+natTUtd0uy06Y+GriH+0ZB+7doJZUB9W2igDjn1fxk2nqlwkoRl6fYcNj3HG38zXAWmiwHxFJcazp94u/J4uPILHP8WzlvoTXptjp/ivXLIt4h8WWMWefKt0WJCM9Cud35msTU9Fk08bbDT49YYcMtoXlP5HH+fWiwFDQtA0/WL2TzETTYE/jmVp+g4wWPH510emp4Q0CaQf2hNqM8mVJlgWQqMfw4GV/OsFPFF/o4S1vDcWUcnAguXWLaPTZuJqXU9ctbm3kttKurC3uiMmRwrMfw9etCQGlqD3/wA76G7W1lnJjvZQhk+kYBJ/E1zl3HqF3dQHVBYzzBgFMMxBjGf7qgfkc1meHre51kywrprzSR8NNezlmf8A3cY459O9dbp1/wCG/D5SHU72K2v5F2rZwQgux9snNAEvifUdF0Kwt1WCTU7x12t58gQL+AI4z7GqU89zrWmCQ6VYxW0YB84MTj2AxjP4Vs2XhcSw3N/fQW1nBMD5T38w3H6KAAPpWFeW1tZaWy3Zk+zE8LICsZPXIUdRz1oAlm1u2tGtjbWk80wwocSMY8gen/6q1Y9TsXQtqWpn7WV3CBVyCPTJyB/OuO1B7q3tvtWlvbpbxjLERkuQBzt5ya5VfFltql5FLaadLPeE7C1wAkhOf7o5A+tAHqt34s8RatbyWmkRW2jaYoIkmij3zEdyrEhVPvtaufvNFiS1P+ky+axzNJFM7XMpx/E/Bb8MVh6nq+oQpCJZoUfHEcXzOi98+lYur61KLbfaXEit/E7OEB/EUeoWJdTe5tp1SONvOH+rT5pJMZ7gZ/U11VtZW8+kQT+ML+O22gGO0yJpm+idF/LNeYjW7naHW7EQ6tLGeW/H+fpU9p4i+xQNc27qZZBgTyfvHPuG6dqQttD03VfEb2dosel2uwJ8qNPlivvzjH4Vg2mqTyxvPcXYaVm5f/XHp7EYrF00tqQa71EGKM5y878t+AP+c1Bqd+kO2DThE6A53QxCUH8+lAzyOzhgJW4tZElt15dH5IJ4+o/L+lLrFr9sEbR7iOoyCQfce1Yem7pLhmDvG0algYztPAJ/pW3o947rLdBI45l25KDAbqMkdCaL3CSfQ0dKl8mxNnKTLEeMsCSvHY44+lbGnbldktbtRKB8qsuAcH1PU9+9czrTbdOMwAySMrk7eamtNzeFlvDLL5gkYKnmEqv0z9KNUtRK/U7KO6eZWVYN9yv3kQbtx6kjH86y21udL/yZ4rmJem+Jgxj/AN5euPwH86w7++mC2nK+YCpWQDayn6jH6102m3R8T6fJHq8UUsttzHcBdsoI77vwHTFMbetkT6jPdpAktpdxTuDxKpCAdeueh5/lS6LqP226DarEWnGCssYZX+vcelT29pA1qDPElxKhYLLMoZxyB17/AI1BPEluRLAojfOMrx/npSF5mhqF49xqJYX1k0aZG6VTDMv4gjPTuKYbS+h+eK6XymPzrI3LA/Uc/gayYYY76WcTIu5dvzqMMcj/AOtW74bnYzS2JWMxIAQ2wbh1749qE7oZreH7FLwtbXeoJbnqjHKofqcenvXU3c14mnjSb+1tbiSIYivIgAfTOeM9+5rm7PUprRWSJYjC33opE3of+AnIH4YrfjDyxrHHNNAj44ikI2/7uc4pgN0/UkhRoNReSW4HCl4/NAHGPu8j8jWkLl5Y42bW7UKPuxuBn6AnDDp3FZUF5NDctaSlblNzYeZQX4P94YNa2r2CyQR3DTz5XBCAqF/ln9aBIuPNc2FsZFvIw0oJCzxEgfRs8VU5WLdcWr3oc8yxSjj6Vb8G2MOuC5W/3MIwCAjbex/wrW022WzmKwMwAbb8wByMHqSM9qBmMWMFkhtZprderRvKGDdM5I6VY0+S3kgAt4pbbj51iQXEb/UDGK0PHE5sNEN7bpGJwM8rweO471xOm6pfrbR6kt26ySZ3woiLG3I7BQf1oFsdr4S1aL+1vJSS/sgCdzWqFY29iGBFdxe2Vtry/Zjq2pt0326mLdj15H8u1cLNdveaSpIWFHDbkiJA7epJ/Wud8FeJNSOrTeVMIUhcoEQcEc9ScnsO9Juwz1aTwla2VnusrTUJplGVWZ0YE/TPFeX+Jl1/Sr77Td6V9mQnbH5QZ3f6LuwfwzXq3hjXr3XtUurO6ZYYYlODBlWODjkkn9MVW020hu/El3ZYeFASTJG7eYfqxJpgYnh97fUtNhXU4PE8Mz4DeZlUPsdowBRceHoNElMttqUtvZS/L9nsG3u5x1fjp616Bf2S2WnMVmuZlXjZLKxB+uMGua8QajPa2CzWgigBHKJEuDxzzjP60Ac/qGhyROj+dFJG3zAPOE4756/SoLzxBq2mxJa2kqW8GRkWg81z6/MQf51uN4muLLT2mhs7AyKm7LRkk/rXB6f4z1rxZPNbSTxaXGDsJ06FFYj6uGP5UAQ+K10u4RZ30BrrVmICz3WGf6kDBpml6Xdx2ayNLaQyH73lxJG4/E9PSo5NEg0vWpLa2nuiZHBlmkk3ySfUkfyArct9SXSZVhtrCydm6zTI0j9PVmI/SgDS0HRdDSATanr0u5zkw2zEFv8AeYZJ/Ait2GXS9MnZ7TTra2x/q5Tb5mYf7781RjeWaG3mWZ4JJxljFhSM46HGR+FQpY2kl1JFLbrNIfvXEzNLKeo+8xPp2oAXWNeu/ELmxtheTzAcwwoVH4sBj071x1xpmoWMpWeKHlvlSZw+36BfrXUoH02V4LSaWOHBOwNheM9hx+lcjOxmv5p58SzBSwZ1BGfpjH6UAGrR6hNF5Ut+jEg4jidUB+pA7+ntXKGO50aORpRawwKCzeRy5HfJIz+tamoaxcrIXcRyYYqFccDr6GuR8a3cl5DFHcBGjYKdgXaBk+gxn8c0AWItVt9SVpLL7OtshO+eUsoyOv8AnBqlqmo20Uf2fzVZz0aOAqD07nJ7+n+FYlndOLs2ZVDGGZckc4Gfw7elS3cXz+WjNGpXdmPCtwD/ABAZ7etArX3IfsryfvNUVfLblYQAA31A5p7paRzJdzQhnHEacbR0/D8z2qSztEazupASphcxqAAQcY5OQcmma3plqqQRvGJWkYL5knzMufTsPyqXKwbIvWkLX6vOiebJj5mLZQe2enp0qDUTMj+XaghxyXODuHt14zUuhMY7ttOi/dwDGWX7zZHfsfyrUbTLdJppU3By204xz19qE3ewH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound reveals a sausage-shaped structure in the adnexa (arrow) consistent with a fallopian tube carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge Londono, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39170=[""].join("\n");
var outline_f38_16_39170=null;
var title_f38_16_39171="Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information";
var content_f38_16_39171=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/8/26757?source=see_link\">",
"     see \"Ovine polyvalent crotalidae North and South American snake antivenom: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/24/19845?source=see_link\">",
"     see \"Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6516314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CroFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some snake bites.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to antivenin (crotalidae) polyvalent or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dust mites, latex, papaya, pineapple, or sheep, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a blood clotting problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12143 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39171=[""].join("\n");
var outline_f38_16_39171=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016538\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016537\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016542\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016543\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016545\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016540\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016541\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016546\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016547\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/8/26757?source=related_link\">",
"      Ovine polyvalent crotalidae North and South American snake antivenom: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/24/19845?source=related_link\">",
"      Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_16_39172="Trabectedin: Patient drug information";
var content_f38_16_39172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trabectedin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     see \"Trabectedin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11392727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Yondelis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11422189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11401451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2898959",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat soft tissue sarcoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11401310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3001682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trabectedin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11401312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11401454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3001761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Redness or irritation of the palms of hands or soles of feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698246",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11401314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11401453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11401315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16067 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39172=[""].join("\n");
var outline_f38_16_39172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392727\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422189\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11401451\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11401310\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11401312\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11401454\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11401314\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11401453\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11401315\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=related_link\">",
"      Trabectedin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_16_39173="Naltrexone: Drug information";
var content_f38_16_39173=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naltrexone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/53/27477?source=see_link\">",
"    see \"Naltrexone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ReVia&reg;;",
"     </li>",
"     <li>",
"      Vivitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ReVia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Opioid Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Alcohol dependence, opioid dependence: Note:",
"     </b>",
"     Do not initiate therapy until patient is opioid-free for at least 7-10 days as determined by urinalysis; consider naloxone challenge test to confirm patient is opioid-free if there is any suspicion since urinary opioid screen may not be sufficient proof.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 25 mg; if no withdrawal signs occur, administer 50 mg on day 2; maintenance regimen: 50 mg/day; alternative maintenance regimens may be used and include: 50 mg on weekdays with a 100 mg dose on Saturday; 100 mg every other day; or 150 mg every 3 days (degree of blockade may be reduced with extended dosing interval regimens and doses &gt;50 mg may increase risk of hepatocellular injury)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     380 mg once every 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F199552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution. No adjustment needed in mild impairment. Not adequately studied in moderate-to-severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F199553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution. An increase in naltrexone AUC of approximately five- and 10-fold in patients with compensated or decompensated liver cirrhosis respectively, compared with normal liver function has been reported No adjustment required with mild-to-moderate hepatic impairment. Not adequately studied in severe hepatic impairment. Use is contraindicated in patients with acute hepatitis or hepatic failure.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, microspheres for suspension, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivitrol&reg;: 380 mg [contains polylactide-co-glycolide; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ReVia&reg;: 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10120352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vivitrol&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM206669.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM206669.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F199530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered with or without food. Administration with food or after meals may minimize adverse gastrointestinal effects. Advise patient not to self-administer opiates while receiving naltrexone therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Vivitrol&reg;: Administer I.M. into the upper outer quadrant of the gluteal area; must inject dose using one of the provided needles for administration. Use either the 1.5-inch 20-gauge needle or the 2-inch 20-gauge needle (for patients with a larger amount of subcutaneous tissue overlying the gluteal muscle). Avoid inadvertent injection into a blood vessel; do not administer I.V., SubQ, or into fatty tissue (the risk of serious injection site reaction is increased if given incorrectly as a SubQ injection or into fatty tissue instead of the gluteal muscle). Injection should alternate between the 2 buttocks. Do not substitute any components of the dose-pack.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ethanol dependence; prevention of relapse in opioid dependent patients, following opioid detoxification",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naltrexone may be confused with methylnaltrexone, naloxone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ReVia&reg; may be confused with Revatio&reg;, Revex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vivitrol&reg;: For intramuscular (I.M.) gluteal injection only",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Combined reporting of adverse events from oral and injectable formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 25%), insomnia (3% to 14%), dizziness (4% to 13%), anxiety (2% to 12%), nervousness (4% to &gt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10% to 33%), vomiting (3% to 14%), appetite decreased (14%), diarrhea (13%), abdominal pain (11%), abdominal cramping",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (&le;69%; includes bruising, induration, nodules, pain, pruritus, swelling, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (12%), CPK increased (11% to 39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Suicidal thoughts (&le;10%), depression (8%), somnolence (2% to 4%), fatigue (4%), chills, energy increased, feeling down, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Polydipsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dry mouth (5%), toothache (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Delayed ejaculation, impotency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (2% to 10%), GGT increased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps (8%), back pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angina, atrial fibrillation, blood pressure increased, cerebral aneurysm, chest pain, chest tightness,  cholecystitis, cholelithiasis, colitis, COPD, dehydration, delirium,  diaphoresis, DVT, dyspnea, ECG changes, eosinophilia (transient), eosinophilic pneumonia, GI hemorrhage, HF, hypercholesterolemia, hypersensitivity reaction (includes anaphylaxis, angioedema, and urticaria), ischemic stroke, leukocytosis, lymphadenopathy, MI, narcotic withdrawal, palpitation, pancreatitis, paralytic ileus, paranoia, PE, perirectal abscess, pneumonia, rigors, seizure, shortness of breath, suicide , tachycardia, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naltrexone or any component of the formulation; narcotic dependence or current use of opioid analgesics; acute opioid withdrawal; failure to pass naloxone challenge or positive urine screen for opioids; acute hepatitis; liver failure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Accidental opioid overdose: Patients who had been treated with naltrexone may respond to lower opioid doses than previously used. This could result in potentially life-threatening opioid intoxication. Patients should be aware that they may be more sensitive to lower doses of opioids after naltrexone treatment is discontinued, after a missed dose, or near the end of the dosing interval. Warn patients that any attempt to overcome opioid blockade during naltrexone therapy, could potentially lead to fatal opioid overdose; the opioid competitive receptor blockade produced by naltrexone is potentially surmountable in the presence of large amounts of opioids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute opioid withdrawal: May precipitate symptoms of acute withdrawal in opioid-dependent patients, including pain, hypertension, sweating, agitation, and irritability; in neonates: shrill cry, failure to feed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eosinophilic pneumonia: Cases of eosinophilic pneumonia have been reported and should be considered in patients presenting with progressive hypoxia and dyspnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatocellular injury:",
"     <b>",
"      [U.S. Boxed Warning]: Dose-related hepatocellular injury is possible; the margin of separation between the apparent safe and hepatotoxic doses appears to be &le; fivefold.",
"     </b>",
"     Discontinue therapy if signs/symptoms of acute hepatitis develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including anaphylaxis, has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection site reactions: Serious injection site reactions (eg, cellulitis, induration, hematoma, abscess, necrosis) have been reported with use, including severe cases requiring surgical debridement. Females appear to be at a higher risk. Patients should any injection site pain, swelling, bruising, pruritus, or redness that does not improve (or worsens). For I.M. use only in the gluteal muscle, do",
"     <b>",
"      not",
"     </b>",
"     administer I.V., SubQ, or into fatty tissue; incorrect administration may increase the risk of injection site reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thoughts/depression: Suicidal thoughts and depression have been reported in both alcohol- and opioid-dependent patients; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; not studied in severe impairment. Use is contraindicated in patients with acute hepatitis or hepatic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; not studied in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Vehicle used in the injectable naltrexone formulation (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis following injection of other drug products that also use the polylactide-co-glycolide microspheres vehicle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Detoxified opioid addiction: Patients should be opioid-free for a minimum of 7-10 days; use naloxone challenge test to confirm patient is opioid-free prior to therapy if there is any suspicion since urinary opioid screen may not be sufficient proof. Use of naltrexone does not eliminate or diminish withdrawal symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Emergency pain management: In naltrexone-treated patients requiring emergency pain management, consider alternatives to opioid therapy (eg, regional analgesia, nonopioid analgesics, general anesthesia). If opioid therapy is required for pain therapy, patients should be under the direct care of a trained anesthesia provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2914152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Evidence of early fetal loss has been observed in animal studies with oral naltrexone. Reproduction studies have not been conduced using the sustained release I.M formulation. There are no adequate and well-controlled studies of naltrexone in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F199535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Vivitrol Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     380 mg (1): $1320.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Depade Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $128.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Naltrexone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $427.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ReVia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $366.01",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F199525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For narcotic withdrawal; liver function tests; injection site reactions",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adepend (BG);",
"     </li>",
"     <li>",
"      Antaxone (ES, IT, RU);",
"     </li>",
"     <li>",
"      Celupan (ES);",
"     </li>",
"     <li>",
"      Nalerona (CN, PE, PY);",
"     </li>",
"     <li>",
"      Nalorex (BE, FR, GB, IE, NL, PT);",
"     </li>",
"     <li>",
"      Naltrexin (KP);",
"     </li>",
"     <li>",
"      Narpan (MY, SG);",
"     </li>",
"     <li>",
"      Nemexin (AT, CH, DE, PL);",
"     </li>",
"     <li>",
"      Nodict (IN);",
"     </li>",
"     <li>",
"      Nuo Xin Sheng (CL);",
"     </li>",
"     <li>",
"      Nutrexon (ID);",
"     </li>",
"     <li>",
"      Opizone (GB);",
"     </li>",
"     <li>",
"      Re-Via (MX);",
"     </li>",
"     <li>",
"      Regental (UY);",
"     </li>",
"     <li>",
"      Revez (AR);",
"     </li>",
"     <li>",
"      Revia (AU, BR, CZ, DK, EE, FI, FR, HK, HN, HU, KP, NO, NZ, SE, TW);",
"     </li>",
"     <li>",
"      Trexan (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Naltrexone (a pure opioid antagonist) is a cyclopropyl derivative of oxymorphone similar in structure to naloxone and nalorphine (a morphine derivative); it acts as a competitive antagonist at opioid receptor sites, showing the highest affinity for mu receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 50 mg: 24 hours; 100 mg: 48 hours; 150 mg: 72 hours; I.M.: 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Almost complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1350 L; widely throughout the body but considerable interindividual variation exists",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized via noncytochrome-mediated dehydrogenase conversion to 6-beta-naltrexol (primary metabolite) and related minor metabolites; glucuronide conjugates are also formed from naltrexone and its metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 21%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Variable range (5% to 40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 4 hours; 6-beta-naltrexol: 13 hours; I.M.: naltrexone and 6-beta-naltrexol: 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: ~60 minutes; I.M.: Biphasic: ~2 hours (first peak), ~2-3 days (second peak)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as metabolites and small amounts of unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kleber HD, &ldquo;Naltrexone,&rdquo;",
"      <i>",
"       J Subst Abuse Treat",
"      </i>",
"      , 1985, 2(2):117-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39173/abstract-text/3007777/pubmed\" id=\"3007777\" target=\"_blank\">",
"        3007777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JE, &ldquo;Naltrexone and Hepatotoxicity,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1986, 1(8491):1215.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39173/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor PG and Kosten TR, &ldquo;Rapid and Ultrarapid Opioid Detoxification Techniques,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(3):229-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39173/abstract-text/9438745/pubmed\" id=\"9438745\" target=\"_blank\">",
"        9438745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tang J, and Weiter JJ, &ldquo;Branch Retinal Artery Occlusion After Injection of a Long-Acting Risperidone Preparation,&rdquo;",
"      <i>",
"       Annals Intern Med",
"      </i>",
"      , 2007, 147(4): 283-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39173/abstract-text/17709768/pubmed\" id=\"17709768\" target=\"_blank\">",
"        17709768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9679 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39173=[""].join("\n");
var outline_f38_16_39173=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709163\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199546\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199547\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199577\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199550\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199551\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199552\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199553\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199527\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199513\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10120352\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199530\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199528\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199585\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199575\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199533\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199517\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299740\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199522\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199523\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2914152\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199556\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199535\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199525\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199536\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199516\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199532\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9679|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/53/27477?source=related_link\">",
"      Naltrexone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_16_39174="Cortisone acetate: Drug information";
var content_f38_16_39174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cortisone acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/18/19750?source=see_link\">",
"    see \"Cortisone acetate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/33/16918?source=see_link\">",
"    see \"Cortisone acetate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If possible, administer glucocorticoids before 9 AM to minimize adrenocortical suppression; dosing depends upon the condition being treated and the response of the patient.",
"     <b>",
"      Note:",
"     </b>",
"     Supplemental doses may be warranted during times of stress in the course of withdrawing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"     Oral: 25-300 mg/day in divided doses every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Physiologic replacement:",
"     </b>",
"     Oral: 25-35 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/33/16918?source=see_link\">",
"      see \"Cortisone acetate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If possible, administer glucocorticoids before 9 AM to minimize adrenocortical suppression; dosing depends upon the condition being treated and the response of the patient.",
"     <b>",
"      Note:",
"     </b>",
"     Supplemental doses may be warranted during times of stress in the course of withdrawing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"     Oral: 2.5-10 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     20-300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Physiologic replacement:",
"     </b>",
"     Oral: 0.5-0.75 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     20-25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F154732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insoluble in water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of adrenocortical insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cortisone may be confused with Cardizem&reg;, Cortizone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Increased appetite, indigestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hirsutism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataracts, glaucoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkalosis, Cushing's syndrome, delirium, edema, euphoria, fractures, hallucinations, hypersensitivity reactions, hypertension, hypokalemia, muscle wasting, myalgia, osteoporosis, pancreatitis, peptic ulcer, pituitary-adrenal axis suppression, pseudotumor cerebri, psychoses, seizure, skin atrophy, ulcerative esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cortisone acetate or any component of the formulation; serious infections, except septic shock or tuberculous meningitis; administration of live virus vaccines",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tesamorelin: May decrease serum concentrations of the active metabolite(s) of Cortisone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F154725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Limit caffeine intake.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6472607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Cortisone is found in cord blood; endogenous maternal cortisol (active) is metabolized by placental enzymes to cortisone (inactive), regulating the amount of maternal glucocorticoids reaching the fetus. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to cortisone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F154717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May need diet with increased potassium, pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus and decreased sodium; may be taken with food to decrease GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cortisone Acetate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $108.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adreson (BE, HN, HU, LU, NL, PL);",
"     </li>",
"     <li>",
"      Altesona (ES);",
"     </li>",
"     <li>",
"      Colirio Collado Cortioftal (ES);",
"     </li>",
"     <li>",
"      Cortal (SE);",
"     </li>",
"     <li>",
"      Cortate (AU, HK, MY);",
"     </li>",
"     <li>",
"      Cortioftal (ES);",
"     </li>",
"     <li>",
"      Cortisate (DK);",
"     </li>",
"     <li>",
"      Cortison (NL);",
"     </li>",
"     <li>",
"      Cortison Augensalbe Dr. Winzer (DE);",
"     </li>",
"     <li>",
"      Cortison Ciba (CH, DE);",
"     </li>",
"     <li>",
"      Cortison Nycomed (NO);",
"     </li>",
"     <li>",
"      Cortisone (FR, NZ, PL);",
"     </li>",
"     <li>",
"      Cortisone Acetate (CY, IL);",
"     </li>",
"     <li>",
"      Cortistab (GB);",
"     </li>",
"     <li>",
"      Cortisyl (GB, IE);",
"     </li>",
"     <li>",
"      Cortone (IT);",
"     </li>",
"     <li>",
"      Cortone-Azetat (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Oral: &sim;2 hours; I.M.: 20-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 30-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Muscles, liver, skin, intestines, and kidneys; crosses placenta; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.5-2 hours; End-stage renal disease: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Beitins IZ, Bayard F, Ances IG, et al, &ldquo;The Transplacental Passage of Prednisone and Prednisolone in  Pregnancy Near Term,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1972, 81(5):936-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39174/abstract-text/5086721/pubmed\" id=\"5086721\" target=\"_blank\">",
"        5086721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39174/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39174/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39174/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39174/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sun K, Adamson SL, Yang K, et al, &ldquo;Interconversion of Cortiosl and Cortisone by 11Beta-Hydroxysteroid Dehydrogenases Type 1 and 2 in the Perfused Human Placenta,&rdquo;",
"      <i>",
"       Placenta",
"      </i>",
"      , 1999, 20(1):13-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39174/abstract-text/9950140/pubmed\" id=\"9950140\" target=\"_blank\">",
"        9950140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9297 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39174=[""].join("\n");
var outline_f38_16_39174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154760\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154730\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154747\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154731\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154732\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154710\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154697\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154713\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154711\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154767\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154758\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154716\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154701\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299096\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154706\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154725\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472607\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154734\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154717\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524430\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038589\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154700\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154715\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/18/19750?source=related_link\">",
"      Cortisone acetate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/33/16918?source=related_link\">",
"      Cortisone acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_16_39175="Vilazodone: Drug information";
var content_f38_16_39175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vilazodone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/55/34677?source=see_link\">",
"    see \"Vilazodone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11595292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12891739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viibryd&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11416304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Selective Serotonin Reuptake Inhibitor/5-HT",
"      <sub>",
"       1A",
"      </sub>",
"      Receptor Partial Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11596741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial: 10 mg once daily for 7 days, then increase to 20 mg once daily for 7 days, then to recommended dose of 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of vilazodone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing vilazodone and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate vilazodone in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving vilazodone and potential benefits outweigh potential risks, discontinue vilazodone promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume vilazodone 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment for concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Strong CYP3A4 inhibitors: Reduce vilazodone dose to 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate CYP3A4 inhibitors (eg, erythromycin): Reduce vilazodone dose to 20 mg once daily in patients with intolerable side effects",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11596762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11596763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh class C): Not studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12891740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viibryd&trade;: 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11595299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11595294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241524.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241524.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11596765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11416245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11595897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (28%), nausea (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (9%), insomnia (6%), dreams abnormal (4%), fatigue (4%), restlessness (3%), somnolence (3%), migraine (&ge;1%), sedation (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (3% to 5%), orgasm abnormal (2% to 4%), sexual dysfunction (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (8%), vomiting (5%), dyspepsia (3%), flatulence (3%), gastroenteritis (3%), appetite increased (2%), appetite decreased (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculation delayed (2%), erectile dysfunction (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (3%), paresthesia (3%), jittery (2%), tremor (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (&ge;1%), dry eyes (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Night sweats (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal feeling, abnormal taste, cataracts, mania, panic attacks, pollakiuria, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11595413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either vilazodone or the MAO inhibitor); initiation of vilazodone in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11595419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Vilazodone is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticholinergic effects: Relatively devoid of these side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin, or other anticoagulants. Bleeding (including GI bleeding) related to SSRI or SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly; reversible with discontinuation of treatment. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Vilazodone is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizure disorder: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Agents which lower seizure threshold: Use caution with concurrent therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Electroconvulsive therapy (ECT): May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of vilazodone therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F11598314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2D6 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C19 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12608867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vilazodone. Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11595944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid or limit use and monitor for increased effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Management: Take with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava, gotu kola (may increase CNS depression and/or increase the risk of serotonin syndrome).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11595409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11595410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. An increased risk of teratogenic effects may be associated with maternal use of other SSRIs. However, available information is conflicting and information specific to the use of vilazodone has not been located. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy. Consideration should be given to using an agent with some safety information in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11595412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/consider risk:benefit",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15236088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if vilazodone is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Maternal use of an SSRI during pregnancy may cause delayed milk secretion. Long-term effects on development and behavior have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11596764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Viibryd Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 &amp; 20 &amp; 40 mg (30): $165.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Viibryd Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $165.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $165.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $165.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11596781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patient periodically for symptom resolution, mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks, signs/symptoms of serotonin syndrome; akathisia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11595949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vilazodone inhibits CNS neuron serotonin uptake; minimal or no effect on reuptake of norepinephrine or dopamine. It also binds selectively with high affinity to 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors and is a 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptor partial agonist. 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptor activity may be altered in depression and anxiety.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11595984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~96% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively hepatic, via CYP3A4 (major pathway) and 2C19 and 2D6 (minor pathways)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 72% (with food); blood concentrations (AUC) may be decreased ~50% in the fasted state",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: ~25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (1% as unchanged drug); feces (2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins-Obstetrics, \"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39175/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39175/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39175/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page ME, Cryan JF, Sullivan A, et al, \"Behavioral and Neurochemical Effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-hydroxytryptamine(1A) Receptor Partial Agonist,\"",
"      <i>",
"       J Pharmacol Exp Ther",
"      </i>",
"      , 2002, 302(3):1220-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39175/abstract-text/12183683/pubmed\" id=\"12183683\" target=\"_blank\">",
"        12183683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rickels K, Athanasiou M, Robinson DS, et al, \"Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2009, 70(3):326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39175/abstract-text/19284933/pubmed\" id=\"19284933\" target=\"_blank\">",
"        19284933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, \"The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/16/39175/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16102 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39175=[""].join("\n");
var outline_f38_16_39175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595292\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891739\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11416304\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11596741\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11596762\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11596763\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891740\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595294\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11596765\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11416245\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595897\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595413\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595419\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11598314\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608867\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595944\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595409\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595410\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595412\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15236088\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11596764\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322884\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11596781\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595949\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595984\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/55/34677?source=related_link\">",
"      Vilazodone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_16_39176="Optic pathway glioma";
var content_f38_16_39176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Optic pathway glioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Lawrence D Recht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/16/39176/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/16/39176/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 26, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic pathway gliomas (OPG) (also referred to as optic gliomas) are low-grade astrocytic tumors that occur in the optic nerve, chiasm, or both. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2071?source=see_link\">",
"     \"Diagnosis and classification of low-grade gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=see_link\">",
"     \"Classification of gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classification, diagnosis, natural history, and management of OPGs will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic pathway gliomas account for approximately 2 percent of cerebral gliomas. They are typically slow-growing neoplasms that occur mainly in children, with 90 percent diagnosed before the age of 20 and 75 percent before the age of 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic pathway gliomas (OPGs) are classified by anatomic location and by whether or not they are associated with neurofibromatosis type 1 (NF1, von Recklinghausen's disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-grade gliomas may involve the anterior visual pathway of the optic nerve (25 to 35 percent of cases) or the posterior visual pathways (chiasmal and postchiasmal).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anterior visual pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior tumors can be subdivided into orbital, intracanalicular, and intracranial prechiasmal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/2\">",
"     2",
"    </a>",
"    ]. These tumors occur most frequently in prepubertal children, and most are classified as pilocytic astrocytomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2071?source=see_link\">",
"     \"Diagnosis and classification of low-grade gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tumor may appear either as an infiltrative lesion or one that is sharply demarcated from the normal optic nerve. Invasion of the leptomeninges or a dense fibroblastic reaction is frequently seen. As the tumor progresses, it compresses the optic nerve. As a result, the optic nerve becomes demyelinated and optic atrophy develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Posterior visual pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior tumors may arise in the optic chiasm, hypothalamus, or anterior third ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/3\">",
"     3",
"    </a>",
"    ]. Chiasmal and hypothalamic lesions present at a mean age of about three years. Histologically, these are typically pilocytic astrocytomas. Occasionally, gangliogliomas occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Association with neurofibromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;OPGs are the most common central nervous system tumors associated with NF1. If all children underwent screening, estimates indicate that OPGs would be found in 15 percent of those with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. NF1 tumors more commonly involve the anterior visual pathway, while tumors in NF1 negative children are more frequent in the posterior visual pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/9\">",
"     9",
"    </a>",
"    ]. OPGs have also been described in patients with NF2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history and clinical presentation of OPGs in patients with NF1, along with the potential role of screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;OPGs are generally classified as low-grade astrocytomas, although they have a range of growth rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/1\">",
"     1",
"    </a>",
"    ]. For this reason, it had been suggested that some OPGs may be hamartomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most evidence supports their designation as true, slow-growing neoplasms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OPGs are virtually identical histologically to pilocytic astrocytomas seen elsewhere in the nervous system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2071?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis and classification of low-grade gliomas\", section on 'Pilocytic astrocytomas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Their clinical behavior may be aggressive; this is never observed with hamartomas.",
"     </li>",
"     <li>",
"      Allelic chromosomal loss occurs in some pilocytic astrocytomas, suggesting that they are clonal lesions arising from inactivation of a tumor suppressor gene. As an example, loss of chromosome 17q (the location of the NF1 gene) is demonstrable in some cases, even in patients without NFI or NF2, suggesting some link between this gene and tumor development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      OPGs in patients with NF1 exhibit a characteristic loss of neurofibromin (which functions as a negative growth regulator for astrocytes) and increased RAS activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of OPGs usually develop over a course of months to years and depend upon the location of the tumor.",
"   </p>",
"   <p>",
"    Orbital tumors most often present with proptosis; less frequent findings are strabismus and symptoms similar or identical to spasmus nutans (pendular or dysconjugate nystagmus, torticollis, and head bobbing) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Unilateral visual impairment is a relatively uncommon presenting symptom, possibly due to the young age of these patients at presentation. Funduscopic examination may show edema of the optic disc",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pallor due to atrophy.",
"   </p>",
"   <p>",
"    Chiasmal and hypothalamic gliomas often present as large masses even though they are typically well differentiated and low grade (most often pilocytic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/2,11,19\">",
"     2,11,19",
"    </a>",
"    ]. In patients with chiasmal lesions, the chief complaint is usually impaired vision. Obstructive hydrocephalus also may be noted at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/11,20\">",
"     11,20",
"    </a>",
"    ]. The diencephalic syndrome, manifested by progressive emaciation and failure to thrive in an apparently alert, cheerful infant, can be seen with hypothalamic gliomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38233?source=see_link&amp;anchor=H7#H7\">",
"     \"Poor weight gain in children older than two years of age\", section on 'Increased needs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocrinopathies due to hypothalamic extension are present in 10 to 20 percent of patients with OPGs. The most frequent is precocious puberty due to involvement of the hypothalamic-pituitary-gonadal axis; this occurs in up to 39 percent of children with NF1 and chiasmal OPGs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, all children with chiasmal tumors should be screened for endocrine abnormalities.",
"   </p>",
"   <p>",
"    The primary presenting symptoms tend to be different in patients with and without NF1. While patients with sporadic OPG are more likely to present with signs of increased intracranial pressure and hydrocephalus, those with NF1-associated OPGs are more likely to present with precocious puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of OPG should be considered in any child presenting with unexplained visual loss, monocular or asymmetric nystagmus, a diencephalic syndrome, or optic atrophy.",
"   </p>",
"   <p>",
"    The diagnosis is best made by magnetic resonance imaging (MRI), which allows visualization of the entire course of the optic nerve. MRI also delineates hypothalamic involvement more clearly than computed tomography (CT). However, CT is superior for bone detail and detection of intratumoral calcifications, which suggest low grade histology.",
"   </p>",
"   <p>",
"    Three typical patterns are seen on neuroimaging studies (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55797 \" href=\"mobipreview.htm?26/35/27187\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tubular thickening of the optic nerve and chiasm",
"     </li>",
"     <li>",
"      Suprasellar tumor with contiguous optic nerve expansion",
"     </li>",
"     <li>",
"      Suprasellar tumor with optic tract involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of tumors in the region of the hypothalamus includes suprasellar germinoma, craniopharyngioma, glioma, and infiltrative disorders such as sarcoidosis, lymphoma, or Langerhans histiocytosis. Cyst formation is unusual in optic gliomas but may be seen with cases exhibiting extension into the hypothalamic regions. The presence of a cyst within a suprasellar mass is more suggestive but not diagnostic of craniopharyngioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24520?source=see_link\">",
"     \"Craniopharyngioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suprasellar masses without apparent optic nerve extension or optic tract involvement are less likely to be OPGs, and biopsy may be required for diagnosis. Although some experts advocate biopsy of any lesion in the suprasellar region, we recommend that a biopsy be obtained if the lesion does not appear vascular, and there is no apparent primary tumor from which the lesion could have metastasized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical behavior of optic pathway gliomas (OPGs) is unpredictable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/28\">",
"     28",
"    </a>",
"    ]. Spontaneous regression, malignant degeneration, and metastatic dissemination through ventriculoperitoneal shunts have all been reported. In children, the variable clinical course is more a function of location than specific histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/19,29\">",
"     19,29",
"    </a>",
"    ]. In adults, in contrast, OPGs tend to be histologically anaplastic, displaying aggressive clinical behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracranial and intraorbital tumors of the optic nerve have an excellent prognosis in children with a median survival of more than 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/1\">",
"       1",
"      </a>",
"      ]. Approximately 5 percent of optic nerve gliomas invade the optic chiasm; locally invasive recurrence can also develop following complete intraorbital excision.",
"     </li>",
"     <li>",
"      The outcome for patients with chiasmal gliomas is usually less favorable. However, some children with chiasmal gliomas may survive for long periods without treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/11,33\">",
"       11,33",
"      </a>",
"      ], and cases of spontaneous regression have been reported, all in patients with NF1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/34-36\">",
"       34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with OPGs associated with NF1 tend to have a better prognosis, at least in part due to the predominance of anterior lesions. However, compared with patients without NF1, those with NF1 have approximately twice the recurrence rate following complete excision of an intraorbital glioma, but a similar prognosis following radiation of a chiasmal glioma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/8,37,38\">",
"       8,37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the prognosis for survival is good in most patients with OPGs, visual acuity may be seriously impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. As an example, one study reported that 5 of 27 patients (19 percent) were blind as a consequence of the disease or its treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/39\">",
"     39",
"    </a>",
"    ]. In this series, treatment had an inconsistent effect on visual function, with 19 percent improving, 52 percent retaining stable visual acuity, and 30 percent deteriorating further following therapy.",
"   </p>",
"   <p>",
"    Although the prognosis for survival may be better in NF1 patients with OPGs, significant visual impairment is frequent, and it is unclear whether treatment with either chemotherapy or radiation improves the prognosis for retaining vision in these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to children, the clinical course of an OPG in an adult resembles the behavior of the tumor's histology, which is more commonly a malignant glioma. In adults, malignant OPGs can result in rapidly progressive visual loss, and middle-aged or elderly individuals may present with the rapid onset of blindness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Tumor invasion into adjacent brain may then become apparent, leading to death within a few months of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/47\">",
"     47",
"    </a>",
"    ]. Standard radiotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy of these lesions typically leads to disappointing results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of optic pathway gliomas (OPGs) is controversial. Treatment decisions should take into account the patient's age, the presence or absence of NF1, and the location of the tumor. A multidisciplinary approach is strongly recommended with close consultations with the ophthalmologist, radiation oncologist, pediatric oncologist, neuroradiologist, and neurosurgeon.",
"   </p>",
"   <p>",
"    If possible, a period of observation should precede treatment initiation in young patients and those with NF1. Tumor size and visual function should be closely monitored both clinically and by serial brain MRI; an untoward change in either clinical status or size on imaging may signal the need for active treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/28\">",
"     28",
"    </a>",
"    ]. Adults should be managed aggressively, as dictated by pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Optic nerve tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation without specific treatment is appropriate for tumors that exclusively involve the optic nerve until there is evidence of either extension into the optic canal or progressive visual compromise. In patients with symptoms due to visual loss or abnormal eye movements, serial neuroophthalmologic examinations and MRI scans can be used to assess tumor progression.",
"   </p>",
"   <p>",
"    A minority of children with isolated intraorbital gliomas and NF1 will experience tumor progression within 5 to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/7,8,24,37,39,49,50\">",
"     7,8,24,37,39,49,50",
"    </a>",
"    ]. Chemotherapy is usually the first choice in this situation. If there is progression associated with proptosis and a significant cosmetic problem, and there is no vision in that eye, then surgery should be considered; however, surgery invariably results in complete loss of vision in the involved eye. Radiation therapy is generally avoided in children with NF-1 due to an increased risk of secondary malignancy and other sequelae.",
"   </p>",
"   <p>",
"    In a child without NF-1 radiation therapy may be considered if there is progressive visual loss or radiographic progression after a trial of chemotherapy. Radiation may prove useful to save, and at times improve, vision in an eye that has not lost vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/51\">",
"     51",
"    </a>",
"    ]. Upon further evidence of progression, amputation of the nerve within the orbit may be considered. It has been recommended that resection be performed flush with the chiasm to prevent centripetal extension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/52\">",
"     52",
"    </a>",
"    ]. However, there are few data supporting this concept.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Posterior tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive imaging studies are not able to reliably differentiate OPGs from other lesions that may require different therapy (eg, craniopharyngiomas, germinomas) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/27\">",
"     27",
"    </a>",
"    ]. For this reason, a pathologic diagnosis should be established in all cases of pediatric diencephalic tumors except for those patients with NF, in whom the diagnosis of an OPG is virtually certain. Biopsy of small lesions should be carried out carefully, so that remaining vision is not jeopardized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following diagnosis, patients can be managed with observation, tumor resection, radiotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy. Although these treatments may improve tumor-related symptoms, there is no evidence that any routine intervention enhances long-term survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tumor resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular shunting is indicated when an OPG is causing obstructive hydrocephalus. However, the role of radical resection in other settings is controversial.",
"   </p>",
"   <p>",
"    Traditionally, patients with OPGs have been treated nonsurgically or with conservative surgical approaches due to perceived morbidity and the uncertain influence of surgical treatment on outcome. A retrospective series examined conservative surgical strategies in 33 patients with OPGs who would have been considered eligible for radical surgery in many centers today, but who were treated with no surgery, with conservative surgery (&lt;50 percent resection), or with biopsy alone, followed by adjuvant therapy with radiation (29 patients)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy (18 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/40\">",
"     40",
"    </a>",
"    ]. After a mean follow-up of eleven years, only five of these conservatively treated patients had died (three of tumor progression, one of acute shunt malfunction, and one of intercurrent infection). Twenty-three surviving patients had functional vision in at least one eye, 12 required no endocrine replacement, and 16 were capable of meeting standard academic requirements.",
"   </p>",
"   <p>",
"    There may however be benefits to radical resection other than prolongation of survival. These include a delay in the time to disease progression in older children and a delay in the need for radiation therapy in younger children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 45 patients with extensive gliomas of the chiasm and third ventricle, 77 percent experienced stabilization or improvement in visual function after radical resection. The surgical mortality was 6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 16 children with chiasmal or hypothalamic tumors treated with radical resection, three infants died of progressive disease. However, 11 of the other 13 were alive without disease progression four to 54 months following radical resection; six did not receive adjuvant chemotherapy or radiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with progressive chiasmal OPGs with or without NF1, five- and ten-year progression-free survival is better in patients who receive radiation. Despite this, the survival rate after 20 years is equivalent to that in patients who have not received radiation. There is also no clear evidence that earlier intervention for chiasmal OPGs changes prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/7,22\">",
"     7,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, external beam radiation (&gt;45 Gy) has been used in patients with progressive tumor to diminish tumor bulk, decrease recurrence rates, prolong recurrence-free survival, reverse the diencephalic syndrome, and improve vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/1,2,20,57-61\">",
"     1,2,20,57-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy can arrest progressive visual and neurologic impairment, although the maximal effect can take years to be observed. In one retrospective study of 29 patients with chiasmal OPGs, the probability of at least a 50 percent decrease in tumor size at 24 and 60 months was 18 and 46 percent, with a median time to response of 62 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/57\">",
"       57",
"      </a>",
"      ]. Stabilization of or improvement in vision occurred in 81 percent. The 10-year freedom from progression and overall survival rates were 100 and 89 percent.",
"     </li>",
"     <li>",
"      Two separate series evaluated patients with glioma of the optic chiasm or optic nerve who were treated with radiation. After 10 to 13 years of follow-up, the 5-, 10-, and 15-year overall actuarial survival rates were 94 to 96, 81 to 90, and 74 to 90 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. Fifty-five percent of the patients in one series had a radiation-induced complication, most often involving the pituitary gland [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long-term sequelae of radiation therapy may be functionally devastating (especially in young children) despite the benefit of disease stabilization and objective tumor shrinkage in the majority of irradiated patients. Significant cognitive and endocrine deficits are most prominent following irradiation in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/57\">",
"     57",
"    </a>",
"    ]. These radiation-induced complications have led to the use of chemotherapy as the initial treatment, so that radiation therapy can be deferred as long as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/49,63\">",
"     49,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Occlusive vascular disease, angiographically similar to moyamoya disease, and usually presenting with ischemic stroke, can also occur following radiation for a chiasmal tumor, particularly in patients with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=see_link\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one retrospective study of 47 patients treated for optic glioma, moyamoya disease developed in 5 of 28 patients treated with radiation (including three of five patients with NF1) compared to none of 19 who did not receive radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/65\">",
"     65",
"    </a>",
"    ]. A second series documented occlusive vasculopathy in 13 of 69 children with OPGs, at a median of 36 months after radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/63\">",
"     63",
"    </a>",
"    ]. The major risk factor was NF1.",
"   </p>",
"   <p>",
"    In addition, malignant gliomas can develop in previously irradiated fields [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/54,67,68\">",
"     54,67,68",
"    </a>",
"    ]. The use of radiation therapy in NF1 patients is of particular concern because of the development of second primary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/68\">",
"     68",
"    </a>",
"    ]. In an observational series of 58 patients, 9 of 18 patients (50 percent) developed one or more additional nervous system tumors, and five of these died as a result of the second tumor. In contrast, 8 of 40 (20 percent) patients who were not irradiated for their OPGs developed second nervous system tumors, and no deaths were observed. A more contemporary study reported a threefold increased risk of second nervous system tumors in patients who received RT compared to those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer radiation therapy techniques (eg, proton beam irradiation and stereotactic radiotherapy) may provide adequate tumor control while decreasing treatment-related morbidity. As an example, one study compared proton beam, three-dimensional (3D) photon, and lateral photon radiation treatment plans based on the same CT data sets in seven children with OPGs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/69\">",
"     69",
"    </a>",
"    ]. When the normal organs at risk for toxicity were studied based upon these models, proton beam therapy reduced the dose to the contralateral optic nerve by 47 and 77 percent compared to 3D photons and lateral photons, respectively. Reductions were also seen for the chiasm (11 and 16 percent, respectively) and pituitary gland (13 and 16 percent, respectively). These differences were all at clinically relevant tolerance levels. Furthermore, proton beam therapy was associated with reduced exposure of both temporal lobes and the frontal lobes. Further experience is needed with proton beam therapy to know whether this approach improves long-term outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the benign histologic appearance of many OPGs, chemotherapy results in surprisingly high response rates. For this reason, chemotherapy is often preferred as initial treatment rather than radiation, especially in children less than age five years, for whom there is a high likelihood of deleterious effects on cognitive function with other treatment modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/39,70-74\">",
"     39,70-74",
"    </a>",
"    ]. The use of chemotherapy can often postpone the need for radiation, a delay that may reduce neurocognitive morbidity without compromising survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/39,75-78\">",
"     39,75-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of this approach in deferring radiation therapy was illustrated in a multicenter study of 85 children with progressive OPGs (median age 33 months) who received chemotherapy with alternating",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"      procarbazine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"      carboplatin",
"     </a>",
"     ,",
"    </span>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     ,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"      vincristine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"    </span>",
"    every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/76\">",
"     76",
"    </a>",
"    ]. This chemotherapy-first approach was successful in avoiding the use of radiation therapy in children in 75 and 61 percent of children at three and five years, respectively. The median interval between the start of therapy and the need for radiation in the 25 children in whom it was delivered was 35 months. Delaying radiation did not jeopardize outcomes; the 89 percent overall survival rate at five years is comparable to that achieved with initial irradiation, and visual outcomes were not dissimilar.",
"   </p>",
"   <p>",
"    Between 40 and 60 percent of patients eventually progress after chemotherapy and require further therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/39,75,76\">",
"     39,75,76",
"    </a>",
"    ]. Patients who have OPGs in the setting of NF1 often have indolent disease, and fewer require subsequent therapy.",
"   </p>",
"   <p>",
"    Various combination chemotherapy regimens have been used to treat these tumors. Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and actinomycin D, vincristine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or carboplatin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , or a nitrosourea-based combination regimen are most frequently used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/70-72,75,79,80\">",
"     70-72,75,79,80",
"    </a>",
"    ]. The following describes the range of findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 78 children with newly diagnosed, progressive low-grade gliomas, including 58 with diencephalic tumors, were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/75\">",
"       75",
"      </a>",
"      ]. Forty-four (56 percent) patients had an objective response to treatment, and the progression-free survival rate at three years was 68 percent. The three-year progression-free survival rate was higher in children five years or younger at the time of treatment (74 versus 39 percent in older children).",
"     </li>",
"     <li>",
"      In a second series, 34 children ranging in age from 4 months to 16 years old (median 45 months) with unresectable low grade glioma received ten monthly courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/16/39176/abstract/72\">",
"       72",
"      </a>",
"      ]. Twenty-four (70 percent) achieved an objective response, while the remainder had stable disease; no patient required elective radiotherapy. The three-year progression-free survival rate for the 31 previously untreated patients was 78 percent and was significantly higher in children older than 12 months (87 versus 33 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of optical pathway gliomas (OPGs) is uncertain, and depends upon the age of the patient and the location of the tumor. There are no randomized clinical trials to guide clinical decision making, and current approaches are based upon observational studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anterior pathway lesions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with asymptomatic or minimally symptomatic OPGs arising in the optic nerve, we suggest observation rather than early surgical intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Optic nerve tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In such patients, lesions should be monitored for progression with serial MRI scans and careful neuroophthalmologic examinations.",
"     </li>",
"     <li>",
"      Active treatment is indicated when there is evidence of progression or lesions cause unsightly proptosis or significant visual loss. Chemotherapy is usually the first choice in this situation. Radiation therapy may be considered if there is progressive visual loss after a trial of chemotherapy. If progression is associated with proptosis and a significant cosmetic problem and there is no vision in that eye, surgery should be considered. However, surgery invariably results in complete loss of vision in the involved eye.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chiasmal and hypothalamic tumors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with neurofibromatosis type 1 (NF1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients without significant visual field deficits, we suggest initial observation because of the relatively favorable prognosis in NF1 patients. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgery may be required if symptoms of obstructive hydrocephalus are present. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Posterior tumors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Tumor resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In young children who subsequently have evidence of progression or have significant visual deficits, we suggest chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgery may be indicated if it is judged that appropriate resection can relieve pressure on the optic apparatus and thereby improve vision. However, surgical morbidity with radical resection in young children in this location should not be underestimated. Radiation therapy should be deferred as long as possible to minimize the effects on the developing central nervous system. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Posterior tumors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"       \"Complications of cranial irradiation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients without neurofibromatosis type 1 (NF1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a biopsy to determine whether the OPG is a grade I pilocytic astrocytoma or another type of tumor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Posterior tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a pilocytic astrocytoma who are symptomatic, chemotherapy is the preferred initial treatment in children less than 10 years of age. For older patients, either chemotherapy or radiation therapy may be used.",
"     </li>",
"     <li>",
"      For children with other histologic tumor types, the treatment depends on the type of tumor. (See appropriate topic discussions).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult patients with malignant OPG should be treated as high-grade astrocytomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/1\">",
"      Alvord EC Jr, Lofton S. Gliomas of the optic nerve or chiasm. Outcome by patients' age, tumor site, and treatment. J Neurosurg 1988; 68:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/2\">",
"      Tenny RT, Laws ER Jr, Younge BR, Rush JA. The neurosurgical management of optic glioma. Results in 104 patients. J Neurosurg 1982; 57:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/3\">",
"      Benes V, Julisov&aacute; I, Julis I. Our treatment philosophy of gliomas of the anterior visual pathways. Childs Nerv Syst 1990; 6:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/4\">",
"      Liu GT, Galetta SL, Rorke LB, et al. Gangliogliomas involving the optic chiasm. Neurology 1996; 46:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/5\">",
"      Sutton LN, Packer RJ, Rorke LB, et al. Cerebral gangliogliomas during childhood. Neurosurgery 1983; 13:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/6\">",
"      Vajramani GV, Dambatta S, Walker M, Grundy PL. Multiple gangliogliomas of the optic pathway. Br J Neurosurg 2006; 20:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/7\">",
"      Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994; 125:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/8\">",
"      Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997; 41:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/9\">",
"      Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 2008; 81:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/10\">",
"      Dossetor FM, Landau K, Hoyt WF. Optic disk glioma in neurofibromatosis type 2. Am J Ophthalmol 1989; 108:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/11\">",
"      Miller NR, Iliff WJ, Green WR. Evaluation and management of gliomas of the anterior visual pathways. Brain 1974; 97:743.",
"     </a>",
"    </li>",
"    <li>",
"     Burger PC, Scheithauer BW, Paulus W, et al. Pilocytic astrocytoma. In: Pathology and Genetics &mdash; Tumors of the Nervous System, Kleihues P, Cavenee WK (Eds), IARC, Lyon 2000. p.45.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/13\">",
"      Whittle IR, Mitchener A, Atkinson HD, Wharton SB. Anaplastic progression in low grade glioneural neoplasms. Acta Neuropathol 2002; 104:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/14\">",
"      Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/15\">",
"      Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007; 61:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/16\">",
"      Lavery MA, O'Neill JF, Chu FC, Martyn LJ. Acquired nystagmus in early childhood: a presenting sign of intracranial tumor. Ophthalmology 1984; 91:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/17\">",
"      Arnoldi KA, Tychsen L. Prevalence of intracranial lesions in children initially diagnosed with disconjugate nystagmus (spasmus nutans). J Pediatr Ophthalmol Strabismus 1995; 32:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/18\">",
"      Koenig SB, Naidich TP, Zaparackas Z. Optic glioma masquerading as spasmus nutans. J Pediatr Ophthalmol Strabismus 1982; 19:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/19\">",
"      Borit A, Richardson EP Jr. The biological and clinical behaviour of pilocytic astrocytomas of the optic pathways. Brain 1982; 105:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/20\">",
"      DeSousa AL, Kalsbeck JE, Mealey J Jr, et al. Optic chiasmatic glioma in children. Am J Ophthalmol 1979; 87:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/21\">",
"      Gropman AL, Packer RJ, Nicholson HS, et al. Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control. Cancer 1998; 83:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/22\">",
"      Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr 1995; 126:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/23\">",
"      Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995; 127:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/24\">",
"      Fletcher WA, Imes RK, Hoyt WF. Chiasmal gliomas: appearance and long-term changes demonstrated by computerized tomography. J Neurosurg 1986; 65:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/25\">",
"      Jakobiec FA, Depot MJ, Kennerdell JS, et al. Combined clinical and computed tomographic diagnosis of orbital glioma and meningioma. Ophthalmology 1984; 91:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/26\">",
"      Imes RK, Hoyt WF. Magnetic resonance imaging signs of optic nerve gliomas in neurofibromatosis 1. Am J Ophthalmol 1991; 111:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/27\">",
"      Barbaro NM, Rosenblum ML, Maitland CG, et al. Malignant optic glioma presenting radiologically as a \"cystic\" suprasellar mass: case report and review of the literature. Neurosurgery 1982; 11:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/28\">",
"      Shuper A, Horev G, Kornreich L, et al. Visual pathway glioma: an erratic tumour with therapeutic dilemmas. Arch Dis Child 1997; 76:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/29\">",
"      Rush JA, Younge BR, Campbell RJ, MacCarty CS. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 1982; 89:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/30\">",
"      Hamilton AM, Garner A, Tripathi RC, Sanders MD. Malignant optic nerve glioma. Report of a case with electron microscope study. Br J Ophthalmol 1973; 57:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/31\">",
"      Gibberd FB, Miller TN, Morgan AD. Glioblastoma of the optic chiasm. Br J Ophthalmol 1973; 57:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/32\">",
"      Hoyt WF, Meshel LG, Lessell S, et al. Malignant optic glioma of adulthood. Brain 1973; 96:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/33\">",
"      Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999; 89:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/34\">",
"      Venes JL, Latack J, Kandt RS. Postoperative regression of opticochiasmatic astrocytoma: a case for expectant therapy. Neurosurgery 1984; 15:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/35\">",
"      Brzowski AE, Bazan C 3rd, Mumma JV, Ryan SG. Spontaneous regression of optic glioma in a patient with neurofibromatosis. Neurology 1992; 42:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/36\">",
"      Perilongo G, Moras P, Carollo C, et al. Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. J Child Neurol 1999; 14:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/37\">",
"      Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989; 114:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/38\">",
"      Deliganis AV, Geyer JR, Berger MS. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 1996; 38:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/39\">",
"      Janss AJ, Grundy R, Cnaan A, et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer 1995; 75:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/40\">",
"      Sutton LN, Molloy PT, Sernyak H, et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg 1995; 83:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/41\">",
"      Dalla Via P, Opocher E, Pinello ML, et al. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol 2007; 9:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/42\">",
"      Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer 2010; 46:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/43\">",
"      Spoor TC, Kennerdell JS, Zorub D, Martinez AJ. Progressive visual loss due to glioblastoma: normal neuroroentgenorgraphic studies. Arch Neurol 1981; 38:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/44\">",
"      Spoor TC, Kennerdell JS, Martinez AJ, Zorub D. Malignant gliomas of the optic nerve pathways. Am J Ophthalmol 1980; 89:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/45\">",
"      Rudd A, Rees JE, Kennedy P, et al. Malignant optic nerve gliomas in adults. J Clin Neuroophthalmol 1985; 5:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/46\">",
"      Dario A, Iadini A, Cerati M, Marra A. Malignant optic glioma of adulthood. Case report and review of the literature. Acta Neurol Scand 1999; 100:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/47\">",
"      Taphoorn MJ, de Vries-Knoppert WA, Ponssen H, Wolbers JG. Malignant optic glioma in adults. Case report. J Neurosurg 1989; 70:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/48\">",
"      Albers GW, Hoyt WF, Forno LS, Shratter LA. Treatment response in malignant optic glioma of adulthood. Neurology 1988; 38:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/49\">",
"      Packer RJ, Savino PJ, Bilaniuk LT, et al. Chiasmatic gliomas of childhood. A reappraisal of natural history and effectiveness of cranial irradiation. Childs Brain 1983; 10:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/50\">",
"      Packer RJ, Bilaniuk LT, Cohen BH, et al. Intracranial visual pathway gliomas in children with neurofibromatosis. Neurofibromatosis 1988; 1:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/51\">",
"      Pierce SM, Barnes PD, Loeffler JS, et al. Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects. Cancer 1990; 65:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/52\">",
"      Cohen ME, Duffner PK. Optic pathway tumors. Neurol Clin 1991; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/53\">",
"      Scott EW, Mickle JP. Pediatric diencephalic gliomas--a review of 18 cases. Pediatr Neurosci 1987; 13:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/54\">",
"      Hoffman HJ, Humphreys RP, Drake JM, et al. Optic pathway/hypothalamic gliomas: a dilemma in management. Pediatr Neurosurg 1993; 19:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/55\">",
"      Wisoff JH, Abbott R, Epstein F. Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg 1990; 73:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/56\">",
"      Konovalov A, Gorelyshev S, Serova N. Surgery of giant gliomas of chiasma and IIIrd ventricle. Acta Neurochir (Wien) 1994; 130:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/57\">",
"      Tao ML, Barnes PD, Billett AL, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys 1997; 39:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/58\">",
"      Wong JY, Uhl V, Wara WM, Sheline GE. Optic gliomas. A reanalysis of the University of California, San Francisco experience. Cancer 1987; 60:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/59\">",
"      Dosoretz DE, Blitzer PH, Wang CC, Linggood RM. Management of glioma of the optic nerve and/or chiasm: an analysis of 20 cases. Cancer 1980; 45:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/60\">",
"      Harter DJ, Caderao JB, Leavens ME, Young SE. Radiotherapy in the management of primary gliomas involving the intracranial optic nerves and chiasm. Int J Radiat Oncol Biol Phys 1978; 4:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/61\">",
"      Kovalic JJ, Grigsby PW, Shepard MJ, et al. Radiation therapy for gliomas of the optic nerve and chiasm. Int J Radiat Oncol Biol Phys 1990; 18:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/62\">",
"      Flickinger JC, Torres C, Deutsch M. Management of low-grade gliomas of the optic nerve and chiasm. Cancer 1988; 61:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/63\">",
"      Grill J, Couanet D, Cappelli C, et al. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 1999; 45:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/64\">",
"      Rajakulasingam K, Cerullo LJ, Raimondi AJ. Childhood moyamoya syndrome. Postradiation pathogenesis. Childs Brain 1979; 5:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/65\">",
"      Kestle JR, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg 1993; 79:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/66\">",
"      Ullrich NJ, Robertson R, Kinnamon DD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 2007; 68:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/67\">",
"      Dirks PB, Jay V, Becker LE, et al. Development of anaplastic changes in low-grade astrocytomas of childhood. Neurosurgery 1994; 34:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/68\">",
"      Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/69\">",
"      Fuss M, Hug EB, Schaefer RA, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys 1999; 45:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/70\">",
"      Packer RJ, Sutton LN, Bilaniuk LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol 1988; 23:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/71\">",
"      Petronio J, Edwards MS, Prados M, et al. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg 1991; 74:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/72\">",
"      Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002; 20:4209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/73\">",
"      Friehs GM, Park MC, Goldman MA, et al. Stereotactic radiosurgery for functional disorders. Neurosurg Focus 2007; 23:E3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/74\">",
"      Li G, Patil C, Adler JR, et al. CyberKnife rhizotomy for facetogenic back pain: a pilot study. Neurosurg Focus 2007; 23:E2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/75\">",
"      Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/76\">",
"      Laithier V, Grill J, Le Deley MC, et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 2003; 21:4572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/77\">",
"      Lacaze E, Kieffer V, Streri A, et al. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer 2003; 89:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/78\">",
"      Riva D, Massimino M, Giorgi C, et al. Cognition before and after chemotherapy alone in children with chiasmatic-hypothalamic tumors. J Neurooncol 2009; 92:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/79\">",
"      Moghrabi A, Friedman HS, Burger PC, et al. Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy. J Neurosurg 1993; 79:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/16/39176/abstract/80\">",
"      Chamberlain MC. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. Arch Neurol 1995; 52:509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5226 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-510B38B3F6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39176=[""].join("\n");
var outline_f38_16_39176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anterior visual pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Posterior visual pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Association with neurofibromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL COURSE AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Optic nerve tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Posterior tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tumor resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anterior pathway lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chiasmal and hypothalamic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5226\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5226|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/35/27187\" title=\"diagnostic image 1\">",
"      Optic pathway glioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24520?source=related_link\">",
"      Craniopharyngioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2071?source=related_link\">",
"      Diagnosis and classification of low-grade gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38233?source=related_link\">",
"      Poor weight gain in children older than two years of age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_16_39177="Hyperplast colonic polyp Light";
var content_f38_16_39177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperplastic colonic polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a hyperplastic colonic polyp shows a serrated surface contour and marked luminal infolding of the crypt epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39177=[""].join("\n");
var outline_f38_16_39177=null;
var title_f38_16_39178="Light microscopy in minimal change disease";
var content_f38_16_39178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71232%7ENEPH%2F58414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71232%7ENEPH%2F58414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy in minimal change disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AY8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3fxk8K6mPtDAAWwKjvnc3Oa5G3so5IGuWyzv83Xkc16JrC2tzqK2kwUzGHcM9hk/4GuGntjaanPZ2e6dSfuAfdNVTlq0d1Kb5bIxPFL3tja2MrEjdkkg/pVcH7TGsznjqPrW9r2m3c9kZLqEGJRxzwv0rk/EME9v4flisWCzEhSw7A+lddG00lfU7XUiqV+qLH9p6fNKbSaUASEBgM9ak05GguzByz2pLIM/fj+tcLpFvObhEcNJcqcb/AMMHNepTaFv02C4S623MaZ3L1PFXVUab5W9ycNiHJOM9mRS3YnTfb4CYGSOx6fnWXf6PHMXdfvHLM3qaZYtI7TSOh+QjzVXow/vCp/EWpW9jpaT2oyjYGSeCT1zSinGSjE2mnhndGBPBPaIGIIXp1qGORXKxoSzNjjPWqljrFxd6rDbSOHW5ZgwznGATW3pGlGPUVL4+9wPWuiXufEdeHx0atNuW6NvSbU28S7+5B5PQVX8TSP8A2XJJvB4I/CtZ4mRX3Egg7ea5jxfMHWC0jG6WRun/ANaueHvzTMaLdSqmdd8K7FWsoZ+6At+Oa9NAymRxxXMeAtNNloyKww+ApHTpXUY4xXkYupz1WzzMbU9pWk0fMfi3wU+n/EF1Kb4ZJjcqfUZzz/KuwsYWklcvkhmJYY71oePLwzeJbjyPmEIWH6nv/OsiS9/s/cQwMr/MSOgxXtqpOrCLe9j0cDh3Cn7u71NSSO0tyEdto9AM5/xrn9S1cw3MywRKkAARMjJAz1z61Rmv2uGd2JO1S7Mx4ArLt4p9TkEipIlkvM0/90DqRWkadtZHpKlCgueq9jRfUZbiRQhfceFA6muSnnmu7x1+fe0nlRqOd5HXiut0CVYdVaTT4W+zRZzJKuSR681u+EtEh0m7bVU0l54zIzxysd2w5JJA+tW6ipp6HnYnGzrq2F0Xcg8P/DK81KxSa8fy2I5AzkV0ulfC2xZ8Xkjsi8AZ711uj+LdPlBjmYwOCQd1b63EDxiRJVbcOoPBryKuLxF2noc1XG4te7JtHinjv4Q3YH2jw3LvIGPKc89exridP+H3jk3nkC18ts5MjuMAevFfVA2soO7OeevWn4w2ex4pQzOrGPK0mckcVXi7qb+8+fpfBHjG02skqTADnBz09q46+17XdOumt7qwuCytyBFkHn1Ar6xCAZHY+1V5bC2mA8yCJz6lQaqGZfzxudLzSu10+4+WF8e3CmON4GRAfuspxXR3NhquvaZCTYyPD99GUkYr3K/8PaPJAxnsbZge5QD9am0f7G9giWqxBE+XavQVrLMIpc0IgsfOUX7SCaPm238FiwlMtxpc7SLyCTu/nXSf21a2sC7pZoZyMogG0D1OK94a1hkB3IhHY461434++Hsh1ie/gDyJMRtTHCDjitaOMjiJctTQUcbTgtKa+Rz8niLTWud1zLudxjBqS7FtqulS2VpeiGSTkMR2FTaV8L7nUNRtXu4nhRGDSMe4HbFeh6z8ONOvnZ4SYJsY3rxzWlTEUabS5jaOOp1k4VVyo8Z0Lwr/AGdfG6uZTJk/L15PTNdvp13HG/DkhSee1ZGqWmpeG9Qe1uw1xbI3yuOeKZY3kLufLPB52Hgg1rNuor7nfDDQVO1PY7J5JEC+U2CxzuJ+bHTFSQzStPiYswUBs9ce1YYvT5MasMoOmPvKcfyqLTJ7m7vCqcpnnH8ia5nTdmedUi6b1R2duiuwdzu38+nvTtWuxBaFgCCpynoM4rNOqR6XY3t7KpkFsMhB69q4aPxtretXMiBIUtkyRujx78/lWcKEpu62Rx1qqi7Mg1LW9cuNRYxXUf7tsrgkDGetet2sUOt+Ere/YATNDklT1bv+oritD0fTtW0+21CZGtizYljz1Nb93q0Xh+xFvaAyW8C5Vexz/wDXp4hqTUaas0YxU4u7ehl27SRxzWzdSeTjrWXezXc8ohtmYRrhTjv7V0UBt7zThLxGWBLA9zWXbIoumjTgLySe47VcHq7nq4dxleVhljpEtw/+n3bBOMohwCPc1auLSysoZfs6KB/ET6UkshiLzTMUjAI6c/h61zuoahJcJ5VkrzSEfMzfdUVUU5M6YQc5X6FO+vXklEFrnzHPX0q3a6ONyLds8jPyeaNK042qtPIQ00g3ZI/lWzGojWKQ8t97d3Oe1aTnbSJpWxFny09irNpUKM32TesftUAa504C4STManDAnFYHiPXLlNRntrUhFiXIAPJPU1paTJc6n4fUXG0TDOeMZp8klG8tjz449t8u5sXMsOr2i3lqAt7F1A/iFXtLksWshdajKyR52lVPOa5awjk0m5hkJJjc4Yegq94gt3jXfb828p3lewPr7VnKCfup6HRVpudNcu/T/I9d8V3sen6sZ1DPd/ZQI0Azn5m61meGL+CBLn7aMXRcu7Y6itHxawGsL5n+rECbsdcFmGKo38dh9qgtYEYSMPm7fLXnS5WrM8uCXIr9Rvii8+2WWLOQNEy8qOSTniuMS5+xpNFMA4lOclfSvRP7GhFohthhwOPc1w3i3T3juGjtwkj78sy9v8mtcNKL9xHRhXBvk7lRIreOUm3jVc87lpB4misJpYAjMQuSf4cYxWXY3L2tx5c44Pc9qrXOjq9w1ws6shI+bd1zXZ7ON/fNMRSnTsoI3NOvUtZmvI4vOsZgQ6jlkPtWb460A3+kK+lMzQTYkCqehHOa1dNt1S08pEHlDPzE9fX+tT6LItrdnTJSPLkbzYSfTOStSpuEuddDVP2kWpq7tr5/8McB4N07OuR3NxF5MVsGHzNyzYx/jXoZijjuvMgYtETuXjpVHXfDqPdy3Fs5TB5AOBnHesmF9TsVZIEaUZIAq5v2z5kyqWCgo/u5fedDq+pRwRmachTjOKzvBGizeINaGoXIItYjhM98VlWekXmqXoa+fC5yVr2jw5bWunaNFHGQkaDDE8AYrCvNUIWjux15RwlO0NZP8DXhjWGJEXgLxj2qh4g1ZNL0+SbIZyDsT1Nc7r3xD0i0Etvp0i3t8vy7I+Qp9zXnmr63qWpsj3A3sF4A6DNceHwc5vmnojhwmDlXak9ivJctvmmlYtOzMxOerE5Jrnru/Zw5l4BHJBq9qN1FGgiVgP3XUHq3+e9cndybVKgjJ7k55zXuQitz6ihTUULLcSzu8UbsQRkgegr3vwf4UtbrRf8ASYjHDJGo2Dgcd65n4efDhL/S1vNWYqspDoqcFhj+Vev2EEVjbx20Cnyo1Crz2rzsbik/cpvVHz+ZYx1ajhF6L+mcb4y0i00rw9GlnCqbpACQOTV/Tke38O2TqQY3XnI+7mj4hHz9FkRBh1IIOM4NcXbfEG20/TYtGubZ3lRR+8DYAzkg1lThUq0lbV3OeOlCL8zW1rSYrkNLCAkwUnC8Zrg9XvNSSeO0t72SAJygBwS3pXovhzU7fVrZp0dVkzjb6ema4vxlJDYa+l3tjmSJwzoeh7cV1YeTUnCSu0dSUq0XRT16G14K8W6j/YqvqfMiMULMccdv5VpxeNL+8LPZ2beT2bbnvXiOteL55buR12RWbOdkOTlh2r6A+H95p9/pdm0QRWWJVMXocVOKoRornlHc54eyjBtrma3KreN762A+1WTFepO09K2NM8ZWV/bySRq3mJjcpI4rpGtbeVMNEjL7jNeK/Ey1i0bxTbR6QdguYsyxoeM54rkoxo4iXJy2ZVCFHFT5FHlZveIPFc+oSC1sSViwfMI/xrIsb680+bzIGZcDkdjUvh6CG4tgiuFmU/MjdRzW3qGnWlnYSzSkp8ucs39K6/3dP92kd37ukvZpHW+F9Ui1PTYX3DfyG+tZ3i/xbDo0sNvbwte3smf3SdFA7k1514YuL6/uDp9tO1rEEM+e7gt2/nXUW+jwadJKxL3Fw4Pzsc8VzPDQhNuX3HHPC04VHzP5DrHx/I75u7ZV5wUSuisLiXVts/m+XHn7oP8AOvLniSO6d5hhMlmwe1a3h3Xpn1CKO2jkKO21R2wK1qYWKi3TVisVSpUrKG7PTL3SrS6gZHiViepIrh9R8A2N3MVR/KdhlXWtLxB4wXRbJVmRhIy53AZCjFYngzxnb37THUbiOEbhskZscY6frWNKFeEXOOxyUqtSi3aVjltZ8N6xoRbzB9oteoI61QtNSlt5N1u2yYcbJOK90le0v7Ax27pcBlO0qd2TXlXxC0Vba2EqxtvbLlkH3T6fpXXh8T7X3ZrU76WYxkrV4hBqsM8ctvfxhROm18dG+npVRtDlg3ppt4j2T4yCuW6VxlpqGo22/wA62mmgQkb/ACz0rfguXu7eW4sJfJnCllT7ueOBiumVJw2JqYWhiV7Sm9jvrM2NpoUVnBlpI/lDddxzyTWdqelRX8KqZNhHyEEdQOleUt4s8RWlyqm3lmYMB5ZhPJz6ivVmbU3tbae4t/KNxEGKhc7Dj/8AVXPOjOk733OKEIVPcix8MUdjpnlSvuAYEuevSqmn5RWu5G2gDgsOcVWuLiFdpu5GlKfLgDhT6fzqC7vBfhbW2AjhU8kt8zn86cYv7z0aVD2cfJkE89zrc5VQUtVJBPdua0JYY9PAhiC5XkEemKSFPsyRrD8rDg89frVO/bfEyqAcHOfSnvoti3J1JKMdIjHvnL4JyqjantTo79Q6ZGVAA57VRMZK+YoJTpVn7C3kq/QuCR+VaNRRvKlC2pBfeHbXULprxLl4mYfPg5B7flWraWsVtapDCf3ajgjuPWscSvtIViFPBFaNlcMVVT93aR1pS5rWucksFGn70S7NbLNbuJsFSPlIFZVpLOLeSCQ740PCntzWwsuyJtsjA4ADDpg9ayNOJl+05XaA2OT71Mdnc1w+zT2PSvidcpZ38UxP7zyV2AeoZuvtVfwnqmn34We5nhEqoRtkOCCDmofi6tjHqltcXzsB5AQBf95jXArCgCXtmhe3BBG5eD6j/PrXMqSnTXQ5KFCNShG7sz1CbxBJIZoNPt2lRDneDxtqi1nGlmbgSqxbLybupB7Vc0TUoL/TZHt4FR2XDIBycdBVGwhWSaNTjYpO8Hv3xWEbQvpaxzJODataxn3ui3Gp6fuiijhYEkE/eI7CsZ/Ct8LZD5qM552A16NdXxgEvmRKkh4B7CuRutb+zOZY8hwCAO2T161tSq1JaI7MPWrP3YnJ6XetbXBSZSAG2nrxV7xCvm2IuIs+dDiRSvbFZ8kz3d8SAAGYEcVvsFezkSTOCpBwK65aSTO2s+SpGRYtZ5harJ/rAyhmA78Vg3Pim30+cxR2zzruw2T8wP8AhWnoF6i6JHLPuZYw8YAH3jnAzWNeaRHqq3GyT7O8vzFhzkn0pQjG7UjjxEKiv7PoVdT8VzWgM2npmQZ3EqPlrOh1bxB4juFtrySYWjLuJiG0A+ldQNI0/SdIlur3y+MFncDtVnTL21dUa3KlXwVCr0GK05oJXjH5iUJVGpSfyMvTPDdlptt/o7FZHyWb+JvxpdUkRLQpD8rZ4c+neti4cLIQ2FRTkk1xviDUDPdrbWw8zd8qBR1pQvN3Z6WFp3adtEc/qiv9t2pl2JxtAzj6V2fgj4b3Os3EN1qLLDaL8wjz8zH+lamg+C7nTIE1C8hjm1Kc4gt2bCp/tE+1eheDNO/sW2ebUtRjnu5fmfawCJ7AVlicVywfs3qcuY5ipx9jS+bOisFNtCkGAEjXagH90cD+n51K7ITuTgjHFZN/4n021k/fcsDtDY4Oe2as2t7HqFoZ7Ehipwynrn0rx3TkveaPBad9SrrCG+ke3QLyNrD68ivHPHvhCaz1FLiLCv1yPusM8Zr037aTqW+djGPu7en51F4tgW/05vLQu6/MvX8v8+ld2GnKhJJbHdThqqc/hZ5d4Lt00qe4lnm8vzFGEBzk1W1iC613VGtYIy4xlwOijpzVaXStT+0SyIojCtgEnBPpgV3/AIIlttF0i9bUN32qcbzJ3JA6f4fWvRqS5b1Fqz0404YWH7tczPK7nwVe2V6blRbzxxrgGZgQmc/rXSfD/wAP392iCGVykWELKxGefbtUlqJfEuqtbxlhA0nToMc9f89q9v8ADukWujW4gtIwI8dfessXi3ThZ7nNVUMEnKK96Ry3/CN+JFhf7LrMkOBwpO7JrjrjSdS03UPt+qn7VdRkfO+TwOeK9yaTqAMiuY8XS272RhkwZsbgO4Hr9K4MPiZOVmtznw2Kk58rS1PNLS8ieX7SgImZssFGOc1taVbNr2rql+7CziBaTJ4wOa4wFo9UZIwVRzn2HPNejahb2ul+Ary4nMkdxMmAw6lj0UfnXdW92yW70PQxcvZx93d7HFa94phv/HNnFoVuEFsfK81APmTpg+1ehTwuLaWa2bMIT9479N3oK474ceHDpCS6lqaxvdXKfICMFM9T9a67xhfW9n4UdIflxjGTznvWNZxc4wh00ucEFP3Kb3OB1Cxv9Rt7ltPQymFwGVf4l5J6VpfDrR7tNUV7kyRxg5CSDBUk9B+lS+BPEtjZX0caiQwzgRtJt439a7+8Iluv9HiZP9puKdatKN6bWj6mVeSqVnJPY8+8X6VqXijWb600xUxD8rMxwPavKNb0ufSddm0/U45YHMYVCTgZ4Ofxr2vRfFFl4fvNa+0xnZNceYu3ryAoH5/zrk/F2sad448Q2NskDQPAH3t/F7D36GujDVKkHyuPupbiq0nUkqdraXRvfs+TSHQ9RjnZ3WGcBGY8FcdvxrtvEdxFBaSNcR5QvjNYejXdj4a8LyQWcONp2KccyMehNc9qV1qWqlYy+VZ+FA6Vxyp+1rSqbIeHwspO8tkbH/CWaKzSQ3FiY0KkBjjH41z+paHbavLHdeG98sZJMhTICn0PpVb4m+FZ9O8PWt4jElTtkA4wTzUHwA1mUeJ9Y0+4P7q4jSdFAwobvj8K3UYwpOtSd7BVqqjNOhs/0Mq51+40LUHi1C3dVjfZvZea6zSdR/tUfaheMyhSCpPYdBXoWv8Ahqy1mCVJYkWRud+M/nXhE1neeC/Fn2aZZRazPhTnIxRSqU8TH3dJIulivay5aiV31N3VUD6gqxk+W2WAPcisc2M0E0kkYdvcduv+NbeoXAuPENnb28WyKOBmBLA7iT1rooIEhtRbxEGSQZdzyB3/AJVo6jgkdOLi2opmFLPiFGKkOyrwT3FQW6TXEzBVwo5I9KdqGyXUY4LZNrjGQOeTXYWNn9htN08PzYyxFTKahFPqzaLjShzdWcdcARr5WCSOOKgNxIqGP5lUr0FbLxA3jboWCO/y/wD16pay0QEbA7ZFGCuOtUpJuzN1UUmotEOn28TqWlYHd8oA7Z70l9bppko3ToQy5HzDI/Cq7SGBt8ZIwCw74P0rjWS9u7mOUkyQurCTJIYOScD+VaxhzPfQ5cXiJUJLqmehwyKbQuXAyucYzUGmKShlkTMLHBI61HscW1pbhCs7jLknoO9Lql5aaPYxedciFZWO1WbAJHcCs7dF1NIySjzbXOm+Nkm/xRZQOB5a2iyNn/fcVBo9uJdHhVUXbknaB/Oug+LK28WoQ3F1EXjaAI2B2Bc/zNcH4dvCjtbxsxhwCgbt7VjG8qSt0MqX7zCR5fskl3Nd2GpIlpK6JG2VVScH8utb2n6mEicMQcgkn3PJquqxSvct0kAKrkDr9fSuZPm+aUXO4kjj+lXyqpuLDUFPmcmdnFrP2ywdnLvsYjLc5P8Ak1neJ4Fh02zKAEyNuL5z26U3TLSSO28tMu7/ADuvoKsap/punRICSVI+YjjAH+RURSjPTYIuMKto7GFpQhtnN3eOUhB2gjnn1xVjWtQW7hjSwkCmQ4GD0HrVfxLYy2+kwtasz7k3SDbnYT9OtYGjJcPqasEKYRzsZcdABx+NdKhGS57k/WHUxVmtDvobKCDQVtVO8qfmI4OazomEMuIz0IQjPCjNc54MuNY1HX4VCyRxiQrKGUjeB14PpXXeIBEniuZbHakRZVx1GRWbi4ScH6jweI9s2vmc/wDE+0v7zSksdNhe4+cbnB4+prZ0q0mtNJsRfRxiWOJEmK9NwFW45QJJXnLKgGeO5B68VznibxKFDw2oGSePamuaSUF0NqGGlKq5ITxfrMclzKIhsT7oA6/XFSeD0i06ziu3hEt/Kcrn+FT39qwtM0e81acARvPL/EqqSF92NdXfaPrGjaU93aWZup42BeFjtMkfdUPQP6A8Hp3zVVHGEeS5215U6dP2SZoXt/f3s4EkqAgcAelTT6Df7FkhaR1ALHZk7a5l9YttQs4r3S5PMjf5dpG1kIOCGB5Ug8EHkV6/4C1H7Z4dtnkjIPzKWx97BrmrTdKClFaHBXqexpqdNaHlmqWtzqVm8Ed1tubch48d29D+VdN8PNVu7WZ/tyFDNhSp4AP/ANbmqfiuZbLxhqMdipLtCjEAZ2n1pi6Rp8FvG19fXX9oTkscNgJ3xirnadOz2ZzTw0ajVR6JnpGoQ28ssbuitIOje1MvpYo9OcqFUgEAH6VxHhfVbm31iLTrt2YO2yN3XO4E8Yq18ZJbjQ/CbXdjLIWDhZB/snPPtzXEqLVSNNvcxlR9lNQk9DEk12wivLuW4KhFX5VUZyfauP1rxBJfwSiz2qvA54J5q98PTperyfZNVVZJpkDIwb8e9djq3g2CHSrk6dCGARucA5r0OaFGfLLc9KhiMOmnG/zOf+Ft5DHqHkyhA0j/ACsx6HFezXFylravNPJGigdzgV83xaPqUcYvLA5VRvIXtmum0PQdX8Qw/aNXv5ILMHbH5rnDnp0rPE4eM5c7lZDxuFp1Je0c7I6S+8f/AGFpFQl2c5UnnaKxn1xr3NxI4kkbknPH0rmfFun2+la61hBM0gjhyXz1OO1XvDWm31xcw29rGu/rn7w9c4rWNGnCPPE2hh6NOHtI9Tp9N8POGj1LU4hHbPgKmcHrnOK6DRIP+Et1R7i/bGnWTf6Na9mbkb2/LpWNr39rxTRW1/KSqsFBVcDpWlpazabHHLCdm9dynI5yelc1S8o3vq9jhqxc4899XsbevW9rpJS4aXZEzbCnU8+leW/EzUJboxW9gxMBBXHcn1P5V2WrRXWsXCxhpJpcj5fQf5zUE3gq8OTIFEnVAeg4Ix+pow7jRalUeplpSpNuXvWOG8H2Ms08clsU2hwnlJnOAB3r2/V7qLTrATS7UkRcc9+OazvCPh2DR7TzJNhkCr90YC4HJrzn4xeJ7i6ksrSyOLWSQp5nqcdz2pS/2usox2R59GFtZbLc5vxZqo1C8uLmMKkchKvsbjqP1rA0Z4tN1dbmO5LSFssC2SAR3rMu7S5OlXVi6k3BYSJzneMnO31xWfpFq4O5sp5bAknOTjPFevGmoxt0PTo4pVqkFTpn0SLu11fwtbvCVSaCUMBnlj6Vz9n4tTSdbiS7iJiUjcMZwKhhsS/gy3vopjbmBASD/H3rzi+1xL/V12rLPLLwXXhVGOBz16VxUqEZ8y3WprGVKEpwq6R6f8A+gNW1jS/EujTRpOjQlQ2wjnd6Y9a8kkEvhnXrK/02PakcoL49OhFafw+046jqUKhyYyu/aByQK9D8WwaDommpNdW8tzczt9ntLODmW6lI4RAfoST0AGTgCsHOGEfs90znqqlh/dvc67SNQi1OxSeE/eHI7g1neLfD1rrunsk8KPMiny2I5B7Vzfw0k1GxvrnS9ZWJb1Yw7xwksiE9AG74GBnjNegI5YHcpUgkc15s06NS8DgqR9lO8dt0fO9o7WdzYyzErLBK1vNkdgDjP6U1PFd/cxo9lbQNZszBQHIc7Rzx+Va3xGsP7N8UXEOCYbtRMox/ECa5i10DUUltxYiIW7Bisp6lW9QO4r3Yck4qcj0MfKc4QqQ2f9f5na+BJba/8R2l5IP3EwyFY9GxjH4Gu6vZEk1KdMjYDtHbJ71534ctY9LktrWd2DRHkgYyeSTj8a9Nd4JHSR/lRTlmI4ArgxOk00TW5vdlLscfqi4nMshEYVuB/eH+c1ia5skmDkheMLg9R712OtLYXGPJV3kPVh068AVxWp2UgvHEasAOue1aUJX1Z1YXWzZnkswUZwOmfarenpEiFXijLq2emDTYbfnE+7joKv3DLZxySNwsYJyR/n0reUuiNcQ1JKJC9xE2s4ZwuUwzHjj1FefeP717rWUk00CQW4MKocHd6nmvVfAfhX+20k1XVh/o8x/dp0+XOPyqt8TfBul2Vxa39tEIkkYxuijAyF4NKlXpwqqHU4sVy1f9ni9fwOh+MEjHWooRna1op9h871wvhyIpdNvC7QNoGetdn8ZZiviG3jDbd1mpHH+29eW2dtqDarBCIHHmncZDnA565/z1ooxvS3LjWVHCRVviO+1BxEgEShWyffimR2DxTytIQJG2sv4//r/WtGTT4oYopJH3gjox5zVlo830flkDco6npjoKwU7LQiM7Ky6mJqer2mkywAl1upkO2JOpx1Ppin6XqNvqEUj25KrnaYyuSD9K5/xrZrFq1tfzxyzxbAv7oZETZOc8dDmrHgSOdpry7CbUlbCIQRlcCt3TiqfN1OONWbquLOnmzKu05lQDJKjnArk7yXyvFNmUYOGVkK9NoPetvV7wWcDSO21l6YOM+2KyPDsD3eoSancR5jQYQPxSpqybZ62Eg0nUex0B1OUWkVtZgxspKNJjG4e3cVklWF9mQlipG4jnFXZpY4zLsJ8wAcemazdS1aDSrGSVxukc4A/2vaqjG2yOilCytBbjfEt7K0aWluw8+QbQRj5RXJ2unFzO2JJDEA7OCBkH09apX5vdQe4nKzKMAptB+cHnH869A0P4a69caYs/2uAxzR4WJ+qqR0z+NbtxoxXM7HnYvMZ0m6NDpu/M774NrZnwin2ZV87e3mseST7/AIV0viG3Q6PdMDsYISOnWvPfD/gTXfDumtbW160ilt52OVAPfA71DrqeIrWzc30ty0R+U5O7ivJdGNSs5wmnqZQoqtUVSM1rrY8m8VPNp+sT6ppCZlmP+k2wxtnAH3h6SD179D2I9J+HXxI06Lw/DGykx4IQ4wQw6qR2Oa4280q31KcEyPHIdy4A6jvXF+P7S68J239qaKkztJ+7nCxbolAGBI/91hkAHv0PavRrU6fJ72x3VrR5var3PLf1/wA/vPYNJv8A+0fEs98867pZNxDDoo7e1egXvh+y1KQ3Mdykk0nzoikfXivmvwN4il1fRIriKQLebvJnUcfOO/sDkH8/SvQLaz1fSbtLl5pEDLywY9D2FZ1KXPaUJWNKlFVoxqUpWVtDtPF8CQNYXFu6NNayBSo6gdRXXa7DF4i8JPaXFu8hu4cbRjg+ua810n7LrWsW9t9rAjJBlJcZ4r0/WtSg0XTkMThtu1VHUgdM/wCe9cldOLhFayR5+KSXJDdo8b8BeHbHTPFUNte3UyzR5Uxy8AkfdFe+SrCmnyhiqwbDz0AFfP3iaSW+8cNdowVdqvEUGAcHk10ereNni09NPSUM+djKW5POcZrbEUKleUZF1sDpBw0v0K1jOljDrKqhkjDlEOeBkZH6mtHRruzudGS1v2eFldcMDzjr+tV/h9Lba/Bqml+Vsu5B5qynnAHH9azNXhudDvXtJwA6hmjcfxgdq1spScOp2NRlN0paMwPEPl/8JHfi7aRy3Fs38O3t79K9W+ElvYW2kGUlBdljncfmArz3WpU1fTLQ2sJGpQS4G3neCOBj2/rWrpHhvU7i0kutNvDPODieIkqyvgdR6U66U6fK3YeL9+goN2PTfFtt9tsD5ChmQbwwHcZrmdAv4tV057Tcomt2DDIwQO9XF8ZTaZZ/ZdX0qcXOzankoWDnHSvPdP1WPTZZXO2a8kk8140YjZzkr9QK5aFGfK4tbbHnQXsqbjU010PTNI1G2sDKoiZpD/y1J5b2qaXxVaxuhnQoqn5ieccHmuAs9fh1S4EVkz4YEsH4KtTtVmhy1uqr5mMdPpiqeFi37y1N44SnUtJ9T1K1uYtUtmkhY/Z3GBtPJrzC68P2R146VrCGS2nJEaA/ebPA/Gu+0K2+waXbRSMNrLuYJ1yRWT49iktrfT9XtoTJNp06zFfVc8gn6VhRlyTcI9djkpyUJSprZ6GJY/CddPvkudPlEfl5EKTMZBGD1A/xrkPGPgy+0aSSadEktieZIxgKT0zXtFz4q0lNGh1M3SGGYAxgfebPbHrXk2rfFFte1O/0aKwUW4+d2kPKqP8A6+K6MNVxNSV2rpbiweInQqqMevQj8Fn+3dNuPD95IVjZP3bY+6ccc+lYlr8J9ZbVmTzIYbNZ1Uyqc57ZAqtpWoS6ddSXdnleduPbPTP0qH4m/Fa90LQFg02RY9RuWAjPB2KCCWI/QfX2rqqSqUbyhszvzDD2bqvZfmdxrkEPw3ay1JXNw8kht47VCDJOxHCgH6HnoBya6Tw/p00csnibX5orjXLiMqPLOYLGI8+TF+Q3N1Yj0wB5L4CW48Vaa3iPWzctqkoaKNZlKrFHnhYgc/KeCW6k+wFbOq6nqljpdxC0hFuQOn3tvQ1y+wdezk9TB0faw9rUlt+R0/ww8U/238SfEhm2KHjVYscH5Dj+tevZz65r5q+GwNt490680yFyjjZcHjhSOmfXNfSXJ4bKkjt1rmzGkoVFy7WR5k5Ob5meW/GyNIbrQ7wk5EjRt6bTWR4buv8AQ5Ityq0blV6cjPT2rr/jJYxzeD5JPvTwsrIep968s0/V/J0q5ljYJK6j5h16HOPwrrwvv0Eux7FKSeBv/KdLfQSG584HLZBZ26fhXYLNFJDgyB92CMdMEdMV4XDfSSXUX2ee489mHBbd5hzySM8DAP516Gt5LIlnbWww4XLHPfPWta2HaSuyKFT61Dtyl/UpTaEneN5GMZrNjluLkr5agOx4zz1rDOq2lzqSwPdNIS2zeRhWb0Hf8a7K3YafZvcLCrbFOMtwrADt+NKUfZq1tTV4inGHuO7I/wCzHhZTdLkN8o/wrA8UTefPFp8S8Fg0mGPArOv/ABzfffuGaaKOVVKqAcDOOD+H61Wv9TWzh1PVXUuFwsYPJJJxVwpTTvIzwteNRyqSfwn0HoyRR6NZpbYEQiAX6Y9a8z+K2vR3UkNtayq62xJdgP4jxj8q4VfGWt2lvbWU1xstpiq/Z45Nsiqw3Zx6Yrd0jTm1iVpYkYW8fEYYffPc/hXPTwvsZ+0qGWEjTTliL3SOm+OGP+El08gqXW2X5T/vtWdpsvn6ZHlyNoxz2q38aI3l8cRBTgLpkZ47fvZP/rVleGcPBsY7yrdB3FaJfuo+RvS9/BRfYvFskQyK7y5HGcjFX5Ec5kGCgT34qDygl15rZYn5sD+RqtrfiPT/AA5MpuUdxdqY0t4ly2Tgd+OtRZydoowqyUInGXfivUIWMpeHyPM4t9obAPqevrXd2Fylxp8M2BtKZABxt9a4Wfw2L3V7v7G8lpK6q8kEo3bQecqVPIrsIxFpejeTuz5YK5I71vWUHbkOXCe0k2pamCYJ9cuZFUExxNklRkAf5Ndf9iMEGn20SFUkwT2xzWB4ME015cRRHZHKMt7jNb/xO1JfCejWUg/eahcHES9kCj/69ROTc1TXyPXxeIjQai9EjE1GPy9XuGYbyFGQPasrwX4dbxr4xne7JGnWrbpADkHnhR9arR6zPNoFzfXLIbhh5W9AQD9AeR6V6Z8ENOSy8OmWVSs1w2/J7jsKWInKlSbW+xdSt7LCurDd6I7G80jS7LSpCtrCkUERI+UcYHrXH6BrPiiLTIp7ewg1OxB2qN22XGemehrpvH90Lfw7JHn5p3EYqfwdDHbeGrReANpcn6mvNjJxo801e76niwtGi5yV7sz9A8daZqcNyt1usLi3bbLDcHBFSXXjHw/Nvj/tCGRRwyjJH0rgfE9lBq/xAt7eFtlvqD7ZCFwflXJ/lXoCeE9As4Y7dNPiRgMBl+83uT3rSdKjBqTvrrbsbTo0afK5X11suhxOo2Phu91D7WtxcxDcSRCuMev/AOqq0WoW+nXbiGxufsdxH5Ze6j/1gPXIPWu4tfB+nQakk43vGG3BXPGaueObSG48Ozu52iAbwfpWqxEHJQ1aZs8TTcowV2vM+adR8KWmh+J7i70+L7HDcgs0KDETDqCB/CR7cdeK37nxBqV5pn9mrMtypwBg7TjIyN30qj43vftun2UEV0omQ+SZTzgHpn2FUPhdbajrPiWCEbY5Y87nVdw4JG7j2r1VBRp87WxvWqxhL6s42TTd+253Xw98ONDdR3kts8FurBmZz90+gPWvWNUeG/s2D2zHptLD+lZieAtPa2SNrm+aYfM0gmIJb1rz3xRqWteGNWuNPi1HfERvSST5jt7A+9ebJrFTvF6o48NhoVZclOWvmUPFP7nW/MiGIkXZ7DHauZvNFOq6isltexw3IOSCTkgHn9K25ZrzXEYopaM/elC459Kx7e0udM1C3nIPyE7mI+9kYr0qd0t9T08VB8kKNru/TobmjXI8Navd3GmzvLJAixK6DILnqD6jrXoc8sPjXSINiJb6tb5kWNv4+o6+9eXaetrLDNDcybZJDnJOB7ZrSsNA1PSLVr/TLzyoUPDCXLHjJxnrWFWmm+a9pGGLpTp1IzT0SWrNrwtdR6P4pjj1O3a2J+XLrxn2z2rsfFsMNvFJrGk6kLC+ZQm9OVlHYMvc+9U9A8UaF4ytxpniC1jW7QAfvRjeR3Bqe/8AhppdyrpbajfRxbdyx+dvUMOnWuOpOPtP3l4v70zGdaEqilV0f3pnPaNrHi9bpZTapqcRHITg4PevPvFcN5omrT3WoWNxaCbJAYcknrzXr/hTw3rOjKxjleRclc7wSQD0qh4t0XU9SCvqSSSRoTgsoYL+FdFKtCNRpWsFWFKvOysvNf5Hn3w90WXUbC71dbwRXSymOOFerEDkZ9zivSLLQ002yW71VMbjuLsQTux6VX8DXA0vMc8Mf2dSfL2AcE96v+IrC41vSma3vz5W1l8sOFZfcH8MVFarKVSzdkYylUw0fZp3SNnS9S0uaZIoXbzOmSfatppIHspUu1WSNlKkMeoPGK8V0iwudEaJg58tcLiRt+fxrD8R+ItRi1GUy3ckcKSqIreJiMnqGJ7gVH1Hnl7sjlk9Oad0XPGngTVIbgfZkkELZIRTwrH6GsG00O5s5H+1ea1yVEWSMBEAzivUvAXjV9Umlt9TbzJkZVjKDoO+fwrudR0rS765WF4gSQSzIOeeOtaPGTov2dRHbTxEYzjVqQu+5856vdhLOJdwGyNcpn7zE84/AVzuiW2mnWZtY1K0W+nZzHAkw3LCOMBV6ZGep788V2fjLwm+keM1hiH2u0kjLRlnCbePU+nf6Vx8iWluUtor1dm1tzqTzJ6g16EYwqxXXqTOtP20qk1ePS/4HoGj6j9pVVjfAfLjjA9MfpWzqFvJHcacbmHEc8oUhsEEe+e1Ufg/psbW0V5rkmLeEN5YPAZs9f8APeug8S6rb6lr1hBbITbW7CR2zyAP/r1x1JWqOMVt1O91+dqy6a/dsdT4cg0+XWZDb20cMajESKABn1/SuxaMdefzNcRoFmuo6nBew3SmCE7iqLjLZ6V3Ejohy7gAn6V4+J+PRniVn71kZWtaLBqts8UucsMcngivnt9OGka/f6VfLuiVj8pzyp/lX0yAGHBzXi3x009bXV9K1SEYE5MEvHXoR+ldGArNT9m+p25bVvN0J7SKemaBpdlFLLa4E7phZHO4jPp6cVZ0ewuk1CQ43YGzOeueKo6W5tisGSY2GUz1Ge2fStLVNeh8PQB3X7RNPlIYM4JPr+Fd0+dtx3ubVP8AZYOC2Zwuq+DNX067PkmKazyPKdCC6fU16DZXEb6YsT+YZWAL4GAeBn9ao6F4mtvEEc8B/wBHliX5kJJB6cj3qWaSOBHMxAVQSCOBj0p1JzlaM1qjkw9GDT5epzeuWuj2MUszFkkYFscbSM5yfyqt4I02Txtpeqix+7bSIsYK5D5OSx9ua6Xwv4XPi+HVbm5+SHyzHCMZGe38q4X4c3N7oY1q0hkmt5vtRjIXqQP69a0U3KMoxfvKx0OCjVWFpJa7/dsauv8Ahu10LWFs4C095hVlnfksSeg9B/hXo+jabOI4RbOscarsDckHA5H6V57ciRdZge6JYs6MWLbs57k17NouBY+TE6+evIRhhSPXNc+KnKMFd3ZrjYKhShCJk/FexH9tG+JwWs44QPpJIf61wmhTeRcBCflfI4PSvQ/i3IguYEz8/lAsP9nc1eYwykSnaflHII5zVUFenqb4CPNheU7RAJS77QoyF61yXizTJ7m+WeGN5rcAbgiF2XGcYX3z+lb1jdi5RNwIYYPJPPaud1XxLJHqklpbOcRnDkAcfnToRlGTseXiopLlmS+E7S4bU7jUL1Xt/MRY03KQ5A5LMDyK0PEE4ZktomDxnknHXNObUN1lFMuEc+/4VkWzC8mwj7+Tkrzn2q0m5czOzAUlFKV9jsvClgLIxT7NruAeen0rjf2gpX1HxBohiYgeQykAc9ea9Z0DR2gt0kvNylgCEYcj/CqXjLwhZX9zZ3s7Oyw5UBffpXLSxEI1+d+ZxYySrzt1ueSXVi1v4WtwwAR3GQTzz0r2jwpfQWXhqzSRQhjhXIJx2rx/xE5k1+G3yREjgEA9OeK7a51pJbRrGz8yL92ULYDAjHStsRB1IpP1PSxUIqnTpE+q6lc6/q1tboPMt9wCKB2PU13epxpB4eaO1bARAnHpXkXh/WbjRrLzJIwzL8wLjJGM9Kh8QeLNRvrQxWrbFc7mCtxn0ArOeGlKSUdEgng5TlGMNIouatNGpgvIZWW5tH83KnBHuKnn+Ly2kcQFm13cY+aRm2L/AJ5rzeS91CeJkb0+Y9z9KqLpN9c3McFpbSSTHBVV59yea63h4SXvrY76mFo8nNW1sehXHxcu54/LhgjtmYkl8b8d+BWNc+IfEHih0tTLNJBnmMIeT2zirkOjWSW0SajZKlwfmkcMc/kK6/SvE+kaVpskGm6eTeYHlEIdrPnjJNZ2hT1pwuzncqdJXo079jj/ABH4eTSNJhW/2pcP8xJUAcnpT/A8lt4euINS0qWNxICsm0fKfbNYvjvVLzWbsf2teRTG2wZIVPlgkjgV1+pxw6J8H7Tcd2oysLmNccxjHHHXGMc981pK/JGE9XI4auOvLklFO27/AMjr77x/Bb2Qk8rc464fI/HvXGaRAnjXXxJd5aNpOSDjC+1cvqscuhzwQ3s63d9dRbXjDBgoZcqRjvmpPCOtX+marCZY/KtGPyqRnkcHn1qI4ZQg5UtyYYqhTp81NNSeh9GW2jafaWQtILWNLfGNoWvMfFej2WneNtMjuQw0+RXlKgZ+6K9A1rxCml6Bb6jNExMoXCDjBIzzXkup+LG1zxdam5iEaxRtGpUkrg9ea4MHCq5OXTU58FOXtXG+9yOXwNfa9bXOr6a8ccMsrmG3bglASBz61zmmSXkV0+l31zLa7coCw3bWzwMe54r174e63byaCLe4liia2coWZgN3JxXmXxAkgufEl9dWmHtwdgYdGIGSRXbRqTlOVOS22PWpyliHPDVlp0f5DPD/AIc1H+2WGt5g/clo5HOChyNuP8K6ODxNdQzR2rO8VxG215EPyyDoCK5O/wDEV9faT5U8z/aE2orEYyvHOR6VJpWpRx62hupkYSICHA4PPcVtKDn700YUKHsP3FTV7o9Eg1DxH4c0i7vwqXVkN06pLndjkkD9a5gfGSfUoXh+y28YK/M0TEkfgfxr2m2FtqGlRxko8Uka8A57cV5r4o+DWm6g813Yy/Z7wjI2qApPuBXnUK2HnJ+2jZnl1a15c3Kr9jmtMf8A4SHUrWezuF2yMASrkYx6V6ZFceGrG8e0vr+1W4XAeOSQLgn+VeWjwzeeBmtkDjzbhmAbG4KCOw9q5zWLTVIUeGOK3uhISXkmkJ3n1I6muydFV37stOhrW5+VSgm79j6DudB03VLTdGsJi+8hTkZ7HNZGpfDTRNVh/wBJSRZ15Dq2Mfh6V5JotxqvhnSViGqKyTuP9GRyURcfdzVu7+IGu6VOzQT+ZsP+rc5B46c1isLXi/3cyvqlSVLmk7eTPSPDHgG00e6kljA8lX+XDc/jmuqaKd2RoWQqnBC9fzrnfA3i6DxLbQrdhre6xl4iNuSR2ruUCouCNuOOK4MROopfvNzCtKcGoy6Hk3xkshN4ayYT9qU4Eq5+UHI/KvCkgu76606BLd4/s0YV0HO8jJ3DjvX0P48ik1LVrHdYXd1pdvuM4t13FjxxgcnpWDfWa3+siW0sJLCC3BZWnUozDGMEde9ephK3JTSZ106VOqoOputf+Acf8Ttfew0TQ7DRo3hJTdcOMDgdBVTQ9SW60iWRJGRvK+YgckkjJxXZyabpviGKKHUEwyZZChwwP1/OuK8Q21t4K1MW1naC5tjJvVXkzhP4x06k1tTcWuRbjqc8HUUn7jV/Q9B+H2tTWGoiyuCjeYRsReu3jJP4mvU5rZZxiUNgnPWuB8FabpuuW1hrWmbpLNxtww27SDypHsa9HLc7cjOOnevFxkl7S8d+p5avEagURgLgY4+teafHdBJ4UUeWR5UokDfp/WvTMAgjkHsQcYrzb4vr9h8BC1knmuZCdolmI3OfUkACs8L/ABY+p0YJ/v4+pwVlKLjTraYHDrGMn1rG8X+Zd3NncpE7+VF5fyjlWznP410fw/t9Jv4o7fU7yRPLUKI045Pqewro/F3hFNJi+2Ws7tas6qQxyUz0Oe4/xr2lWjTqqL3PWxbo15uhJ633PPPC7Twm4u7mM+fLgAEAHHr/ACrRulm1W+iiBOx2wQOgyelQ+JJotL02Yb91zKo8oKccHv8AlT/DV1ImlWc7o6kEHk8k59e/1rWWvv2FhVToy9jT1aR7n4X0pNG0eO2jHI+8MdTXj/j+e3l8R3V1axBIkPl5QY3MBljXUp4ovH05yJ8YGMMOcfWuGuLj7VK8YVbhQrhlRgSC3VufeuHDUZxqOc3qLC0Z06rq1Grmeb+2FiWIZJ3ZWVyOCT0r0fShdJaxhS+WQHAxgjr/AIV5ZdHGn29ncFY5oMK2CWMo3fLgdK9TS4vY/C8U9jbO8oVEYbcscYzjPFdGJWit3OWeKnWg/aLVMsfGRl/t6BXHymzBP/fb15ZZ6uslysTwEbmwCG6egr1f4wD/AInsBIBBtFXB7/M9eRW2mPBqCXEjKq5Py9zVYe3s9Tuwrn7GmonU22olY0SWMbAcBgKx/Emn/bbo3FsdhlISQLk7x/SteyQMSrqrYGQu71/yKe8sQkeEECUfMAO1OL5ZXRdalTqaTRUhgeKwht/MzsUqK7L4U+GUW7nvLhQ6W7fuzn+M9/wFYGkRoZJHdcbV+UH34r0/wC0Z8PRmLBZnYv061y4yq402o9TlxtqVK0Fbp9503DE5XB+n61j+K5ltNIkcYjOcAnpWleTLDHucjA/WvMfidrsr2ohA2gdj1Yn0rzsLSdSoux52EoupUXY5rwzow8R6zfvM5CDKqykj5vY9q0i9jousOdS/fqDs2jjBx/hXbeAPCkeneGrYXDMLmdfNfBxgnkD8K8p1PTLyLxld6bdytCZZsQPKmd6E4BFenCqq05Rvoj0708ViJXekV+Ro38mj+Q0/2krCxJEIJJwfb29a5G51bSYZ1SOJ5lVsPhzhf8TXo+t/C+3k0+SO21CVLllHzPDkFvoOxrjH+Ffic3im4ithbkgZhXI+uD0ropVqLjrMyqY2UWo0du7J5Lu1mtoJLSFEhKAMoGOc5zmqMWqRx3YZAUO3hskHr7V2tr4Fh0zVrXT7jN1ZSRjMqrt2t3PtVrxl4L0/SLRLi3O1Xbbgntx1qVXp8yinud1LHUpWhLczvD1rLqyliJrhsAZyTgZ6Z71rX+iTW8f+rePHQZxmu98OadbaPptnb26KuUyx7k461p3aw3CNHIu/jP0rz5Y18+i0POnj/f8AdWh88f8ACK51hZ7gI0ckm8x7ep68n0r0K98KS60oe9ljFqY/LO1ecY4Ue1bt7oaJE9y5AMRztHOff/61eWat8RtS0++NgYsQBiqY6OeODXWqlTEa03qjGrVpJLk0Len+H9O03x9ZxNdzagSA2ZcYQdMDAr1V/BOgyX8V49iheI7kUH5c5znFeL+G9bj1XxOs86/Z75STKrjHpjA9MV7/ABTgxRlXyrjKkDr/AIVhjXVhJau9ia9OMacHT21K3iex0+70eWLVJFitRzuJwFPYivnDXNmnXckluTdK2WjckfImTgY9elek/G7xAmlQWsRmEWVJVmXPP078V4nJcDWFMdl53lq6l/Nwp24ySfx6V1ZdRap80nozGlKUZrk+Loa+mahdE+Z5g6nKoOOe3I4616Bonga81m2je4lkiZxnavCqD2rjdDtsajCpjKxowbaB2Br6C8Ly7bIlwFyRx0x/nFGMrSpK8D3cVXqYelFX97ueNeK/AWo6LEGgD3Vuq/MUBOAPWuJtNMumOEI2qfN+787DpjPpX1sjs4woB569vxrgfilp1rBpttqVvDHFJbTjJRQu4Mec4/OscNj5SahJas5aWNWIlGNaN2tmee+AteudD1Im6ab7H1APQn0+le622pLe20U0OPKk7g5P6V5z4x0iA+BvtunLm6TDsRyemTXC+GfiVf6TYyWzKrI+VQkE7W68c8H606lH60vaU1qhYp08S1JaS21PRbnZr3jLyZstHASF7gD/APX/ADrF8HaFbX2t6hFc5JhlIz2wPSoPCXiFbSG9vDNE08kbYRmGenJ+tdB8JIvOivL04EkznjOe/rRU5qUJW2VjSqpUYSa2SSRd1TwLbXVpNGJMcfJnkg/WvINU8OTWmqRRXxMkbMFD4ya+nPLUIy+vrXl/jURT6pcoig+S4I2+y5P9ayweKm5OLM8Di5zk4T1RFbeG7qKC31OzGdsYIKHB46HFZl/8XbvTZTYz6RLcMDtMu4KD9PWtDwP8R7X7GtlfQSFUYgyLg8H2qX4haJpl3YLqMTQmJxuDgjk+xq96nJiI+hlObrz9nK176M6bT/GOhHTLW5ju4yZU3MqHJU9wffOao+Jdf02/0aSVW+XeNpJ2mvPPDosIfDcVpFbwy6leSEKyj5kXPJJ7AV1Flolppt9bx3UQmClPMLfN7k1Dw9OEr63NPqtOk/evdfiedrfXlvf3EltuZWOVwMgDNZXiTT7y5nhvUljnYIdxVuYieOR616P4/wBT07RdbtGtbKK4gkO4+Ww7ew6daRPEGh6lpJgvLC3inAZV5HIzx9a7o1pJKajozfEVPrFJQ5Wk9zuvhZYDS/Aml2uza20s3PUknmummjWQAHKsOcjrXFfC+5E2kXFvFds8VvIRHznaD2/z612UTy79hKu/rnFeFXjJVZPzPGqw9nNxXQZJO8OFKhlx19f84NeN/GHxRY6t5enWMrPNbyZlXaQMY/WvX9dne10S/mjGXSB2A9wDXyR4YWa/1ia7kJeQZXCgnPp+tduXUYzvVfQ3wOuIikdV8LPDGu6vLJcyWk8Ni7ZZpF2rIDx35P4V7R8QbxNO8IrZEK005WBAfQdW/AD9a8Ys/GHibTrQ21jPc5D4WNbZm2cdz2HbFdfoVvqN7arqXi1jDK/y7DwzKORgH7oNdeJpylUVSbVlsluGHpx9r7zvbXY4rxZo19JOLpVmkRlVcFNwxj9Kdp92ukabFBfJcSM4PkxAFnCg8nHoK9Mh1ZVD2MMRFsCNjBvmU54/wrjviFb39z4h0/UrFYHlhQwyxKw5U9x781rTrOdqclZGs41aU5Vqa1Ymm3g1HSXNhMSMbWP8Qz6ijQLf+z9Qa5uZlMEYLCFVJ3uf5CqvhW1urOW4uNSTzZ7raChIwgXuMe3FdNFBFeRL5OGQLk8fNj3+lKpJRbS2OuP7+EZVo2YXRt4Xuo7ZbdJJcOI3IYKxHOD+IrU8G6+IoRaXrJG4B5x3Fc/Npsb3R+yfO2OAO5FZN/Hf2t2EKmJmLEluP5Vk6cakeU2dCFSPLfc9o8d6IdSvo5QhIWELkDOMMT/WvJvEOk/ZrxLcTozvyRt6DNe3eJ9Uj07cXcIfLyGJxjk14fc6o13rdxdW0asmcBn/AIu1Y4WU3fsjmy11XHyRetLBbGMPNLgHBHcn2q+BppG8xSNP034A4rKeSacK8jBtvGOv4U0TvBGQygnPX29DXQ436ndKN9ZGxdQ26Wu63UrlcHceQfWt3wEdjCO4yse35TngkmuGaWVx85AQ8da6SC4kt0VoRjA5wP1z61FWnePLcyr0nKHLfc9E1q80+z0+Wa6kj+6SOcnNeOmd/EXi3S4JWxE8gbjnCg8Vd8ZztFa2n+rImycdj6VW8Exk+N9JWXCs0RHHqAaijSVGnKfkzLDUFRpSnfWzPdSuzaVOAoxx6Vx3xNt7ZvDj6hOqJd2ro1tIQNwbeOB9a7IoNigjdn1NeS/Fzw7qQk/tm3nE1quAbdyTsY4AIHSvPwcVKqru39bHk4fl9onJ2R03hvW4dW10RtJ9xdyZ/jNdv2zzngV8raXrWqWOo208ZYurb1dBwrA42tjsa9jPjzWb+OOHSPDk7XbAbnlz5a+/FdOKwU4yThsbVqUarUqL0/I63xHPb2VlJKXijmONoY9fwxXlHinU5Ne1Wy0/T2lvHXDeXHkhW9z2HHWuzsPBl/qM323xVqDTzP8A8u8Pyont/wDqrr9J0mw0iHytOtYoE5ztHJ+pPJqIVadDb3n+A6daGHXu+9L8BbW2mj06BJdpnRAGI6ZFQ25NnHI9+xJZic46DsK0ULEckZ6fjTZEEish2gnt6Vx3ezOPm7mcETUYnKErbyoDzwSCDg4PSvMPEnwwe+v0jRy6SOSsm7BjbHU16ukZWeRXkHQYzXO3vi3TdMupluXlcREYEUZYk856V1YepVg37I1jTdR2Suedt8MNT0SQaiJbacwAbjGSGI7nB7/jXc2Xi6GK3SFoG3oAp/8A1VreHPFen+IriS1giuIpEUOUni25GeMVo6rplneA+dbx7yCN2ADWlSu5vlxC1NoTVOKo1Y7HnvxD8O6L8QdOhge7ks72I7o5CO/PB/OvJZPCOreGNdNvqDpcYgO1ll3AoOjEdsdq991HwoBYO9jNsuFXIDcjNcP4u8HapY20uqeet1GqYcjIKjHPHcdeldeErxiuRS07MqnCiqiqUnr0IvhbpsV+WuXYgsu2MEDHXk/rXrcMcVsF6bCMHHUsO5rxzwBqC6cygsFUjKAHuf616PD4gtm2OrDC8lsY59KxxkJyn5HVjqVWU9TpEl8uVlDhEIyM15F8dfGDWUI0a3WOUnbLP1LbQc8AdK7P/hM9Ot5pEvW8ogkjkHcAOSK8w+Jn9la1qseraVfSxTTxiCeMxZV1HfOeO1LBUOWqnUWn6nB9WxCadOLudl8NdcXUdDuLDUlBS2j3hv76EcV41rukCDVL2HS5S4kfCop465/PFdt4As531K5tLZmjh+yNBllPzYHFUfD3h3VI9fLadYG6jtJAZVTpnPck4zXfT5aU5yT+R3Yqny1HFxunvraxwkFq1vqcKWS3aRkEz/aDnLdyMcAe1fQvwagij0O8hBPnJNhuegxxx+dcp4q0i1v2YQ2tzpep53rDMBtkH+yRwar+APEQ0TW/Mv5T5UieRP6Z/hbj071niW8RSfLuaRw3+yOFNtvc90ZmVc7xgeteZ6Ht1bxPrTLgpGzxZI4OTgmulHinR2t2lGowuVUsRnr7Vg/Dy/to4PEOo+UfJkuWkWQclhj7uPrmvNpQlThJ210OKlTnShJ28jzbxj4Vg0K+SazuYxLn5oA2WI7Ypuqxala+Hl84usBG4pI3fPasjxlq9zqGq6tf2sDrBE6mWY8iEMcKufX6VY0h9Y8R6db2jAMOBluMr7k9uK9pKSgnJnoYR0lVaW637HW/DPw7c3d9DqdztW0h6IOSc812/iOOW21kSFNsUmCCBkcVh+DJbjTG+ywFyuAHV1xsxxkY9R3rrPENldX2n/IHE6kGNhyFrzK037a72MMRWft7yemxwfxL0iynSyvrGMRSSo3mBOhPbj65rzjW7a7jsHmazZcqFadUJEeO/FdjrVzfwTC3vkZnRiNo5/KvRPBuo2Go+C74xiNljR/OhODj5e49K6VVlh6afxI1xKlHDqL1V9zhf2dbSe/tLzUPMmS1VvLx0Ekg747YGK9tKOGBTgjsfWuW+EVhFYeBbIRIqCcvOQBj7zHk/gBXX8hW4Az0zXlYyrz1pP5HizbvZ9CjqSGfTJo7lPkkXaxPTB614D8PtJGnz6hJbnekMzYYjAK5xXtvjfVP7I8MX1yTzsKJn+8eBXi+m3NzaadHYWLZubkb5CV+4M5ya68Cpezlbqz08vo3hKpby/zOinlht8zOxN1OcxWsY+bHqT2FJDbXjy+ZcXKwynIRPvFcfXpUdlarZOrb2a4YHzJXPJ9s9qLu/RIshjvbPHtXR5RN3N35YBd6Wkjtc3M800rfL/rMfjxinHTNOlhXNtGrLGSWY5388fjUUFnrGqpm1t5PKxnK8A/iaiurDW9Mjf7RazJGFILsMgDvyKNdubUOWb0c9e1yzFocU0a/Z7q4jdl3BR82PTr1/CmWV1qHhzUVa7MYEoOyTbw59GHY/Wn6dfjaGWTy3VSmeg57d6XVF+22jxXEpVCoCkjnOOCPep1vyy2EpzT5auqZ3uk6VZ6nawam0QRp487YvlB9c/lVm78KaRdIUktdp/vKxz+tct8H9XlltLvSLk/vLRyyHHUE8j8+fxrZ8balqOltaz2Ug8l8qy7N2TXDONVVfZqVux5lfnpVHG+xifGC3ubvxFbwxuVt1s1Zx0H33z/KvNrbVbFZBHsYRK4Xc5C5+nr617H8RAja1Crd7dc/Tc1eLTaDcQX9zb3VqdvmhopAuWwCcHH5V6eGcZQszSWKrQowjDY6rWJrWx0GOWyCrJKxO8n+EY5571R8JrFqd1e21xNIfLUNHK5H7wNjnP1rQutG87TbePzId0IJI6qNw5Hv+VULawOm2k04kR7hyqEAH5UHb86cbOFk9Re2rRnzXdiTWrBtInCtKjg87kYH3rbstTt722hRDtkxmTP+elcjcQ3V1qQtIbZJYSgZphJ9zjpt/wAaZZ3TWN/ECcLuKMMdqtw5lvqerhKn1ym+ZaxN7xJEktrETub95xz056+1UZLhtG8QaFqDghIpVDFTjKk/4E1f1bL26OOYS4yx9awr3ULTXdCuTZMS9qwIB64oUbxs9v8AM3Uoq0G97n0hBIk1ujxNvjYAgg5OKg1S3jvbCa1ni3RyqUI+tc98NdYTV/CVpKpxIi7HBPQiuqG0MSevfmvn5J0526o+aqQ9nNxfQ5jRfBOmaXcCYRCaUD5PMXhPoPX3pdR8V6bpOoSW1x55kjGHMUW4L6Diun+bA5x65ryzX7pdP8Xao+V3AoQGOQcrzXTSTxEnzu+hthaSrScWddp/jnw7eAhdTiR0GSkoKY/MVPP4v0ZLOeeK9Sbyl3bYwSTj04rxbxpq/wDa0yS/YxEFO1nVf5Vn3OpRpC8MOQSuMocA5rsjl8HZ6ne8rThzK9+x0l58S7mHVHuJlla1aQKIlHQAdvfOOtWNJ+Ld5Pdxz3lios9xV0Q5ZB2yenbNcdp1np9/coL+/t4BM+WkJZljA9QR1I4q3J4Y0+LWZwt7JNE5BCxjCN355Oa65UMO9GtTz44bEN8vL956Frvjx7kKNNjaMYKlpO49a5aw1Kz1LWbOyeeM73wWz1bI4pmo6T9t0yX+zDI9xCpWWMjLAZ9B+NeZ2MCW91c3N4Jo2hJ7fxdsdqdGhT5Wo6HpQkqNoRXqfQl3qNvZfELTWWdBFcQ+UXBB5BPFd1cyllIjBOO+ev0r5mtPEp1mO2jdmguoHXy5AOSBxz78/wCNfQ+k4vtLtZ3kYt5YyemTjnivOxeH9nyt+hzYiklGM07rY4/4ja9daBBarBM0Mt4zZmIBVAATzngHOPzrhdA+I+s6rpl5pWrWhvbaWMql3GvllDjv2Ndp45toLnxdosWsSE6XO2w/w8eh+pwK7PxFDpujeEL1Ft4YLSKFtkaKAM44/HNXGdOEIRcbt9fmZRSU4N636I+dhe+TNFsUoYiN59QPUV0uiaZqmuW0t28rW1iuWGQcue2PWuf8KaNL4j8QwWoBETuGlJHYH9a+mtPsLW0tY4raJVjVQB8vWujF4lUbJbnt5jjFh7QitTwjUvDt0LI3lnFPLnIcMjN+IPbpWLp2kyXErRNNHG542uOv9a+mdgCbTjFeD/F3QZ21Y3lhG5BwrhPc1GFxbrPklocdDMak01bU2vCF0PD1/dab4gh2ySpiG4x8rnHC57Vc+HPiGy0ie+0q8Pl7pjKsxOQc9cn2xXn/AIk1+e503T7a5ELXUCbXkmYhmHGMn1FZSz3Fhq9qb1Fe8YB0VfnVlb3HH51s8N7SL5uv6EV3TneFSXLJ2vfY9++JK2svgy8uZChCKJIZRzhuxBrzTwppcGq6MjNkybv3h75PesNNf1CTR5tNv7hXt3k3JAMEKRzjjp9K9B+F0ls2jahb4R51fzeRztI4P86x9nLDUWr9R0W6OFbi7u/QwtZ8EmytxqVsjXVpnbKnRgM/eHar1/Euk+Grd7edTbXGdyLwwfHA969HaSKLSGWcAxBMMG7nFeI+K7iG0s8bpVUklAT9057e3TNTQqSrO0ujNcNVqYlqMns/vMLSvBV94hv3SD5IJSDIrcK2055r1LSfh5JZwKtzf7XHA8tMZ/Guc+F3im10tmh1BnzPwHVfevWdV1Sw0yFZ7+6jhibpvPXNGLr1lPkjsZYydShWkoKyf4nEQrL4d8Sw2mpTq9rMN8NywIwR1Vq7971LiKJYcNv+YHPBxXn3xOMGteEor/TbyKXZKUjKNyNwIIJ615p4K8d3vh/UNPF0GmtJ+iF8lecZx27VH1Z4in7RfEjiqzjNRlJ6np3xc0Dy9JTVoVdpIW/fhRnIPcV4poWpaxZalO1tO0MbqI7hWGTsc4zjuMHNfV9rPDqNssm1TG4zhuQQRXK3Xw08Oy6xFqSWzxzxSiXy1OY3b3HelhsdGnB06qMFXqwsos6Lw7ZDTdCsbBH8zyIVTdjAOB1rSYEjgkZ65qE8ncD7HiqeuakmkaRd3j/diQtjrk9hXltOcvNkJOcrdWeU/GTW/tOtW+jRnMFuBLOB3Y9B+X86h0extNPhha81Wytr+7TzPLmkAYg9BjPAwO9YGhW0mra2+pX5eQNJ585Hv0H8q4vU5Gj1XUJNZMYuhK7vvBDMuflA9sH8q+hpUFyqlF7bnq42r9UpxoQ+Z7HqyvbLunVVJGdw5z/iOlN8BeHV1i6ku78GS1iOMHje3p9K5rw0tyng947t2liMpa3L/eVDjHHUV7V4VskstAs41Xy2ZBI49WPJrjxM3Qg4p63sZvEOGH5o6ORoxxJDEkUKCONOFVRxiqGrTo8U9u6F0MTFsYwPrV6eISqFLEL144qrBp+2OVGkJVwyAgYxn0ry4tLVnnRavd7nnV3pFndafJIimKUEHaG459PXpWRpxPnywSMX2EYLHHtj869CtPC1rbGVrm4e5RhhA3G36Vwetj+ytQ3qjKsruFyucde+PavUpVVO8Ys9WjVVaLg9RmjTjQfiDaz/AHLS9XY2egbGD/SvWtWsobu2aK4AZMg5POPpXiurRf2nY71f98uJYm7gjtXqfw81w694cgnkwLqE+VOAMYcd/wARWWMhKyqLdaMxxlNuKqdtGUviRbeZrUEm9IgLdQXY/wC03GK4+53o7eWhmjTlgBjg9K7vxz5I12384k5twAMZ/ibnFU2mt5tiSxEJLwZNuN2On0qozcUtCaFRxhHS5zeni3vLUPDIscpI3RStgAA1da2ilUSxKPOIIdBjacdzWbq1lb3Msj2rCFsnHy57+nr9Kykh1nTm/dxi4U8MYWyWH0Pf6Vvy8yunY6lShUV4ys+zOgvTDZW0s+1V9wB8w+tcC5W4ndiPmLlvStlrmfVJ0hnbDr8vltww+orRtfDSBnkkJUnldoznHrW0LU17252YaMcNH3nqPmja70BIJn2woN3Tk+3868t8J6PqGieL54jHKbC6DrvPzKVPI+lezG3K2iL8ygAgkLu46Z/+tVC9S0F1NKFULJ2U4IPPNFOpZOPc5pQVSamt07r+vMzvhZ4jXw9rVzpF+NkMrkxs3ADV7gJAUUqQVYAg186eINOF3AJoyy3aNhc9T65Nes/DHVYtY8I28VyRJNGDFKr8kgHqfXgiuLHUV/FXzM8yw8bKvH5naBc43MAo/Cua8YeF7PXYkaB1t9QQ/u5ccH2YdxXRbscDoPxqRWUDjGcdh0rz6dRwfNF6nkwnKEuaL1PFJY/swubPVbcQ3CZDDZw/+0p7iuc0Tw/d6teGGwi2xyNtLkZ2r3PNe0fEG1UaDLfrGkk1qNwBH3l7ivNfhh4mNr4gFrrMP2RrkMsWTkDnpmvapV5ToucVqevTzC8Gl8R6dong/TLLR0sWtYnTHzFlyW9yayb74c6ZkSaZcT2xHLoG3KfoDXdqARnOR2/+tTJ3jhiLzOkcKjLMx2gD615UcRUUrpnmrE1VLmUtTyrVvDdz4anjutA1BvtLna5mAKvnsfbiq11o+meIvA1xeTW4h1NpSJmB+VXB546AYqp498bw3s6W+mKCkbkNOG4YdsVxP9oah5Mluz3CwXEm90/gdjXr06dSUVKTsz26eGq1Kac3Z/oYOkQ2Vv4le3nuXlg3YZ4ioI98H6V9AaDBd6Bqen6fPffaNKv0P2d3HzRuADtOOOR0NeGQ6ALe4hE90sNrLdq88Cpuk25/h4+vevctQuZ/EEVrYabpUkMdo8c8cs7bTtToB7n1zVY33rK+nU861ZXjOPLEtfFLSbNvC13cupM8KfIWOe/6V41e6nqWpWtvBd300yqfLRZGyo7Djv8AjXd/ErxLc6jo00FjCwgjI89ic7W4BHHoc15DCZ3v7e1iZmIzKT0zx1FGDpSVO8jswU1QShU+JvTyPb/hhoo095Jid8pHLDHy1teI/GZ0KRontXJY/uzj7/0rE+GOp/2hLJG7vGyJskUjAJ7fzP5VseOtPvNRt3SCJJoYE3ksOc98VxzSde1UxqpSxLVbUoy/EQsFgn065tnl4V2GBn8PWrulXNtqik37xgRLnDHnB6Z/WuHngmv7KWW/vNkFuEW3TjljyC3NXbC1Zo4Iw5k2oItzH7/ufWtXQglaOhs8NTStDRmV8SL3wffCxtQyx3Yykko+VRnjJ45qjq/wyez0+G+sNUFzGVCgxyc49FznI56V20Hwz0/YJJp2V8fMuAR9Peup8MaHp2khbeCMsyHIkbnr6DoKbxUaUV7KTdjgnVTdnFNLvqz521TSXsIOdzMhCtvGCozyPUGqeka1eW14s9uskYOc7c5QDpyPoK+o/E/hvTvENoyXaKs+3CzqPmH+I9q8Lu9AOh6u8N9AZ7dGHzAdv/1c10YfGQrxs1qdWGUMQ06XutdO51+iya54vto5ryYJbRkL8vBkIxn9DWb8XtEtIbCzubCVg0Rw6Pk5HYnPfNbvgzxDpT3DQT3H2aGQ5gG7AJHUfWui13w5pXiSxMD7gGP3o25yK5XU9lVV1aJU688PVvayXToeNeFdNinP2rUS32eRCIzCOFI7kdRWbqz31x4lRrmYXcaEeW08jLGwUHAOOfyr2Wx8G2fhbRri3ik3m5VYyJW3FRnk15P4riFlrE9tbyF4VIYPXXRrxqSbibRjHMk41H6WMrQdPvLTWYN8fmky+YqW53xtk5CAnk/jXoUvwnfxBq82oXYXQxKwkMEAD7mHc+n0FcfoWry2t558TR/I2V3A5OOwx0/+vXpV38XdOiCQ3Fq8d6AN0ROcd+1TiZV7r2S1ObF4WNBKnBJ27vVF3Tr7V/B2rWGl64I7nTZ28iC+iXac44VlzXoqyI+WRgxHYV5Xod/feO9csrt4Qljp03nCNjgs/avTtwiViwC564HevIxULNcy97qcNdLTa/WwKiq5kbrgruPYV5n8Y9eGyDR7chnYeZMAMkDms3x/4l1DWIr620udbXTbM7Z5A3zufp1ArkNG87U57d7tzNLKQm7PJUdq68LhOVqrPp0OjLaSnUc5bROm8P2ottOiQsBM/wA7eg9ia09Tt7aWKL7daQSBRlWdFcg9eCf6VF81s2bn9zDgLGHIGcVFq6vdW2Y1ZlXDnHIOa1veVzolarU97qWNJ0p9fvomjcpa5wzBcYA/rxXrEcapEqKcAAAVynh+QR+H7RbCKNfkywIA+cVoaPf3l6LlbxFt9p2gEc4NcGJcp+iOLEtzdtkjVWaOS7MSuGAUEqCD3pxcIpYt8uO9c/o2mx6VdyNAVMTghj3zxj696vX7Sz2yiGQf6zBIPGB9K5nBJ2T0OdwV9CPVL9YXiYlQHYKA351z2s2cV/ply0UbkuCwb/aByPp6fjWhqEf2m6jhU+ZOgDKP7p9ar6vHe2diNyRRRdDsJyfb61007Rtbc6afuONtzzmwmki22wiHzng45rS8B6j/AMI94xu7W5ZhZ3aF8L0DAZ/xqpvN3qZYIsZjJJHbPrVTxFGIzDdQAs8WVJ9jXpSip3g+p604Rm3Tf2vzPRPirdNa6nAQp5gTDAdw7d/yrnbTWTdbUcLlTwFONxPeu88dLbT3ttb3BOXVT0yFG49R0/8A1Vxmo+GUHiCKw00kThd+/YSB9fSuenKHLaR52GqUnTUZqz7j0kRZhO4KsATkdFz/APWpLe+judRVbRjtjxgjOSc9a0ovCj6rpbFrkw3QYpIpGV3A8+4rnNS0C88My2tzPIssZfG4DHPoacHTm3FPU0pKlO65tehsaxo+nXNsr3KmW8DYyGwVJJ53dsVl2+na4HMWkXqXCKMhZzjH0atWJTcYl2L5e3pzg/41rzXFjpmgtfazKsNuyEJtIBY+mBRzyirbmbxEqSs395zRv5PPOnavby2lxnBQtlG/3SKkvI7FPtLGziZVYHbtyQB3Bz/Oo7PxLoniy2+xTwTQXBxseXqQOBgjuOuOKoRTy2lxJa3jGS4jJCzY4kUHAb/GtFF7NWa6G1Gca0fd0aI3tCRHKySCCbLjA28Z4Iz0qHwVrLeHvEtxbTDdFdHcC3GK2dY1aa5jiluRuKHZtC9QR1+tcN42zbyWlzGNr46oemK1jH2keSfU7qUHWg6U+p9D28v2u0SVMgOuRmpo4yEAd2JA796yvA15HqHhXTZ0IO6JR9CBjBrcaMM2RkZ4PpXhSjyyaPnJxcJOL6GbfxxXUbWsiAowwdxzmvLvGkWm6ZqQ08QIXZd6tIcNnrkY7+9et3SrGpJZVAGctgYr5y8X63e+JNfjNxlLK3lMSFQMtjgt6/8A1q9LL4uUn2QXaScdzo9A8VeJSv2DTbsOqkqGnjDbPxrrLbwhd6r5c/inVLu9Zsn7Or7I/UcDiud8PD7PGmIzsOMkDp+FdZN4lvLiNrdIGklxtGyM7sdP61tWT5v3aS8z1ZQmkuRK/VlfVYdL+zHTNI02Er0+VBlmHfPWsLVtLh0y30xSsm5W8yUFflz1GD0rrfCunyRaoXvbZ4QV+UScFicdK6XxHbWM+myHUEj2IpKs38J9aw9uqc1DdEPEqlNQWqMkQaH4k0crafZnZB8rhRuQj9RXF6z4nu9PaXSmlV5I1xE6cMSeNpNYlncTWfi/U0tV/cyvjCnjGOvFYnizUFkup4YrUTbAVacA5Wumlh0pWbutzso4Sz11W6uehfDTWdF/sibTtTeCG+V2Eol2nd69ePwp99oXha21KO6sHttoVgFRwyx57AdsntXhUenRx28kqyypdFGBkBzk84A9ulQ200wSJrddl0Squoct0xk+1dDwfvOUZvU82V3XvODTZ7hL4Z1e0uH1XR5UinkjDLb7cBh2Ge/FXo/iVb2FvJaaxaSw3axnJCggt7j0/Oofh94qnvNNj0+4mjR4OEeQ9R2/KuE8eabM2pfa5GJ8xsuW5yO34ZxXNGn7SbhWWx2OnKpJ06qu1sXNQ8RRHSbAW2klbU/K1zLj5nP+z1I5HNdL4OKSG2hY7gGJOOMHOa4vw/4dudRtnuLy6e20u1DGbzCNz9/l9q1vCPiWytdSFva+a8XmBkdx94VvVguVqHQww1SbjKnPfoe0u6M7Rtn9OKkhtY0USliVPQiqIlDoGG/ewHyDqRjrj0pstxOIlRkYIOo6DPb8K8XlZxuL2RoebuuWRc4Uce/auP8AiLAg0aW9lUYiX51/vKDnH1rorOWTpt+YjkH+dM8SW0Oo6LcWpUuZFIKn/ParpPkqJlUn7Oomj5y0w2OuO/kpPbckrxkcdzXWeDfFl7oWora6hJ50LDYrsenv7jivOrqx1Ky1m30sfaQjStEfKIDMmeg9Oo61ejgljttTgkWWNbaRXt2c/MFbP+Fe/VpRmrPVHoYfGyxEvq1da6/ee+6ZqNtqE095ql1DJbQIGC7wVOe5rxrxFeR6x4k1SeyhEVs0m2JRjHHGfxHNa2n6tZweCru3aWNr+4KoIQmdgx1z2rnbOxke48l5PJSZTyRgH1rmoUVTlJnbgaDp3nNWe1hvh3TrrVL94rKPkYZTjjHQgn8yK7LWvhtf+fDPAqz+colk4yzOBjBrgo9ZubCUwaYpaSJtgIXLBvw7V7r8LNSm1Lw3b/bhML4EofMJAOO/0qsVOpRSnHY8GvVhXqycVobPgDRE0bR1TcHmkwz4/h9ufSumdAysBye+ayCk0Tv+8UDqFH860LcTFFLyLgrwAteDVbnJzb3MZq2tz5u+Icssfiu+soU8sbyJcKOcnI61raHDHZ6tp0akBUiOD2zjmtTxnbQ33jpLdpW+z2wLzSYHWuXt4f7P1xbuR3aGSYhQWzhD0r3oy56aXke1hKSp0+VK7knfy7HQ61pGp6lcebZhfIRgFwcg98c1csVudI00RXbEuzcpuyB7YPvXQXVzbwmMPMsTSLkRdMn1x+NZWqFrqLaNpiBLZKAEf/WrmVRySi9jko017S7Oi0y1EFv9s83aZxuEY4AH9OtWftsgfcrNkdxiqPhzUIbzTobWYFZlJVXI4I9quXcTJc/ZreRA3UtkHaAM/nyK5Jr3mpBJWk1IRLucYIzgnnjIp9vfzINiJtdshfl5FH9kSqymBnnXGCWfBB/lUcJkivAZYgHifDbvSofK9iG4y2NDQ7qBbq4+0osNy+PnbgMo/lUnixrefRLu1knVJZUwmDznIIIridU1lbhp4rF8OSylWGQR6CqFt5t29tLMI1eFdgKHlunWrWG1U27FLDa+0bsVL6H+xLVJbp/MlJ2BFBznt/8Arqkb+C9tZ0ZRE67duSDgZHUitXWYo9RTM0rhQTnHIH0rnZGht7OQKjLZK2CQPnkP+Arvp2ktdzaDm6nPJ+6up7v4gtZL7UxbxyQRDyVLsy7nILHGB7EfrWVYS3OlX17Dco95PKvmRyoB8wxjB9Ku+JtSsLfXEtb6Xyne2DqQcE/M3GfwqhpdzLL9qexTexH7vzGJAA9TXmNOzvseZGMuS7WhCRqKafcXQcRC5kLPCoxt46g9845rLvYXvdD+yNc+cpjJj3Ejj1P48U/7fctc5mlRhGSI1HIJI5rd0qwZLSMRJhyAASMgfStOZ09Wb39naRxOhXc88iaTM5VYR8xx93Pr+lYfxWju2l06SCGWaws42jlUg7C+c5I7Zz+leg6lZJ/wkHlbhC1yoWZyMA5HQf41yWravNa6peaYgMybhymcHj1711UZ3qKUV0/M0nD62/c0Zwvw5sbu+8SxTvB9mtbfLpKzHEnHYfjXot3aJOi5YK6tlXiJDA/Wo4fIh09rtMRsoxtHHX2FYMeo3VxeMIJvMkYgADge9bycqsnPYmn/ALN7q3L9tcNZ3y22pJ5iuf3M6rjd6gjscVQ8SaL9vgkSBghUswB6dOBn3rpbvTontGkmTzJjtIcNjYcdQOprHs7tpZZIZEUTwtsYDpkdD9KmE7+8j1qFVt8y3Rqfs/6402n3mjXD5ltn8yJT/cJ5/I/zr10MM9fqK+Y7G+ufB3jqO+iH7pmJZR/HGx+Yf59K+k0ma7tYZ7J1MUqBg3qD0xXn42ly1OZbM8/NMPyVfaLaQajElxZzQyEYYECvAdG0WZtea0mXaouTzj5WBPftXtdzp88zASSbi3JOeKxtd8Kz6nfwXOmTrZzRIAZdpwxB44H86vC1VSTjfc5qXJDdmdrenTaVOoSMeWw+Vh0zVLTNTuLV/NlOUHOAOn0rQ13V9UsYVsPE9nEUcgQXlvyrN6EHoTWO0VxDCCVYJyVBHbjH9a3p3lC0z0KL9pD37HaXevpdaLcSpbu00aFgRwFOOv4V5/4Jiv8AxneXser6pO9nGdyrGcCT/AVpWN/La2727MBa3IKEkcjIx+tVfB2pReHIZoltwzyNtXAxjn1ojT5ISUFr0Mfq8oN+z+Q7xZ4dt/DZhSylkeW5b92MZdT+XTnFYtrocVxqunaX5jiW8m3XJbghBz19Tgit+0a81HxJNqmpTI8saH7Om7CRD0FJdRS2evHV3khO3bjGAAelaRnJLlb1t+J1RnUUfZt62/E7uLw5othZeSljA0ABOHQMfzrzO40y01HxxcT6TbL9miiCthON3fP4V0mu+NhdWC2dkqG5mGwlT0/wFdF4GsUsNDADRSSzMZZCGGcnsfpXLGU6EXOe7OSLqYaLqVPien/BOYm8BWqKjiaRbmRCYQr7QrdcZrzrXZr2LzdOvW8yRMssjHBIHb3PWvQN1z428T3FtcS+RpWmyMpCNhnHTqPXFX9W+G+m3NvM1lF9nnfBQg52/rW8K/s2lVev5HTRxKotKu7/AKGZpd/o2r+FF0y3lMEzW2x0kHUkYJ/SvM9M0eTTL1ftEqtDBLw4HzbR2FdPceEdf8OTtNLALi2HIaAluPp2qnqt7HdQwtE5DZIYdOa6aVo35HdM6KWGpTnzwdz2rwrdwzWKeW4Yso5PX6GteaKM27o3CY9en415X4C1VrecWcrgmYAq2M/Qj37V3kl2t8JLeOcO38SoRlR788f/AF68ivRcah5GJw7p1X2KumH7VfuFfAXgEfp+lauqWyrp9wyqzssZICnuBWfaxNazeYwCA9eOtXLnU4zGRlenIJHIqZXclymdROUlyniOojTPEFpfW+pfuNUt2E1vOnytIuACAR3FZEEFjo6BYrZpw7cRyPlpCF7tgCu01/wvYw3Kz2peMTTmXYeQvt7Cud8b6VLZSyopeNky8MoyNynGSPavapzi7JPRndh6c3Byil7R7PyM6DWtJtLV5b7R7pZ1GVeJR5YJ6Fj+YrsfDtlpd3HJPrX78MCUgUYZWPfPt/WvOdB0/W9bEWj2kQZJJvOJClQ+Om8+gx0r3/wl4Lg0i1DX8gurpuX4+UH0FZ4qpCkt9X/XyJcqtKD+syd+i6nnXgj4c/bPFU+o3Lyx6XE7GFc58w47n0r2qKygtYUhtIkiVBhQq9KseUgi8tQFXtgYxWTrviPTNDt5JNQuURl6R5BdvTAryq2IqYmX6Hnu9WbdNb9Ca7byLeSW6cKEU7mY4GOxrkPEPxBs4Lf7FoKtf6g64AjBKocdz7VxPi3xTceJGVZybTS85VC3zSD1xTdG1aaKRE0jSpWRRkiOI9PrXVTwVkpVNX26Hp08DyLmqK77dCXT7C7tILqe/bN7fDJyM7fUfXmtXUfDSXPhtnihCT43huhPoK57UNcvP7UWe9tZokU5ERB4Hua7O18Z2FzpU0MpIYjAVFLZ9ia6KntY2aOqoq0OWcV62Oc8OXK3tukt0iPd2p8pgwzjHANazowtiDESHP8Anr2rCh328z6jZ7m3EmSMDqM8H61uQ6p51v5lo5+bhhwee+aVRa3RjiIcsuaOxmWP26zu0WLc+DhC/CqPUeldSl5bNcwIZM3EhzlTkN2ya8m8ReKrw6vLBa3DQrHjbjjfnjqelbWlNf6jZCZnP2iL5d33c5q6lBuKlLQwjiIYmfK9LdT1+bVYxhRt8wfNwcg/X6Vn3k1vKkxguF891yURsk9f15rgI7C72qZJQrMSOGJOPU0i6Q/lowuQSThhjGK5VhoR+0XHDUov4yLT54otRuSEITBxu7Y61ydz4v1Aam6won2fJJyuSvbqK7K1s5IZpJbva2Vxkd65bVPD6NcSi1utqyAERkZY8967qfI5PmJxsalSa9jqbFnrEOp20cUcmH3BHC+nHIB5rZv9Gtr7TmhJKoSCpTKtke9UfC+ix6TbyXcsamQLkKF4xVK81y4vbjydPDljztVetRJXlansjopUZVKfI+m53Hxghca7a3AGVFsq5z0O9/8AGsvRNcWC2ngllKI6EZRec/X9K634ihJNUSKQLj7OrA9/vNXmt3aPbDeV/dHjcDmsqSU4KMjLCctajGnM3/D6zXU7XDlWjLbQG9P6V1ia3e28Qjt4FkjQjOTjb6jNcDoN8Fu4rRgBG5OT6ccV3Wl2Ru51SYN5MLchmzvJ7mssRFJ+9sZ4umoy95aFuJJNcv1nu4ljs4flXLffb1B9KjudNjgljt7eONPNbd8yBs9ehropUjgj8w/KqAe2O35VlagZ7t82rshQ/eGOmM5z6VyQm29NEcMJ2emxzF1p6XEE0aqIigCnHRj6CuItzJompzr5f705HzcjHtXprC4tdPFmyq8cj7jOTkqT7VW13QV1BpxcBVXAWJ0Pc12U6yWktmdeHqwUrVFdGBYzC+jDgHceCM9BWX4g054o55opWj3RmCaQdVzna/4E0tkJdG1ZrW8yoVwrHPT3ro7iETKWjxIHGB6flW1+SV1sdc17J6bM8Z8OzXniKzu9K1YEarpbYE//AD0U5wT+Vej/AA08dvorpoevFhbqcRTH+DPY+1N02yWz1C4tHWMFhvSQAZZfQkemfyqPxJokN1aFmAS5i5RsYBHXBrSooVLwktGbU4xlSVCs+ZdH+R61Lr+miYxvNtVD8zY4z9a1ba5inhEkMqPGejKcivmawuJ57nyLiZwm3nLfex2P0rU+EXjL7B4nubS/kcWUrELITuXOeP8A9dclXLrQcoO9jwK9N0arpS6HuHivTV13Rp9PKN8/zK+PuspyMVwd1qWonTItJu4UW4t/lJVTl8dDXp8lzFbW7zTuEhQZLk4GK8wk+INhNr10YdLe5JOIZeMHAxk8etY4XmaaUbpHRhZNO3Lf/M0fC3h+a/uI5tSVvJi5AI4JrodW8HabfxkIrQydmU9DXNnxZdqEkKAeYxIUZGPYYrs/D2qHULb9+NswGSvqKdZ1ovn2NK7rxftNjjb3wbfWtkUtpTKx9+a4W/sLnTLrF5bPtzguckZr6BkKqm5yAM9Saz9SsLXU7Z47mJJYyCCT/T3opY2S0mh0cxnF++rniV7Zxz3NvHAPLywyVJ6E16BaeBLGGRfInuwvdllK89sc1xGo2UunykwmRlU4+bsRXTWnxPto4oLaSFpbzIXYnU11VvayS9kdeIqznFOkxmoeDdU0GS4vtJuHniYb3jB/eBhzn/a9xXZeFfEdrrNnEc+VcFRujPHzdwKx9Q+I+iWulxahNK6R7trQlfnB5GMVwi6tYar4ok/sRvscN2nmRq52fvQR+WaxVOdaL9orNdTl1xD9nX0ktn/me3uiySFWxgDkHvXkHxO8M2lpcLqWlzBRI4Elqh6nuV9OOtdJc+GtdmVWkvzzwVSQgn6VUuvh9cC3LQXJadW3hixzn0qKHJRlfnHhXDDzUvaHllhqtwJo5baMwGDdgZ3D2rR8O6zc2WqxX1nHHJIziKfd94kN82T7jmofE9q+l61NGpxhyGx646jpzW3p+l6LNHoOpsgS6mnMF1blyBI4X5Wx64/OvUnKHLdrRnTmOHdSEJxd3/metyvDNKFdwFcAjnH0qC4tN8qvkFcYOO9WZYfs7rujUjtnmrMFl5yiWaRju5CqeB/nH6V4SlbVHmc6jqY+oaXbahpNx5hWPywSrE4wR3rjNTka/wBE0+7mVJBGDCyfxHGc/mK7/wAQ2UUWiXkhkdQqb354IHavGrPUp7m+b7MHawS4RGUD7uTjP6npXZhVzpyT2OmhVjGHO3szQ0nUbnw/qDSaMY5bUZIt5pOVznKgj8K19c+JmtwKi6boKTSOM7lkMgX64A/WrPxXXQvD+j2FwyLDNLKsKFf4gR/EPT3rhbrUpEj+zWpYSSAJhf61vCEMQlUcTrjGnjVzRXvLv+pa1zxn4wu0SCe7isw5wyWqDf7jPWsnT9Eu726eSZ7hn6madtzk9ePTrXaeHPCUyBtRmUyhQC2OMjnOK6Wxt7dmSTGyKPkFeDjsD/ntTdaFPSmi5YmnQXJSSb8jldJ0C1guYZp4jLIeofn26Vk+LvG2p6NP9n0COO2gDlTLIAXYj29PSuj/ALcN54lhsXWIKzBUlQctz1Na+q/D3TdSuI7q73MI33/dzu+tT7WEZJ1zycVXlWV76mV4ZuLzxb4de41BYGmhcI8saFfM4zyPXOBWJr1hpVjbm6uHMcrsUj8hsMxHU/SvVINNj0nSINP0pFgiBxg9x3ryj4heFtfGsW91otu09uSUck7vLUnJ4PvUUKsZ1Gk7IKWIqUqfuvUxNFurlnkezlkm8s8r2cAZIPviuhEcF/Il3pb/AGa5fkqQdpPfd/jVXwnpep2PiSS8a1lhRImX96mAxPBYD6VYVRpeqNASyw3AJj/2X9CPeumpJOVonfhq9StTfP8AF+Zhz6TFJc41MSWy78kKm5G78H0+tdRp7W62qJAyiMdCD71i6Tqc82smxuXlKtkOGXIGOhH5Vcl0GPUL4xWKN9obA3QkgE0T7TYqFOjUvJLlNCR1AfMi8jcDnG01Un1W3gjdZXViehzjNbll8Kt8aHUdYuwSOYojjH41cX4VaJDG+2e+kk/haSUED8AK5PrFBaOVxe1w0XrJv5HBSXlzqMqJDmOHpnPB/wA4rb0/S4raREJUyMM+aDnIryn4lfb9N8QvplqLiKO3kCBkYgMTXU+Fbu7j0llvmk3HhS5yw9ea7pUvcUovRmtLExrzdKkmrHX6tf2um2/2e3lkvb6QlfLAwqn/ACah0XR1tbVm/wCXljl2AGFz2FGg6dkedNnzG5D98fStK5kXJ5kRM5wOmenArlbt7qCpNJOnB+vmX/i7Dqdnrdrq9tGZbBLdYZQoztIZjn8iK5yKe31Gx/dEESdAvY17hexRy5SVVYMuCG715V4s8ES6TI+qeHELW5+aazz931ZP8Kxo14y9yWj6HHhcRGUVCWjWz/zOLuLaW2nIkBwPSut8G+LhZPJDqI4bBWT0AHSs7SpItRdMFdrjBDHkdulSeJPDyWsKPax4kVvn+bPHrXTU5anuTPSnOFX91WR1M/iI63NJBYkJZxfNI78F/QCtuDU7NY4oVbIK5c5xntg1w/hu3MVmVIUszhs8ZJrbGmxT7ZbgKhlkOSWwDgZ/KuSpSgvd6I8uvThCXJHY6Yz2dzYyxweXJPsPy56Ej1rJtZVtrOKSRv8AR0XJYnOT7Vla0i20AMDeRJwWJPAJwBitixNnLpFvZo6yBQBuP8RGc1Chyxv0IdPljdanH+MLZtU1SK4sUbDKqnIP3vWrNlHDZ6fG99eRwIpwSTgfnWzd3rrJLBcugjXARTyWI4/CvLfiPJNdavEAhazjg2IEUkA55PHfkda7aMXVtB6JGtXEzjSUUtEdfM1tfxRPYXMMlxH8ybGyOc8H2IqNyNU05Xg6SZjkXujYxj86828N2Gum4tIoLW6iVX4ncbVK8dfWu9mKWOsXjFvLgmhM4x2ZfvY98YradLkdk7m2DruqnzKzRx2o2F/pV6r7AUY4UsMgmqduqX9pLp8ltBFeIp+zSZ2Bhn19RXaN4o0jX9VtbXT7SWMMOBIch2Hp71S8U6RFEouIV+ZGBwOx61rGo00pKzOiqqWZU1bSff8ARm14Skn8XCy8P6pceb/Zy4kljY4kX39SMYzXq8fhzSICix6fCpVcBgvYcV88eEfGieHvHEckkSxW0iGKUAfeBwc/XPNfS2m31tqNpHc2kqywSDIZa83HRnSkktInk1eeEVFPbR+pVvdGsrq0MHkrHxhWQYK1y914f1a0Z5LOUPj7m08iu7wCf60Z4xxXHCrKGnQiniJw039TzS/03xBfWzm+MixwHcEV8lie+ParXhLxDDb2d3Yaoxhv4m2qrn74I4INdT4n16z8P6W93dMHcHakKn53Y9gK8QuNUl1vWGN0ptWwXDHso554ruoxeIg1JWR6OHi8VBqSskemaxpXl6eZ76SI4XcAANuf85rgrzTLJNRhuoxbx3K/NG6nLc1wOr+M4/taQxPPeRAkJvk2r9cVuWFs17oFrrNtA8dsLjErbeFOfX0rshQlSXvPc0w/sJS5OdN+hc8X+H2eG3lBeZJFDyR+jZPI7GuM0ex+zXlx5CTSQMSWSQ9B6j0Newv440TSr2O0YrftHCEMuPkXPPP5/rXI6zbWkV4t7pVwk9rdjO3p164FXRqTtyyRpSlTxFRX0kuv6Mm0fx1rmimCB5muLONsoJeSBg/KT1712Nt8YLWVQJtNnjc91IYVx+j6Mdc1j+z7JI5JPLDvIcgIB1H61V8Z+F7zwzcwrcbZEnB8vy/Udv1rGdGhOfK1qdNShhKlTkkrSY7xVqdrql9Pc2jviUlyrqQQfft/+upfDlyo1a3aXK2cyhZCCMIcfK2PUEH8DSQ+BPExtI7tLRGjkTd5Yf5sH1qG3jTTNIvHvIpXurdhEtuvXeTj5vatU4NcsXfoOv7B0dJaR7HtGh61A00trqkoSeNQY3c/LInqD6+tdDFPAygRSxsBgYUg9RkV49ZQ3V/ocU94WWRT8sTcED274+taNvcIqTRWiCGTjJU4AOK82phU3ozyZYSNT34M6rxhqcU9tLp1s4aSSNt2DwOOlYPhFNH0/wAKXl/9nVp493mJ1YNjpism4CW+nSS3MsZueSAp71nWkjfYjNCcyswYYHGQOmO9axoJQ5E+p0rCRdLkT6nCay154rnhu9UkleSI8rIcrCuegH0r0Hwb4dSOKTUJ1xKQDGsnUKeh+tY+pLPNqkNrcoqs43SBRj3r1LS1lktmmLRD935ccYXIH1roxNZxglHRGbp/U6Ts7uW7Kh1WaCCVNxMIHQr2xXFal4sj05zHKFSF22HGWxxW5qXhnxSL3zrO9t/ICjcj5wSe1a+leBLN4LK61RUklCh5I1GVJ9s1zKVGmryd79jzpVH9koWHg6GeW11WJyCwDANyFBOciuxEytcfZ7cySKTtfaoO38a1HSMRKiBQg4CgcYpLaJEUhAqhjkjHU159Su6nxEKS1IpokhTeAzMOCTkmpwY1hJyOAakKjkEj8qzruPZMqoSVc5K7sVlHXQS94W4s0voyz/KvIU9/rXnus6ZHc2plaPG8kCTHDMD1rX+IHi1fD2niNCDJKpQKPvZxxjH+RWBoXxKsntkstc002qGIeXJncjZ4GeP1ruoUqqj7SKujWnWdJqz1MPTYRJNLHIc+Sfmb0GOpPpWvodwYGaSOQwsGyp9eff1rjfEV3JBDcC2kKpPKRuGRhR1HHrkVZ8PwXrWSvOsjjG1V3Hj0r05U7xuz2HWU6jpvax6XL4y8o7j5ZTjI7+9bUfirRpIFma+hjBydrHmvLG0ySRmw6qMdMGqL2LwMHMQKBsZAzXHLB0pbOxDwVCeidmbfiW3svEV6Lkx7mU5Dr2A5GfWseK28++iiyPLDYx0+UVfjuzJACzYjUdF4BP8AhWfpWp29jqkVzcDcEJJjAyWzXTFSUbLodFOkqUJSitbHZjy44tiA+WQACD2FVkiUuwdC4J3beueKtBrXUYnksG6HLoF+6D6461xniTxLqMTvHoawboCEctgs3X16f/qrmpxlJ2W55LqxiuZn0Bcyx/bFh3AS7AwGeoyaUHggnIxnNcf4xv5bTxVCYeClqr/XLuMfpW/o9697GGcBe3H+fauCrScfe6M5HScYKXc5fxb4T8qZtY0GMLdJ801uPuyj2HY1zy6p/a0Hmnbnowx932xXq11L5MW4Lkema8p8SRQ2PizzLWPy1ucOyA8BjxkflXThajqe7LdbM7MNJ1VyS6bFy2QrZl0xkMDjPbpU6anNeXkYs4WihhUgN0XOO/1qbQbVLm9UylikYztHc4z/AErlfGfi7ULG6h0/T1ht0WRXZgudxPPStowdSXKlcyrVFB6nTappr6uohnm3zynJUDAGK09ORNNjh0+6RQV5X5e/fFYXgXX7jU7c6hdxo04kZG28BsAflW7p982o+NEjmQCOGBiqg9yQM/rWU+ZXg9kaKblC3Tci1zT7LUJ44SjxySt8zA8jI6/nXC6jY3mg6kgEglt2YhJNmQR6V6dqNh5sjs0p+QBhgc/n+NcX43uS9taxleMFhjjHP/1q0w822o9DpwlV3UN0y3bSLLGqDMh4x6r0rI1+GJ4xKFbEEgZs8/KeD+hrS0aZlsSe4UHPfPPeormUXSzRvGoVuGx3z/8ArrWPuyKi/Z1Lva5keG/h2lrrVtrhuFbT4WEkUSrnLeh9q3fE9pDIwjEXlxz/ADZHAFT/AAp1CWbS77T5iXhtpGCZPOKZ4hmM14iMMKT8oB4Wk6k5VmpPYyoUvY13GOx45q2jxyarCHUOC23Ib8ua9B8BeLYfAli2n+JZytqD+7mAyOvH9a4nxI7W3jmO3jOI5YUcj0Oa+idQ8NaRr2hxWmqWEM8TRDqvIOOoPWtsXVgoxhUV0xY9xb9tFfFdP1T3OEufipZavqUcfhq4EsKAbmb5cnPQipL3xX4g1CF0g8i0hUYZ1OW46n9K82m8BW3hD4l29npl5IbWY79jp90Y6ZzXvOn+FNPtYLdgGd/Lyxbox+lYVfYUVFpXuZ06lKNJOcfePFLjWoNN1WK51YXeoXUbh3Ocqq59D0rsfC8+m+NvGhnt4PLtI7T5ogME5JHNZHxAsIYNauUiGwFDKu3tjjHvUPw2/wCJD4lsJ4PnF4pgdDxjgHP1rpqcsqXtIb2IjiKk5yj5Ox6DYfCXwbZXQuItKDyKcjzJGYflmtvxfDb2fgvUo4Y4oYIrc7VVQFXHtWubz5XOz7px96uC+JupS3UemaZjZb3l1Gk3Ody7un6V5VOVSrUXM72MKFJuasec+DvAut6tp0kDWVvFp877/tTty4I7e3evSLH4W6bpukCC1lmlukXh5G4z7DtXocESQxpFGoVEXaqjgAAcU6rq46rN6OyM4zcJucNDyLTdB8SeFNbe8stOTUIZAeI5ADg9jn866Cw8M33iDVBq3i1AgT/UWSPkJ/vHua709aOlRLFSnr179Toni5z1e/cjjhjjj2xrsUDHHYV4Zaz3mp+KNRNrbs6Xl8bdLhj8qsPX24zXtOuXTWWi39ygy0UDuBnGSFJry7wnNJa/Dawu7dtlzPeNIXxnB3Y/lWmFbjFy76HRgZOEZSWrdl+pl3+qR6JdNb312YrqOQKylt27/dHp061pXohvrq2u9MvYJTcp5jReYqs4UDkLnOfavI/GbSy6/NezytJNNIQ2an07RPsuoWVwl0+93UEhcEAkdDmvW+rrlUr6kTxlWnUaUVodtcQt57Q3QkUZPybdrDjrVOPUxN4ittN0+dI2t0LFG5DHHIP511fi/UGFus6xrkBI/m5JBx1NcTpGnw2WrLfIoMzZyenXr/OopvmjdnqOVWtGLW19TotRnin8S2tuEIdEBmkHOfU/livRtMiW2fMUxKMoKk/1/CvMERn82/3kS5KfhW/4c1mb7G1syBhxlieSK5q9NyirdCcVRbgkuh3V/Pd/Z2WHoRjcG5x/jS22vQRpFFIxDBRnisiPUpRcxqqqFAAwefauAtbidtf1JjKSLaYgKejBscEVzQw3PFqXQ8araCs0e1xIrlZkyc9Cf8KlgkXdIhwGU9jxXNeC76a70yTzSP3L7QfY810YUbS/fOK4qkOWTizLcnYhh1yM/Sqt2A7ZA5X7vt/nFR3zG2TePmwp4NeL6r8T9Ulu5IY7eKKOOQJw2SfxxV4fCyrO8BpW1NLxzpT3l/DeyZkFvMwaIHkqe4rkEtdYvFkh1KG3isWYLAw4dUBztA7fWvQIZvtqpPIig+Xv2jp0rlNUu3xNOeWjztBPAxXr0ZNLl7Hdh8JGtU529EUNf2xi2ihibcnBfqAPX9K1fBx1K9S4M6iSGNsAdMe2a4iHWbi+uY45MAEF/wAs9K9Z0YtBYhYG2RSbZHTrk7c9a1rpwha2pLqurVclsi09lEY1eMmPoroTnBxWeqKysrYbacYz0x0qe5co+F48xlJ9s1jSTsswHP7xgxIOO9ckIto6oQclcdqFubdDLCEkjk4Kj+H8K526tQyHeOAflOa7G2A8jy8dGIz6g9aytXsEgimdGO1Gxs7c961pz6HXh66/hyNLwxeQw2EyI7IxQhiBkse1Z7+EtQnknuNPWCa0uMGWOTC/N1696xopWt7k7TnAH40axql9JfvawXMttBAqYEZ5JIycmnyS5rxe552YUI0vRn//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of an essentially normal glomerulus in minimal change disease. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary walls is normal, and there is neither expansion nor hypercellularity in the mesangial areas in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron microscopy in minimal change disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in minimal change disease showing a normal glomerular basement membrane (GBM), no immune deposits, and the characteristic widespread fusion of the epithelial cell foot processes (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39178=[""].join("\n");
var outline_f38_16_39178=null;
var title_f38_16_39179="ACC AHA HRS HCM";
var content_f38_16_39179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/HRS: Pacing indications for hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with hypertrophic cardiomyopathy in the followng setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Class I indications for sinus node dysfunction or AV block as previously described. (Level of Evidence: C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The evidence or opinion is less well established that permanent pacing in hypertrophic cardiomyopathy is beneficial in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Medically refractory, symptomatic patients with significant resting or provoked LV outflow tract obstruction. (Level of Evidence: A) As for Class I indications, when risk factors for SCD are present, consider a DDD ICD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence that permanent pacing in hypertrophic cardiomyopathy is not useful and may be harmful in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patients who are asymptomatic or or whose symptoms are medically controlled. (Level of Evidence: C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Symptomatic patients without evidence of LV outflow tract obstruction. (Level of Evidence: C)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39179=[""].join("\n");
var outline_f38_16_39179=null;
var title_f38_16_39180="Selectivity of NSAIDs";
var content_f38_16_39180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected nonsteroidal antiinflammatory drugs (NSAIDs) and other analgesics: Selectivity for cyclooxygenase-2 and potency in inhibiting gastric COX activity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        COX-2 selectivity*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastric IC50 (&micro;M)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        NSAIDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ketoprofen",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ibuprofen",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Indomethacin",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        0.85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Naproxen",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Piroxicam",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        0.87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ketoralac",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nabumetone",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        0.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etodolac",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        3.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celecoxib",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"       <td>",
"        11.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mefenamic acid",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nimesulide (not available in US)",
"       </td>",
"       <td>",
"        58.3",
"       </td>",
"       <td>",
"        1.49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Other analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin (acetylsalicylic acid)",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salsalate (salicylsalicylic acid)",
"       </td>",
"       <td>",
"        &ge;2.8",
"       </td>",
"       <td>",
"        &gt;100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        &gt;100",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In whole blood assays in man. A number &cong;1 indicates COX non-selectivity while numbers much &gt;1 indicate COX-2 selectivity. Values for nabumetone are for its active metabolite, 6-MNA.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Concentration of drug that inhibits human gastric mucosal COX activity by 50 percent and thus gastric mucosal PG production by 50 percent. The lower the IC50, the more potent the inhibition of gastric COX activity for a given drug.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:413.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39180=[""].join("\n");
var outline_f38_16_39180=null;
var title_f38_16_39181="Pulmonary artery wedge tracing";
var content_f38_16_39181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Pulmonary artery wedge pressure tracing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic diagram shows the different components of the pulmonary artery wedge pressure tracing. A simultaneous ECG is shown to demonstrate the timing of the different components. The peak of the 'v' wave falls outside the peak of the electrocardiographic T wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Gore, JM, Alpert, JS, Benotti, JR, et al. Handbook of hemodynamic monitoring, 1st ed, Boston, Little Brown &amp; Co, 1985.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39181=[""].join("\n");
var outline_f38_16_39181=null;
var title_f38_16_39182="Dissecting instrument";
var content_f38_16_39182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic instrument for tissue dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39182=[""].join("\n");
var outline_f38_16_39182=null;
var title_f38_16_39183="Sulcus sign";
var content_f38_16_39183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sulcus sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This maneuver is used to assess glenohumoral instability. The patient is asked to relax the shoulder. One hand is placed at the acromion and one hand is placed near the antecubital fossa. Downward pressure is applied to the arm to open the subacromial space. The examiner assesses the looseness of the shoulder and the discomfort caused by the maneuver. The sulcus sign is positive when the humeral head (X) is readily displaced by 2 cm or more inferiorly (arrow). Increased humoral movement in the anterior and posterior directions demonstrates multidirectional instability.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_16_39183=[""].join("\n");
var outline_f38_16_39183=null;
